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Background: Folate deﬁciency is associated with depression. Despite the biological plausibility of a causal
link, the evidence that adding folate enhances antidepressant treatment is weak.
Objectives: (1) Estimate the clinical effectiveness and cost-effectiveness of folic acid as adjunct to
antidepressant medication (ADM). (2) Explore whether baseline folate and homocysteine predict response
to treatment. (3) Investigate whether response to treatment depends on genetic polymorphisms related to
folate metabolism.
Design: FolATED (Folate Augmentation of Treatment – Evaluation for Depression) was a double-blind and
placebo-controlled, but otherwise pragmatic, randomised trial including cost–utility analysis. To yield 80%
power of detecting standardised difference on the Beck Depression Inventory version 2 (BDI-II) of 0.3
between groups (a ‘small’ effect), FolATED trialists sought to analyse 358 participants. To allow for an
estimated loss of 21% of participants over three time points, we planned to randomise 453.vii
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ABSTRACT
viiiSettings: Clinical – Three centres in Wales – North East Wales, North West Wales and Swansea. Trial
management – North Wales Organisation for Randomised Trials in Health in Bangor University.
Biochemical analysis – University Hospital of Wales, Cardiff. Genetic analysis – University of Liverpool.
Participants: Four hundred and seventy-ﬁve adult patients presenting to primary or secondary care with
conﬁrmed moderate to severe depression for which they were taking or about to start ADM, and able to
consent and complete assessments, but not (1) folate deﬁcient, vitamin B12 deﬁcient, or taking folic acid or
anticonvulsants; (2) misusing drugs or alcohol, or suffering from psychosis, bipolar disorder, malignancy
or other unstable or terminal illness; (3) (planning to become) pregnant; or (4) participating in other
clinical research.
Interventions: Once a day for 12 weeks experimental participants added 5mg of folic acid to their
ADM, and control participants added an indistinguishable placebo. All participants followed pragmatic
management plans initiated by a trial psychiatrist and maintained by their general medical practitioners.
Main outcome measures: Assessed at baseline, and 4, 12 and 25 weeks thereafter, and analysed by
‘area under curve’ (main); by analysis of covariance at each time point (secondary); and by multi-level
repeated measures (sensitivity analysis): Mental health – BDI-II (primary), Clinical Global Impression (CGI),
Montgomery–Åsberg Depression Rating Scale (MADRS), UKU side effects scale, and Mini International
Neuropsychiatric Interview (MINI) suicidality subscale; General health – UK 12-item Short Form Health
Survey (SF-12), European Quality of Life scale – 5 Dimensions (EQ-5D); Biochemistry – serum folate, B12,
homocysteine; Adherence – Morisky Questionnaire; Economics – resource use.
Results: Folic acid did not signiﬁcantly improve any of these measures. For example it gained a mean of
just 2.9 quality-adjusted life-days [95% conﬁdence interval (CI) from –12.7 to 7.0 days] and saved a mean
of just £48 (95% CI from –£292 to £389). In contrast it signiﬁcantly reduced mental health scores on
the SF-12 by 3.0% (95% CI from –5.2% to –0.8%).
Conclusions: The FolATED trial generated no evidence that folic acid was clinically effective or
cost-effective in augmenting ADM. This negative ﬁnding is consistent with improving understanding of
the one-carbon folate pathway suggesting that methylfolate is a better candidate for augmenting ADM.
Hence the ﬁndings of FolATED undermine treatment guidelines that advocate folic acid for treating
depression, and suggest future trials of methylfolate to augment ADM.
Trial registration: Current Controlled Trials ISRCTN37558856.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 18, No. 48. See the HTA programme website
for further project information.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Depression is common and serious. Only half of sufferers respond well to antidepressants. There isreason to hope that folic acid, which helps mothers and babies in pregnancy, will help. We conducted
the clinical trial known as FolATED to test whether adding folic acid to antidepressants makes them
work better and also gives good value for money. We also studied genetic and other scientiﬁc aspects
of depression.
We aimed to recruit 450 adults from across Wales with conﬁrmed moderate or severe depression for
which they were taking or about to start antidepressants, but without other serious illness. Our target was
for 360 (80%) of them to complete carefully designed questionnaires about their mental health on three
occasions over 6 months. We actually recruited 475, and analysed 440 (93%) of them. Once a day for
12 weeks these participants added an extra pill to their antidepressants. For half of them, chosen at
random, this pill contained 5mg of folic acid. For the other half this pill looked the same but did not
contain any folic acid. Only one person knew who had which pill.
Unfortunately the reported health of those who received active pills did not improve any more than the
health of those who took inactive pills. So there is now no reason to believe that folic acid strengthens
antidepressants. Fortunately recent research suggests that methylfolate may be better at this. So FolATED
has undermined guidelines that advocate folic acid for depression, but suggested another way forward.xxi
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Depression is a prevalent and debilitating mental disorder. It often persists or recurs throughout life.
Guidelines recommend antidepressants for moderate to severe depression, but only half of sufferers
respond to initial treatment. Research is necessary to investigate ways of augmenting antidepressants
to improve this.
Folic acid may enhance antidepressant treatment for three reasons:
1. Patients with depression often have folate deﬁciency.
2. Folate deﬁcits correlate with severity of depression and poor response to treatment.
3. Folate is needed to synthesise neurotransmitters linked to depression.Aim and objectives
The relevant Cochrane review recommended large randomised trials to investigate the therapeutic
potential of folate augmentation of antidepressants. The National Institute of Health Research (NIHR)
programme commissioned FolATED (Folate Augmentation of Treatment – Evaluation for Depression) to
address this gap in knowledge. Our main objectives were to assess the clinical effectiveness and
cost-effectiveness of adding folic acid to antidepressant treatment of moderate to severe depression.
Our secondary objectives were to investigate whether baseline folate and homocysteine predict response
to treatment, and whether response to treatment depends on genetic polymorphisms related to
folate metabolism.Design
FolATED was a double-blind, placebo-controlled, yet pragmatic, randomised trial. To yield 80% power at
5% signiﬁcance level of detecting a ‘small’ effect size of 0.3 – equivalent to a difference between groups
of three points on the Beck Depression Inventory version 2 (BDI-II) – we sought to analyse 358 participants.
To allow for losses across three assessments, we aimed to randomise 453. We exceeded both targets.
We undertook cost–utility analysis from the perspective of the health and personal social services.
We also extracted genomic DNA from blood provided by each participant to test whether polymorphisms
change the effectiveness of folic acid combined with antidepressants.Settings
Clinical Three centres in Wales: North East Wales, North West Wales and Swansea, Swansea, UK.
Trial management, including telephone randomisation The Registered Clinical Trials Unit in
Bangor University, Bangor, UK.
Biochemical analysis University Hospital of Wales, Cardiff, UK.
Genetic analysis University of Liverpool, Liverpool, UK.xxiii
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SCIENTIFIC SUMMARY
xxivParticipants
Patients over 18 years old presenting to primary or secondary care with conﬁrmed moderate to severe
depression for which they were taking or about to start antidepressant medication (ADM), and able to
consent and complete assessments, but not:
a. folate deﬁcient, vitamin B12 deﬁcient, or taking folic acid or anticonvulsants
b. misusing drugs or alcohol; or suffering from psychosis, bipolar disorder, malignancy or other unstable or
terminal illness; or
c. pregnant or planning to become pregnant.Interventions
All participants followed pragmatic management plans initiated by a trial psychiatrist and maintained by
their general practitioners. Once a day for 12 weeks participants in the experimental group added 5mg of
folic acid to their antidepressants, and those in the control group added an indistinguishable placebo;
neither group knew whether their adjunct was folate or placebo.Main outcome measures
Assessed at baseline (‘week 0’), and 4, 12 and 25 weeks thereafter:
Mental health BDI-II (primary), Clinical Global Impression (CGI), Montgomery–Åsberg Depression Rating
Scale (MADRS), UKU side effects scale, and Mini International Neuropsychiatric Interview (MINI)
suicidality subscale.
General health UK 12-item Short Form Health Survey (SF-12; both mental and physical components),
European Quality of life scale – 5 Dimensions (EQ-5D).
Haematology Serum folate, B12, homocysteine.
Compliance Morisky Questionnaire.
Resource use Client Service Receipt Inventory.Results
We recruited participants in three centres – North East Wales, North West Wales and Swansea – between
July 2007 and November 2010, and completed follow-up in May 2011. The trial received 1488 referrals;
screened 863, of whom 635 consented to take part; and randomised 479, of whom 475 were valid.
Of 156 consenters not later randomised, 68 dropped out between screening and randomisation, and
36 reported better BDI-II scores at randomisation interview. Of 237 randomised to folic acid, eight
withdrew within 4 weeks and six never attended appointments; of 238 randomised to placebo, 10
withdrew and 11 never attended. We analysed the remaining 440 (93% of the 475 valid randomisations),
if necessary by statistically imputing missing data.Clinical effectiveness
The main analysis focused on the ‘area under the curve’ (AUC) of each of the 13 main outcomes – BDI-II
(primary), MADRS, CGI (three scales), EQ-5D (two scores), SF-12 (two scales) and UKU (four scales) – adjusted
for stratiﬁcation variables and the baseline score of that variable. The only signiﬁcant result favoured theNIHR Journals Library www.journalslibrary.nihr.ac.uk
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placebo and seven favoured folate.
The 33 adverse events (AEs) reported in the folic acid arm did not differ signiﬁcantly from the 45 reported
in the placebo arm. We adjudged six of those in the folic acid arm to be serious, compared with 14 in the
placebo arm – another difference not statistically signiﬁcant. We classiﬁed four of the AEs reported in
the intervention arm as adverse reactions because folic acid (if prescribed) was a possible cause, in
comparison with three in the control arm – also not statistically signiﬁcant. Fortunately none of these
reactions was serious or unexpected.
We assessed adherence to trial medication at 12 weeks in four ways: we found no signiﬁcant differences
in scores on the Morisky Questionnaire or in the number of returned pills; we found that 83% of those
taking folic acid achieved adherence deﬁned as a serum folate greater than 15mg/ml, and 60% achieved
adherence deﬁned as reduction of at least 15% in serum homocysteine between baseline and 12 weeks.
To test the sensitivity of our main analyses to the assumption that AUC is a valid summary of the various
outcome measures over 6 months, we repeated them in the form of repeated measures analyses of
variance. We also applied this technique to serum folate, red cell folate, homocysteine and serum B12.
These last four analyses summarise a wide range of biochemical predictors of folate metabolism.
By analysing and reporting interactions between ‘treatment allocated’ and ‘time’, they show that added
folic acid has statistically very signiﬁcant effects on serum folate and homocysteine; a marginal but not
signiﬁcant effect on red cell folate; but no independent effect on B12.Cost-effectiveness
There were no differences in resource use or resulting costs between treatment groups. The largest
component was for psychiatric services (£797 in the folic acid group and £886 in the placebo group).
Costs differed more in the 3 months before baseline: £514 in the folic acid group compared with £746
in the placebo group. As this difference may reﬂect an imbalance in patient or disease characteristics, our
primary cost analysis used regression to adjust for these baseline differences.
In responding to the EQ-5D at baseline, most patients described themselves as having difﬁculty with
anxiety or depression (97% in both groups), pain or discomfort (about 60% in both), and usual activities
(about 78%). Between baseline and 6 months those reporting anxiety or depression fell to 75% in both
groups, and difﬁculty with usual activities to about 58%. The resulting utilities rose from 0.482 at baseline
to 0.605 at 6 months in the folate group, and 0.514 to 0.607 in the placebo. After adjusting for differences
at baseline, we found no signiﬁcant differences between treatment groups in quality-adjusted life-years
(QALYs) gained – as estimated by EQ-5D (primary analysis), EQ-VAS or SF-12 via Short Form Health
Survey – 6 Dimensions (SF-6D); or in outcomes for the cost-effectiveness analyses – notably area under
the BDI-II curve. Thus folic acid seems no more effective, but no more expensive, than placebo.Biochemistry
Despite the lack of clinical response to folic acid, it was effective in increasing participants’ folate and in
reducing homocysteine. Nevertheless the few patients who had very low baseline red cell folate yielded
weak but consistent evidence across multiple instruments that augmenting antidepressants with folic acid
improved clinical outcome. However biochemical variables predicted only one of the eight clinical
outcomes – the CGI improvement scale.Genetics
We analysed associations between 104 relevant single nucleotide polymorphisms (SNPs) and each of
seven outcome measures – BDI-II, MADRS, CGI severity, EQ-5D, EQ-VAS, SF-12 mental and SF-12 physical.
We found two statistically signiﬁcant main effects. The rs11627525 SNP in the methylenetetrahydrofolate
dehydrogenase 1 (MTHFD1) gene was associated with MADRS scores [false discovery rate (FDR) = 4.67%;
signiﬁcance level p = 0.04] but none of the other six outcome measures analysed. The rs588458 SNP in thexxv
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xxvifolate hydrolase 1 (FOLH1) gene was associated with EQ-5D utilities (FDR = 3.37%; p = 0.03) but none of
the other measures. We also found one statistically signiﬁcant SNP-treatment interaction – that between
the rs17102596 SNP in the methionine adenosyltransferase 1 alpha (MAT1A) gene and folic acid
inﬂuenced SF-12 mental status (FDR = 2.55%; p = 0.02).DiscussionSummary
Clinical effectiveness
FoLATED shows that routinely adding 5mg of folic acid to ADM has no clinical beneﬁt. This ﬁnding is very
consistent across outcome measures and time points. The one exception is the MCS of the SF-12, which
shows a statistically signiﬁcant difference favouring placebo, especially at 12 weeks. However there were
no signiﬁcant differences in reported side effects or (serious) AEs between groups.Cost-effectiveness
No economic criterion was signiﬁcant: folic acid saved only £48 per patient; folic acid gained only three
EQ-5D-adjusted days per patient, while EQ-VAS showed a very small loss. We conclude that folic acid
is not cost-effective.Biochemistry
Folic acid was effective in increasing participants’ folate. However biochemical variables predicted only one
of the eight chosen clinical outcomes.Genetics
FolATED identiﬁed only two polymorphisms within genes of the one-carbon folate pathway associated
with clinical outcome regardless of treatment, and one such polymorphism associated with the outcome
of folic acid. However these polymorphisms could not replicate these associations with any other outcome
measure, including the primary outcome. Furthermore one polymorphism associated with depression in
previous studies did not modify the effect of either antidepressant therapy or folic acid supplementation.
We judge this consistent with the trial ﬁnding that folic acid does not inﬂuence the treatment of
depression. In future a whole-genome approach to the FolATED data could identify markers of efﬁcacy
beyond those already analysed.Strengths and limitations of FolATED
FolATED is by far the largest trial to evaluate folic acid in augmenting ADM. We powered it to detect a
clinically small difference between treatment groups, and followed rigorous procedures for randomisation
and blinding. We recruited a wide range of patients treated for moderate or severe depression in primary
or secondary care. There were few exclusion criteria, and our sample included comorbidities like substance
misuse, often excluded from less pragmatic trials.
Of our sample 36% achieved ‘response to treatment’, namely 50% reduction in BDI-II baseline score;
27% achieved ‘remission’ at 6 months, namely BDI-II score less than 13; and ADM reduced depressive
symptoms markedly over the ﬁrst few weeks, then more slowly until 6 months. All these ﬁndings were
expected from a study mixing new and continuing treatment episodes. Hence the lack of any effect of
folic acid is not attributable to unusual treatment resistance to antidepressants in our sample. In short
FolATED was both robust and representative.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Clinical effectiveness
Our negative outcomes contrast with positive ﬁndings in smaller trials. For example Coppen and Bailey
reported a signiﬁcantly greater reduction in Hamilton Depression Rating Scale (HDRS) scores with
ﬂuoxetine and 400mg of folic acid than with ﬂuoxetine and placebo, but only in females (Coppen A,
Bailey J. Enhancement of the antidepressant action of ﬂuoxetine by folic acid: randomised, placebo
controlled trial. J Affect Disord 2000;60:121–30.). However their sample was much less representative
than that recruited by FolATED. Furthermore, while FolATED took care at all stages to avoid unblinding
researchers, Coppen and Bailey seemed less rigorous, especially in handling blood results.Biochemical interpretation
Folate is a naturally occurring B vitamin, needed in the brain to synthesise serotonin, noradrenaline and
dopamine. In humans the biologically active form is methylfolate – derived from ingested folates, taken up
by cells and transported to the cerebrospinal ﬂuid (CSF) via folate receptors. Folic acid is an inactive form
of folate not naturally found in the human body, which needs transformation to methylfolate. There is
evidence that commercial preparations of folic acid can compete with methylfolate for folate receptors,
thus exacerbating folate deﬁciency in the central nervous system (CNS). Hence our ﬁnding that folic acid
had a statistically signiﬁcant negative effect on the widely used SF-12 MCS may reﬂect folate deﬁciency
rather than type 1 error.
Thus better understanding of the one-carbon folate pathway has raised questions about the most
appropriate formulation of folate to use for folate deﬁciency. Stahl argues that methylfolate is
therapeutically better than folic acid as it does not need transformation, which may be difﬁcult for some
patients (Stahl SM. Novel therapeutics for depression: L-methylfolate as a trimonamine modulator and
antidepressant-augmenting agent. CNS Spectr 2007;12:739–44). Furthermore high doses of inactive folic
acid may compete with methylfolate for transport across the blood–brain barrier.
Against this biomedical background our rigorous and powerful trial has established that folic acid has no
general role as adjunct in antidepressant therapy. However studies in patients with cardiovascular disease
have shown that higher doses of folic acid produce greater concentrations of methylfolate in plasma.
Moreover the reductions in homocysteine in participants on folic acid relative to those on placebo suggests
that they were successfully metabolising folic acid to methylfolate. Nevertheless we suspect that the
beneﬁcial increase in methylfolate was masked by excess folic acid that competed for the folate receptors
and led to negative results. Before we dismiss all folates, however, we recommend an updated systematic
review and meta-analysis, ideally at patient level, of the many trials of folate augmentation.
At the time of our initial proposal little information was available on the use of methylfolate in patients
with depression. Now there is evidence that methylfolate given as adjunct or monotherapy reduces
depressive symptoms in patients with low folate levels or alcoholism, and improves cognitive function and
depressive symptoms in elderly patients with dementia and folate deﬁciency. Furthermore there are
long-standing concerns that folate may increase cancer risk, mask B12 deﬁciency and exacerbate depressive
symptoms. As methylfolate may reduce some of these risks, it may now be a candidate for a large
multi-centre trial. In that context we offer the design of FolATED as a proven model. In hindsight, however,
we judge that a trial recruiting for 1 year in 10 centres would yield better value for money than one
recruiting for 3 years in three centres.Conclusions
This rigorous and powerful trial has established that folic acid is not an effective adjunct to
antidepressant therapy.xxvii
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SCIENTIFIC SUMMARY
xxviiiThe NIHR commissioned FolATED at a time when there was considerable scientiﬁc interest in the role of
folate in causing and treating depression. Since then this interest has grown, with increasing international
pressure to use folate as an adjunct to antidepressants and in algorithms for treating depression.
The unequivocally negative ﬁndings of FolATED demand reappraisal of this consensus and associated
treatment guidelines.
There is a strong case for appraising whether future trials of methylfolate would yield value for money.Trial registration
This trial is registered as ISRCTN37558856.Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Prevalence of depression
Depression is one of the main mental health disorders presenting in primary care.1 The prevalence of major
depression in the general population ranges from 3% to 10% with more than 150 million people at a
time suffering from depression across the world.2 In the UK prevalence of depression in 2009–10 was
11% in England, 11.5% in Northern Ireland, 8.6% in Scotland, and 7.9% in Wales.3 Unipolar depression
leads to 12.15% of years lived with disability, and is ranked as the third leading contributor to the global
burden of diseases.2 Indeed depression is currently the second cause of disability worldwide for males and
females between the ages of 15 and 44 years and is predicted to reach second place for all ages by 2020.4
Depression has become the leading cause of disability in Europe, leading to a loss of one in every
10 healthy years of life, and the leading cause of early retirement.5 Depression and stress are now the
commonest reported causes for sickness absence from work in the UK6 with over 100 million working days
lost across Europe at a cost of 1% Gross Domestic Product (GDP).7 A higher prevalence of depression is
observed in women than men across the 18- to 64-year age range with women up to 2.5 times more
likely to develop depression.8Characteristics of depression
The core symptoms of depression are low mood and loss of interest or enjoyment in usually pleasurable
activities. Associated symptoms include disturbances to sleep and appetite, reduced energy and
concentration, negative thoughts of guilt or worthlessness and suicidal ideation. The International Statistical
Classification of Diseases & Related Health Problems (ICD-10) states that for a diagnosis of depression at
least ﬁve symptoms need to be present, including at least one of the core symptoms, at an intensity that
causes functional impairment and for a minimum duration of 2 weeks. Depression is classiﬁed as mild,
moderate or severe according to the number of symptoms present and degree of functional impairment,
and the grading of severity is of direct relevance to the treatment approaches recommended.9 Depression is
associated with increased mortality linked to suicide, alcohol and drug misuse, and increased rates of
cardiovascular disease.10 Depression thus burdens individuals, families, the NHS, and the national
economy.11 One UK study estimated the total cost of depression to the UK in 2000 at £9 billion; at that
time, before the introduction of Improving Access to Psychological Therapies (also known as IAPT) in NHS
England, the direct cost of treatment, mainly antidepressant medication (ADM), was £370 million; and
indirect costs of 110 million working days lost to depression accounted for the vast majority of the total
cost.12 The sub-optimal treatment of depressive disorders is therefore of great public health concern.Treatments for depression
In accordance with the joint report of the World Health Organization (WHO) and World Organization of
National Colleges & Associations of Family Doctors (WONCA)1 and the National Institute for Health and
Care Excellence (NICE) guidance9 the majority of people with depression are identiﬁed, treated and
managed within primary care. Treatment aims to relieve symptoms, restore functioning and, in the long
term, prevent relapse. The goal of treatment is complete remission which is associated with better
functioning and reduced risk of relapse.13 While there is some evidence that people with depressive
symptoms improve over time without treatment,14,15 a signiﬁcant proportion follow a chronic course with
signiﬁcant levels of depressive symptoms and functional continuing for several years.16,17
Antidepressants are recommended as a treatment option for moderate to severe depression either in
combination with psychotherapy9 or as monotherapy.18 Owing to their greater tolerability selective
serotonin reuptake inhibitors (SSRIs) are recommended as ﬁrst-line treatment in primary care.9 Patients
treated with an SSRI are seven times more likely to complete a therapeutic course than those treated with1
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INTRODUCTION
2tricyclic antidepressants (TCAs).19 In clinical trials of antidepressants typically 50% of patients with
depression respond to active treatment, while one-third respond to placebo20 with the placebo response
appearing to increase over time in clinical trials.21 With ﬁrst-line treatments about one-third of patients
achieve remission from depression, increasing to two-thirds with reﬁnement of treatment.22 A study of
mental disorders in 14 centres worldwide found that 50% of patients continued to have a diagnosis of
depression after 1 year23 with at least 10% having persistent or chronic depression.24 Furthermore, at least
50% of people will go on to have at least one further episode of depression following their ﬁrst episode of
major depression.25 The risk of further recurrences after second and third episodes rises to 70% and 90%
respectively.25 Cumulative rates of recurrence remain linear over long periods of follow-up (30–40 years),
indicating a constant risk of recurrence over the lifespan.26 Therefore recurrence rates increase with length
of follow-up, and for the majority of patients depression is a recurrent condition.
Depression is a prevalent global health problem resulting in high levels of disability. While effective
treatments are available outcomes remain sub-optimal with a signiﬁcant proportion of patients failing to
achieve remission and experiencing chronic illness, early relapse and multiple recurrences across the
lifespan. There remains a pressing need for research to optimise outcomes from antidepressant treatment.Review of the literature
Depression and folate
Over recent years there has been a growing interest and an increasing body of evidence exploring the
relationship between B vitamins, in particular folate, and depression.27–30 Folate is a naturally occurring
B vitamin and can be found in leafy green vegetables, fruits, dried beans and peas.31 Folic acid is the
synthetic form of folate, which is inexpensive and found in supplements and fortiﬁed food.31,32
There is evidence to suggest that low folate intake is associated with symptoms of depression.33–36 Studies
report that up to one-third of patients with depressive illness have decreased serum and red cell folate
levels.37 Many people with depression have lower concentrations of folate than people with other
psychiatric disorders or no psychiatric disorder.34,38,39 Associations between folate deﬁciency and depressive
symptoms, symptom severity and treatment outcomes in adults and the older adult population have been
reported.38,40–44 Low folate intake may also increase the risk of recurrent depression33 and depression in
later life.43 Gilbody and colleagues conducted a systematic review of observational epidemiological studies
investigating the relationship between low folate status and depression.45 They concluded that low folate
status was associated with depression but could not conclude that that was a causal relationship. Though
low folate may result from poor nutrition or socio-economic disadvantage, confounders are common in
chronic mental illness. Other recent evidence suggests that low folate may be a consequence rather than
a cause of depressive symptoms.46 While there is weak evidence that increased folate intake may prevent
depressive symptoms,35,47 this is not a consistent ﬁnding.48 In one randomised controlled trial (RCT), for
example, giving folate (2 mg) with vitamins B12 and B6 did not reduce severity of depressive symptoms.49The role of homocysteine
Folate is absorbed and transported in the blood in the form of 5-methyltetrahydrofolate (5-MTHF)50 and is
measured in the blood as either serum folate or red cell folate.50
Homocysteine is a highly sensitive marker of folate status51 and functional folate deﬁciency is indicated
by elevated homocysteine. Tiemeier et al. found a signiﬁcant relationship between depression and
hyperhomocysteinemia, folate and B12 deﬁciency.52 Observational studies indicate that patients with
depression have increased plasma total homocysteine concentrations.53,54 A recent meta-analysis showed
that older adults with a high total homocysteine concentration have an increased risk of depression
[odds ratio (OR) = 1.70; 95% conﬁdence interval (CI) from 1.38 to 2.08].55NIHR Journals Library www.journalslibrary.nihr.ac.uk
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can be used therapeutically. For people who are deﬁcient in vitamin B12, exposure to high levels of folate
can result in subacute combined degeneration of the spinal cord, which may be linked to impaired
methionine biosynthesis.56 As methylmalonyl CoA mutase, a vitamin B12-dependent enzyme, converts
methylmalonyl-CoA to succinyl-CoA, blood methylmalonic acid (MMA) levels increase with suboptimal B12
status. The cross-sectional study of > 10,000 participants in the US National Health and Nutrition
Examination Survey (NHANES) observed a novel relationship between MMA and folate:57 in patients with
low B12 (< 148 pmol/l ≈ 200 ng/l) MMA increased signiﬁcantly with increasing serum folate. This ﬁnding is
due, either to adverse oxidative effects of unmetabolised folic acid on B12 homeostasis, or inability of
patients with low B12 to retain intracellular folate.58Antidepressant treatment and folate
Folate is an essential cofactor for the biosynthesis of both serotonin (5-hydroxytryptamine or 5-HT) and
noradrenaline. Thus folate deﬁciency leads to impaired serotonin synthesis in the human brain.59 This may
provide a theoretical model for claims that folate can play a role in the treatment and prevention of
depression.60 Virtually all antidepressants are thought to act by prolonging the activity of serotonin or
noradrenaline in neurotransmission or by modulating monoamine receptor sensitivity.61 Lower folate levels
have been associated with poorer antidepressant response.62 Further evidence suggests that baseline levels
of folate within the normal range predict antidepressant response.63
This raises the possibility of folate being used to augment antidepressants. Initial small feasibility studies
seemed to conﬁrm the potential of this augmentation strategy.32 A Cochrane review and meta-analysis50,64
explored the role of folate augmentation in depression. Only two RCTs were identiﬁed (combined n = 151),
both of which suggest possible beneﬁcial effects of folate augmentation.65,66 Two further small trials have
given contradictory results. One study, 67 with a clinical sample of 42 patients with major depressive disorder,
reported that 10 mg of escitalopram (Cipralex®, Lundbeck) alone produced greater improvement than the
combination of escitalopram and folic acid (2.5 mg/day). The other study, 68 with a clinical sample of 27,
reported a greater reduction in depressive symptoms when 20 mg of ﬂuoxetine (non-proprietary) was
augmented with folic acid (10mg/day) than when augmented with placebo. However, emerging evidence
within an older depressed population suggests there may be no beneﬁt from folate augmentation of
antidepressants.69 Despite this negative ﬁnding in the elderly there is still interest in a potential augmentation
role for the B vitamins in general, with the currently recruiting B-VITAGE trial exploring B vitamin
supplementation in later life.70 These data convey mixed messages about the use of folic acid to improve
ADM. To advance this debate about the clinical effectiveness of folic acid, we plan to update the Cochrane
systematic review to include this and other recently reported studies of augmentation by folic acid.50Folate, depression and genetics
There has recently been much research aimed at identifying genetic aspects of depression and
antidepressant therapy. Indeed, a number of large genome-wide association studies, and some subsequent
meta-analyses, have identiﬁed genetic polymorphisms associated with both risk of depression71–73 and
response to antidepressant therapy.74,75 However, these studies have been unable to demonstrate
consistent and reproducible genetic associations.
Only a few studies have described an association between risk of depression and genetic variation of
genes of the one-carbon folate and methionine biosynthesis pathways. Most have focused on, and
identiﬁed, an association with depression and the frequently characterised c.677C > T polymorphism
(rs1801133) of the methyltetrahydrofolate reductase (MTR) gene.76,77 This variant encodes a valine to
alanine amino acid substitution at residue 222. The variant protein has reduced catalytic activity and
thermolability and is associated with elevated homocysteine levels under conditions of impaired folate
status. Others, in addition to MTR c.677C > T, have also described the p.D919G variant (rs1805087) of the
MTR gene as a statistically signiﬁcant risk factor for moderate and severe depression in postmenopausal
women.78 The MTR gene encodes the protein methyltetrahydrofolate reductase, which is a key enzyme in
the biosynthesis of homocysteine to methionine.3
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INTRODUCTION
4Furthermore, it has recently been reported that the MTR c.677C > T polymorphism modiﬁes the protective
effect of folic acid against depression after pregnancy.79 Others have demonstrated an association
between c.677C > T and folate and homocysteine concentrations.80 These observations further support the
hypothesis that genetic variation in the one-carbon folate pathway may affect folic acid efﬁcacy as an
adjuvant to antidepressant therapy by altering folate bioavailability and increasing homocysteine levels.SummaryDepression is a prevalent and debilitating mental health disorder. It often follows a chronic or recurrent
course across the lifespan. Antidepressants are the recommended treatment for moderate to severe
depression. Only half of people will respond to ﬁrst-line treatment, and only one-third will achieve
remission. Further research is needed to investigate ways of augmenting antidepressants to boost
treatment response and rates of remission.
Evidence suggests that folic acid may be a useful adjunct to antidepressant treatment for four reasons:
1. Patients with depression often have a functional folate deﬁciency.
2. The severity of deﬁciency, indicated by elevated homocysteine, correlates with depression severity.
3. Low folate is associated with poor antidepressant response.
4. Folate is required for the synthesis of neurotransmitters in the pathogenesis and treatment
of depression.ObjectivesThe Cochrane review by Taylor and colleagues concluded that adequately powered randomised trials were
needed to investigate the therapeutic potential of folate augmentation of antidepressants.50 The National
Institute of Health Research Health Technology Assessment (NIHR HTA) programme commissioned
FolATED to address this gap in the literature.
The main objectives of FolATED were to assess the clinical effectiveness and cost-effectiveness of adding
folic acid to the antidepressant treatment of moderate to severe depression. Our secondary objectives were
to explore whether baseline folate and homocysteine predict response to treatment, and investigate
whether response to treatment depends on genetic polymorphisms related to folate metabolism.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18480 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 48Chapter 2 MethodsTrial designFolATED was a three-centre, double-blind and placebo-controlled, but otherwise pragmatic, randomised
trial of folic acid augmentation of antidepressant treatment for people with moderate to severe
depression. Participants were allocated to folic acid or matching placebo in equal proportions. Assessment
took place at weeks –2 (to screen for eligibility and initiate ADM if needed); –1 (to check by telephone for
tolerability of antidepressants); 0 (baseline – to randomise to folate or placebo); and 4, 12 and 25 weeks
(to assess outcomes). Figure 1 shows the ﬂow diagram for the trial.81,82Participants
Settings
We recruited participants from primary and secondary care at three centres across Wales between July 2007
and November 2010. The sites were North East Wales, North West Wales and Swansea; and covered a
population of about 1.35 million people in 2009.83 We screened potential participants referred by their
primary or secondary care clinicians or themselves for eligibility – in a variety of settings including general
practice, secondary mental health services, research clinics, and patients’ homes.Informed consent
All potential participants received a copy of the information sheet and consent form (see Appendix 1) from
their referring clinician or the research team at least 24 hours before screening to ensure they had time to
consider the study. Trial psychiatrists or screening nurses checked that eligible patients fully understood the
study and gave them the opportunity to ask questions. To all potential participants we stressed that taking
part in the study was voluntary and that their clinical care would not change if they did not want to take
part in the trial.Inclusion and exclusion criteria
Trial psychiatrists could assess eligibility of any potential participant. For self-referred participants registered
mental health nurses liaising with a trial psychiatrist could also assess eligibility.
Potential participants were eligible to take part in the trial if they met all these criteria:
1. presenting with moderate to severe depressive symptoms conﬁrmed by a trial psychiatrist during the
screening interview and reporting a score of at least 19 on the Beck Depression Inventory version 2
(BDI-II) at screening, and at least 17 at baseline84
2. being treated with ADM, or about to commence ADM treatment
3. aged at least 18 years
4. able to give informed consent, and
5. able to complete the research assessments.
We excluded potential participants from the trial if they:
a. were folate deﬁcient
b. were B12 deﬁcient
c. had taken supplements containing folic acid within 2 months
d. suffered from psychosis
e. suffered from bipolar disorder
f. were participating in other clinical research5
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FIGURE 1 Flow diagram of the trial.
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h. were taking anticonvulsants
i. had a serious, advanced or terminal illness with a life expectancy of less than 1 year
j. had recently started treatment for a medical condition that had not yet been stabilised, or
k. had a diagnosis of, or treatment for, any malignant disease or related condition like
intestinal polyposis.Sample size
We originally powered FolATED to detect a difference between the two treatment groups of three points
on the BDI-II at 25 weeks, judging that a clinically important difference. As we estimated the standard
deviation (SD) of BDI-II scores in the trial population at 10.7, our protocol proposed a completed sample
size of 400 at 25 weeks to yield 80% power to detect this difference using a signiﬁcance level of 5%.
As interim analysis of baseline BDI-II scores showed that their SD was about 10, we revised the target
completed sample size to 358 at 25 weeks. The original protocol allowed 10% loss at each of the three
follow-up assessments, thus requiring to randomise 549 to achieve 400 completers at 25 weeks. As
interim analysis also showed that retention at 25 weeks was 79% rather than the 73% expected, the new
target of 358 completers needed a randomised sample of 453.Randomisation
At screening the screener took a blood sample to assess B12 and folate status, and arranged a further
appointment within 14 days to conﬁrm the B12 and folate results. We excluded participants who were B12
or folate deﬁcient from the main trial but offered them the opportunity to continue in the ‘comprehensive
cohort’ of recruited patients.
Eligible participants completed the baseline assessments and the recruiting centre telephoned the
randomisation centre at NWORTH, Bangor University. NWORTH used dynamic allocation to protect
against subversion while ensuring that each arm of the trial was balanced for the stratiﬁcation variables.
For each participant the adaptive algorithm recalculated the likelihood of their allocation between
treatment groups from the distribution of stratiﬁcation variables among participants already recruited and
allocated. This process keeps the balance between strata within acceptable limits of the target allocation
ratio of 1 : 1 while maintaining unpredictability.85 The selected stratiﬁcation variables were:
1. centre (North East Wales, North West Wales or Swansea)
2. sex (male or female)
3. timing of ADM (new or continuing)
4. type of ADM (SSRI or other)
5. whether participant had received counselling for depression (ever or never).Intervention
By the time participants entered the trial, we ensured they were receiving antidepressant treatment
optimised to therapeutic dosages – equivalent to SSRI of at least 20 mg per day or TCA of at least 150 mg
per day. Most had received an antidepressant prescription from their general practitioner (GP) before
referral to the trial. For patients not on ADM, trial psychiatrists initiated ADM to meet clinical need and
patient preference in accordance with routine practice. For patients on sub-therapeutic ADM, trial
psychiatrists optimised the treatment regime according to the British National Formulary (BNF),86 namely
citalopram dose of at least 20 mg per day or equivalent. For participants who had been receiving a
therapeutic dose of ADM, we encouraged trial psychiatrists to optimise dose according to the BNF, for
example by increasing citalopram dosage to 40mg per day, or change the antidepressant, again
depending on clinical need and patient preference.
Participants received a 12-week supply of either 5 mg folic acid or placebo in addition to their ADM.
We selected the 5-mg dose of folic acid because that is effective for other indications,87 carries a low risk
of adverse events (AEs), and is routinely used to treat folate deﬁciency.317
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8Bilcare (formerly DHP Ltd) supplied the trial drugs and achieved the blinding needed by the trial by the
process of over-encapsulation. They placed each tablet inside a size ‘1’ opaque hard gelatin capsule and
added lactose BP, an ingredient of the tablet, to ﬁll the capsule. To produce placebo for the trial they
ﬁlled the same capsules with lactose. They packed capsules into high-density polyethylene bottles with
tamper-evident child-resistant screw caps. They tested to conﬁrm that the over-encapsulated tablet
complied with the British Pharmacopoeia88 standard for disintegration in vitro. They also checked each
batch for the presence or absence of 5mg folic acid.Blinding
The North Wales Organisation for Randomised Trials in Health coded the identically packaged folic acid
and placebo randomly for each stratiﬁcation group. Each patient’s prescription indicated his or her trial
number and package serial number generated by NWORTH, thus determining the appropriate trial
package. NWORTH and the local pharmacies held the key to the randomisation codes. The telephone
numbers of those pharmacies were available to break codes in emergency.
This ensured that throughout recruitment treatment allocations were unknown to participants, healthcare
professionals, investigators, and researchers. We broke randomisation codes for two participants. One was
diagnosed with lower oesophageal cancer, and the other collapsed with agitation, breathing difﬁculty,
raised pulse, and reduced consciousness. On both occasions the local pharmacist revealed the code from
a scratch card. This ensured that we revealed only the individual allocation, only to those who needed
to know.
An independent GP monitored blood results, notably to check for B12 and folate deﬁciency at follow-up.
To avoid accidental unblinding researchers engaged in clinical data collection or analysis did not have
access to these blood results. Furthermore we separated pharmacogenetic and biochemistry analysis from
clinical effectiveness analysis, and combined these results only when analyses were complete. Formal
unblinding of the randomisation codes took place at the joint ﬁnal meeting of the Trial Steering
Committee (TSC) and the Data Monitoring and Ethics Committee (DMEC) on 10 October 2011.Data collection
We collected data at screening, baseline and randomisation, and 4, 12 and 25 weeks after randomisation,
using the trial case report forms (CRFs). Though we aimed to collect the data on the day due, this was not
always possible. Hence there was a window for each data collection (Table 1).
We designed some questionnaires for completion by researchers or clinicians, and others by participants.
The preferred mode was face to face. When that was not possible, we permitted completion over the
telephone and mailed the questionnaire to the participant in advance.TABLE 1 Permissible windows for data collection
Data collection
Due date
(days since randomisation) Window
Screening for eligibility –14 days ± 10 days
Randomisation 0 Origin
4-week follow-up 28 days + 14 days
12-week follow-up 84 days ± 14 days
25-week follow-up 175 days ± 28 days
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The main outcome measure was self-rated symptom severity as measured by the Beck Depression Inventory
version 2 (BDI-II).84 The BDI-II consists of 21 items, each rated on a four-point scale ranging from 0 to 3;
a total score of 1–13 indicates no depression, 14–18 mild depression, 19–28 moderate depression, and
29–63 severe depression. As BDI-II scores at 25 weeks are useful in assessing participants’ medium-term
recovery, that was the basis of our original power calculation (see Sample size, above). When updating that
calculation, we also designated the primary outcome as the area under the curve (‘AUC’ for short) of mean
BDI-II scores between randomisation and the 25-week follow-up, because this summarises participants’
recovery across the whole of that period.84 Though there was less prior information on AUCs, notably on
clinically important differences, we judged that the combination of well-behaved BDI-II scores and the
mathematically robust trapezium method of estimating AUCs89 would make 358 an appropriate target
sample size (see Sample size, above). In the event we were able to analyse many more than 358 trial
participants. Because the actual follow-up time could vary by up to 4 weeks from the target of 25 weeks
(see Table 1), we converted the area under the curve to a more meaningful ‘AUC average’, which represents
a participant’s BDI-II (or other outcome) score averaged over that participant’s follow-up period.Secondary outcome measures
Symptom severity
Clinicians rated symptom severity using the Montgomery–Åsberg Depression Rating Scale (MADRS) and
the Clinical Global Impression (CGI) of change at baseline and 4, 12 and 25 weeks. The MADRS90 consists
of 10 items each rated on a seven-point scale (0–6), which yield a total score between 0 and 60. The CGI91
comprises three separate clinician-rated items: an ordinal scale of current severity of illness between 1
and 7; an ordinal scale of global improvement since recruitment between 1 and 7; and an efﬁcacy index
ranging from 0.25 to 4.0 derived from a 4 × 4 matrix plotting therapeutic effect against side effects.
Researchers at all centres received training in completing the rated scales (MADRS and CGI) from standard
training videos. To estimate inter-rater reliability, we collated researchers’ ratings of these videos on
several occasions.Health status
Participants reported their mental and physical health by version 2 of the UK 12-item Short Form Health
Survey (SF-12) and their quality of life by the EQ-5D, both at baseline, 4, 12 and 25 weeks. The SF-12 is a
functional measure of quality of life comprising 10 ﬁve-point items and two three-point items.92 Using
scoring algorithms designed to achieve standardisation to a mean of 50 and a SD of 10 in the 1998 general
US population, these items yield separate physical and mental component scores (PCS-12 and MCS-12).
Though we used EQ-5D as a secondary measure of clinical effectiveness, its main purpose was to measure
health utility for economic analysis.93Proportion of participants with moderate depression
Though we adopted the standard deﬁnition of moderate depression as a BDI-II score of 19 or more, we
estimated the proportion of participants with moderate depression by statistical inference from the observed
distribution of BDI-II scores. This technique is more robust to random variation than mere counting.Adverse events and side effects
Though we asked centres to report all AEs, we focused on serious adverse events (SAEs) including
inpatient admissions, attempted or completed suicide, and other mortality. We asked centre principal
investigators to assess whether folic acid could possibly have caused each SAE, and whether it was an
expected consequence. The chief investigators reviewed these data blind to the random allocations.
We assessed side effects through the UKU side effects scale,94 which sums scores on 48 distinct side
effects – 10 ‘psychic’, 8 ‘neurologic’, 11 ‘autonomic’ and 19 other – and adds two global items.9
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10It rates each item on a four-point scale ranging from 0 to 3, yielding system-speciﬁc scores out of 30, 24,
33 and 57, two global scores out of three, and a total score out of 150.Adherence to the trial drug
We assessed adherence to the trial medication from dispensing records; returned tablet count at 12 weeks;
folate and homocysteine levels at 12 weeks; and the Morisky Questionnaire95 administered only at
12 weeks. This instrument asks four binary questions about adherence, and reports the number of positive
responses as a score between 0 and 4.Folate status and B12 status
We measured red cell folate at baseline; and serum folate, homocysteine and B12 from blood samples
collected at baseline, 12 and 25 weeks. We sent all of those samples to local NHS laboratories on the day of
collection. For homocysteine analysis we centrifuged venous blood within 30 minutes of collection and stored
the plasma at –20 °C until analysis. We assayed all samples from individual participants in the same batch to
minimise the effect of inter-batch variation. We measured plasma total homocysteine using a one-step
immunoassay following reduction with dithiothreitol, commercially available from the Abbott Diagnostics
ARCHITECT system. The average intra-batch coefﬁcient of variation (CV) for homocysteine was less than 3%.Suicidality
We rated suicidality by Section C of the Mini International Neuropsychiatric Interview (MINI)96 at baseline
and 4, 12 and 25 weeks. Summing the scores allocated to ‘yes’ responses yields a total score between 0
and 33, which the MINI criteria categorise into low risk (0–5), moderate risk (6–9) or high risk (≥ 10).Other data
We collected basic demographic information for each participant including sex, age, ethnicity, employment
status, marital status and number of dependent children. We also recorded smoking and alcohol
consumption, which are known to affect homocysteine levels.Follow-up
Thus we thoroughly assessed participants at 4, 12 and 25 weeks after randomisation. Antidepressants
show a delayed and variable onset of clinical improvements in depression.97–99 Previous trials suggest that
50% of those who eventually respond to ADM start to respond within 2 weeks, 75% within 4 weeks, and
almost all within 6 weeks.100 Hence we scheduled the ﬁrst assessment at week 4, 6 weeks after the start
or optimisation of antidepressant treatment. Non-response at 4 weeks may lead to changes in the ADM in
accordance with the BNF and NICE guidelines. Hence the second assessment at 12 weeks could measure
both continuing and late responses to ADM and folate augmentation. The third assessment at
25 weeks addressed any changes in effectiveness after the end of folic acid therapy, but during ADM,
since that is the minimum duration of maintenance antidepressant treatment.18Quality assurance
The conduct of this trial followed the principles of good clinical practice (GCP) outlined by the ICH-GCP
and complied with EU directive 2001/20/EC.101 The research also adhered to the Medical Research Council
(MRC) guidelines for clinical trials102–104 and the Research Governance Frameworks for England and
Wales.105–107 In particular we anonymised all research data and stored them securely. All research team
members received general training in GCP and trial-speciﬁc training in the protocol, recruiting participants,
taking blood, completing CRFs, conducting assessments, and reporting AEs. We also developed a
ﬁeldworker’s manual to maintain consistency between sites.Independent Trial monitoring
We established a TSC and a DMEC to oversee FolATED through biannual meetings or telephone
conferences. The TSC comprised an independent chair, three independent members, and ﬁve members of
the FolATED trial management team. The DMEC comprised an independent chair and two independent
members, with the trial statistician in attendance (see Appendix 2).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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The Multicentre Research Ethics Committee (MREC) for Wales gave initial ethical approval on 6 November
2006, and the Medicines and Healthcare products Regulatory Agency (MHRA) issued the Clinical Trial
Authorisation (CTA) on 21 December 2006. Appendix 3 lists the dates of approvals for individual centres.Summary of changes to the project protocol
Appendix 4 lists all substantial changes to the protocol approved by TSC, DMEC, MHRA, MREC, and
primary and secondary care R&D Departments.Statistical methods
Statistical analysis plan
Before starting analysis we developed our analysis plan for approval by the DMEC (see Appendix 5).Trial populations
‘Analysed’ population
Randomisation allocated all participants to one of the two treatments. The CONSORT guidelines require
that the main analysis be ‘by treatment allocated’. Ideally, therefore, this population should comprise all
randomised participants. In practice only participants who contributed at least one BDI-II measured after
baseline can usefully contribute. To get the most from their data, we used established methods to impute
their missing data.Complete case population
This population comprises only those participants whose outcome data are complete. It provides a
sensitivity analysis of two issues: whether primary and secondary ﬁndings are sensitive to the absence of
missing data, and the methods we used to impute those missing data.‘Randomised’ population
At ﬁrst sight it is difﬁcult to draw inferences about this population because some contributed no data after
baseline, even on the BDI-II. Because we know the baseline characteristics of all these participants,
however, it is possible to reweight the ‘analysed population’ so that they match the characteristics of the
randomised population, notably allocated treatment, stratifying variables and baseline BDI-II.Imputation of missing data for ‘analysis by treatment allocated’
We excluded participants without follow-up data from the primary analysis ‘by treatment allocated’.
For each variable we summarised missing data by reason (mainly participant withdrew; questionnaire not
returned; page missing; item missing). Where < 10% of data were missing, we treated them as if they
were missing completely at random (MCAR).108 If > 10% of data were missing, we explored the missing
data and tabulated them by the stratiﬁcation variables both as reported at randomisation and as validated
after quality assurance; by participant demographics; and by other important covariates. Rather than
exclude participants missing some data, we chose to impute these data (see Appendix 5).Missing items within a subscale
For missing items within a subscale we took account of methodological publications about the instrument.
To impute missing items we used the principle that, if < 25% of the items within a subscale were missing
for a participant at a time point, one should impute them by the weighted mean of the completed items,
but if > 50% of the items within a subscale were missing for a participant at a time point, one should treat
that subscale as wholly missing and impute it accordingly.11
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12Missing subscales
Where between 25% and 50% of the items within a subscale were missing, we proceeded thus: if < 40%
of the subscales for a participant at a time point were missing, we imputed all missing subscales by a
single application of the general regression model for missing data imputation used in SPSS (Statistical
Product and Service Solutions, SPSS Inc., Chicago, IL, USA),109 taking account of all validated stratiﬁcation
variables. If > 40% of the subscales for a participant at a time point were missing, but < 20% of
participants experienced that problem, we imputed all missing subscales by a single multivariate
imputation across all time points that also took account of all validated stratiﬁcation variables. Fortunately
these rules covered the whole of FolATED.Missing time points
If one of the four time points for a participant was missing, we imputed all subscales within that time
point by ﬁve iterations of the repeated-measures model for missing data imputation used in SPSS using all
other subscales at all time points together with age, gender, centre and group.107Data description and transformation
Initially we summarised data by allocated treatment and centre. Rather than test for statistical differences
between allocated groups at baseline, we adjusted for any imbalance by analysis of covariance. Our
analysis plan assumed that residual variation from our statistical models follows Normal distributions.
This is a robust assumption in the sense that only a substantial deviation would invalidate each analysis.
So we plotted and reviewed residual distributions. As none of these was substantial, we did not need to
transform data to improve consistency with the assumption of Normality. Hence we present all data
as collected.Methods for analysing outcomes
All of our statistical tests were two-sided with a signiﬁcance level of 5%.Continuous outcomes with baseline and more than one follow-up
We used the AUC average, not only to summarise treatment outcome across the whole of the 25 weeks of
data collection, but also to take account of the correlation between successive measurements for the same
participant. We calculated the AUC average by using the trapezium rule89,110 to weight the outcome scores
at baseline and the three actual follow-up points. From the imputed data set we estimated the average
score for each participant over his or her total follow-up period as the area under the EQ-5D utility curve
divided by the duration of follow-up, using the trapezoidal rule speciﬁed by the formula:
Uav ¼ ∑
2
j¼0
ðUjþUjþ1Þ
2
 
 ðtjþ1t jÞ
T
  
ð1Þ
where Uj is the utility attributed to the jth measurement, T is the duration in days of the participant’s study
period, tj is the time in days at which the jth measurement takes place for that participant,111 and
values j = 0, 1, 2 and 3 correspond to the baseline and three subsequent follow-ups respectively. We used
similar formulae to calculate AUC averages for BDI-II, MADRS and SF-12 physical and mental
component scores.
As covariates in these analyses we used the validated stratiﬁcation variables – centre, sex, new or
continuing case, type of antidepressant and previous counselling. For the individual time points, which
contribute to and illustrate the AUC, we used analysis of covariance to adjust for the corresponding
baseline score.Continuous outcome with no baseline and only one follow-up (Morisky scale)
We used analysis of covariance with baseline depression scores and validated stratiﬁcation variables as
covariates, to test whether medication adherence, measured on the Morisky scale, differs signiﬁcantlyNIHR Journals Library www.journalslibrary.nihr.ac.uk
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GPs to the usual covariates.Dichotomous outcomes (serious adverse events and adverse events)
We used logistic regression of (S)AE compared with no (S)AE over each participant’s time in the trial to test
whether the proportion of (S)AEs differs between treatment arms, using baseline scores and validated
stratiﬁcation variables as covariates. We transformed all estimated ﬁxed effects back from their logistic
form and summarised them by OR, standard error, 95% CI, and signiﬁcance level.Covariates to be adjusted within the statistical model
We kept baseline depression scores and validated stratiﬁcation variables as covariates throughout. We also
explored covariates of potential scientiﬁc relevance, including demographic (notably age, ethnicity, marital
status, number of dependants and employment status, coded in accordance with usual demographic
practice) and clinical (e.g. referral source, smoking, alcohol consumption and medication adherence,
measured by both Morisky scale and recorded prescriptions). We ﬁtted and retained these if they showed
evidence of an effect at a signiﬁcance level of 10%.Interactions to be tested
Within each analysis we tested for interaction between treatment and centre, not least because of
substantial differences in psychiatric practice and recruitment policy. On ﬁnding no evidence of interaction
we estimated the treatment effect for each centre. We also tested for interactions between treatment and
signiﬁcant covariates.Deviations from protocol
During the trial there were two protocol deviations that resulted in systematic missing data – one within a
centre at one time point, the other within a single instrument early in the trial. First, early in the trial
13 participants in one centre did not receive appointments for visits at 4 weeks as the centre was under
pressure from a large number of referrals; fortunately preventive action prevented any recurrence. Second,
early in the trial 83 participants completed an incorrect version of the MADRS instrument: 40 at screening;
29 at randomisation; eight at 4 weeks; and six at 12 weeks. As both were administrative errors balanced
between treatment groups, however, sensitivity analysis suggested that neither resulted in systematic bias.
We therefore invoked our standard missing data procedures (see Imputation of missing data for ‘analysis
by treatment allocated’, above).Sensitivity analyses
We applied three main sensitivity analyses – to the BDI-II as primary outcome in the ﬁrst instance, with the
intention of applying them to other outcome measures if the BDI-II proved sensitive to alternative
assumptions. First we used ‘complete case’ analysis to test the sensitivity of ﬁndings to the absence of
missing data; and the methods we used to impute those missing data. Secondly we used multi-level
modelling with the same covariates, also known as repeated measures analysis of variance, to test the
sensitivity of ﬁndings to our choice of AUC as main method of analysis; we estimated parameters for three
ﬁxed factors – the three time points (4, 12 and 25 weeks), centre and treatment group. Finally we
reweighted the ‘analysed population’ to match the characteristics of the ‘randomised population’, and test
the sensitivity of ﬁndings to non-response. To do so, we matched the participants completely lost to
follow-up to participants from the analysed population. First we linked them by allocated treatment, centre
and gender. Then we used a hierarchical cluster analysis to identify the best set of variables to match the
non-responders to members of the responding trial population – age, marital status, reported alcohol
intake, and BDI-II at screening and at baseline. We conducted this procedure both on raw data and on
imputed data.Biochemical analyses
The ﬁrst of our secondary objectives was to explore whether baseline folate and homocysteine predict
response to treatment – the difference between baseline and follow-up. We followed participants at13
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1412 weeks, as they completed the trial medication, and at 25 weeks, the usual endpoint of antidepressant
trials. Though many of our analyses of effectiveness use simple linear regression, this is less well suited to
analyse topics where multicollinearity, that is multiple correlation, plays a major role. Instead we use
repeated measures analysis of variance, which examines all four time points (i.e. baseline and 4, 12 and
25 weeks) simultaneously by ﬁtting all four measures and adjusting for stratiﬁcation variables, baseline
measurements, biochemistry, demography and other covariates.Health economics methods
Introduction
There are no economic evaluations of folic acid in managing depression. If shown to be effective,
however, folic acid could represent a highly cost-effective treatment option. As it costs only 3 pence a day,
the main cost drivers are likely to be hospital admissions, use of health and personal social services, ADM,
and other aspects of care which might change following therapeutic beneﬁt.
The aim of the economic analysis was therefore to assess whether the addition of 5 mg folic acid, once
daily for 12 weeks, in new or existing users of antidepressants, represents a cost-effective use of
healthcare resources. We limited this analysis to trial-generated estimates of costs and beneﬁts, without
modelling wider effects.Perspective
In line with the NICE reference case,112 we adopted the costing perspective of the National Health Service
(NHS) and Personal Social Services (PSS). We estimated all costs in 2009–10 prices.Data sources
Resource use
We derived participants’ use of services from:
1. self-completed questionnaires
2. GPs’ records of prescribed medications, and
3. our register of serious adverse events (SAEs), speciﬁcally for hospital admissions.
We based our resource use questionnaire on that used in the Assessing Health Economics of
Anti-Depressants (AHEAD) trial of the cost-effectiveness of tricyclic antidepressants, selective serotonin
re-uptake inhibitors and lofepramine.113 It comprises four sections, relating to patients’ use of general
practice and generic community nursing services, social services, psychiatric hospital and community
services, and other health services, notably hospital admissions and attendances, including at Emergency
Departments (Table 2). Research professionals completed the questionnaire by asking participants to recall
their use of these services for the 3 months before the baseline visit, and 12 and 25 weeks thereafter.
We sought details of participants’ prescribed medicines, over the 25 weeks they were in the trial, from
their GPs. Two pharmacy technicians compiled a database of prescription data, normally supplied as
printouts or screen dumps, and a pharmacist checked it for accuracy. We also checked data on hospital
admissions, obtained directly from participants, against our SAE register.Unit costs
The costs of the intervention were: folic acid 5 mg – 84 tablets costing £2.67;114 dispensing fee equal to
NHS average of £3.03;115 and serum vitamin B12 testing from the NHS reference costs for biochemistry.116
We derived the unit costs of other resources from standard sources (see Table 2). We took drug costs from
the Prescription Cost Analysis,117 which derives products’ net ingredient costs (i.e. excluding discounts andNIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 2 Average cost of units of healthcare resources
Item Unit Cost Comments and assumptions Reference
General practice and community pharmacy and nursing services
GP consultation Visit £36 11.7 minutes/consultation, including direct care staff
costs and qualiﬁcation costs
119
GP home visit Visit £120 23.4 minutes/visit, including travel, direct care staff
costs and qualiﬁcation costs
119
GP telephone contact Call £22 7.1 minutes/call, including direct care staff costs and
qualiﬁcation costs
119
Practice nurse at
surgery
Visit £12 15.5 minutes/consultation, including qualiﬁcation
costs
119
District nurse at home Visit £27 20 minutes/visit, including qualiﬁcation costs 119
Counsellor at surgery Visit £71 96.6 minutes/consultation 119
Health visitor Visit £37 20 minutes/visit 119
Vitamin B12 test Test £1.29 NHS reference cost code DAP841 116
Pharmacy dispensing
fee
Prescription
item
£3.03 Average NHS cost/item dispensed, assuming all
prescribed items dispensed
115
Social services
Social worker (home
or ofﬁce)
Visit £213 1 hour face-to-face contact 119
Home help Contact £75 3 hours/week of local authority home care 119
Care assistant Contact £214 10 hours/week of local authority community care 119
Day centre Day £36 Based on community care package 119
Psychiatric hospital and community services
Consultant
psychiatrist at hospital
Visit £205 NHS reference cost code PS25B 116
Consultant
psychiatrist at home
Visit £328 Cost/hour of patient contact, including qualiﬁcation
costs
119
Clinical psychologist Visit £81 Cost/hour of client contact 119
Community
psychiatric nurse
Visit £56 Cost/per hour of client contact 119
Other services
Day hospital Day £99 NHS reference cost code DCF41 116
Emergency
Department
Visit £116 NHS reference cost code 180 116
Hospital clinic Visit £199 NHS reference cost code 430 116
Mental health
inpatient stay
Night £302 NHS reference cost code MHIPA2 116
Occupational health
services
Visit £46 Hospital occupational therapist 119
NHS Direct Contact £21.37 Cost/nurse adviser contact 120
Ambulance or
paramedic
Contact £246 NHS reference cost code PS25A 116
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16dispensing costs) from actual NHS expenditure.118 We took the cost of pharmacy dispensing from a report
commissioned by the Department of Health to estimate the cost of providing community pharmacies.115
We retrieved the costs of healthcare professionals’ time from the Unit Costs of Health and Social Care
2010.119 These include salaries and expenses, costs of training and qualiﬁcations, and capital and overhead
costs. We took hospital costs from the NHS reference costs,117 which underpin the calculation of the tariff
for ‘payment by results’ in England.Health outcomes
The primary measure of health outcome for economic analysis was the quality-adjusted life-year (QALY),
estimated from the EQ-5D questionnaire administered at baseline and 4, 12 and 25 weeks. This assesses
health-related quality of life on ﬁve dimensions – mobility, self-care, usual activities, pain-discomfort
and anxiety-depression. The three possible responses on each dimension are ‘no problems’, ‘moderate
problems’ and ‘extreme problems’. We converted participants’ responses into a single, preference-based
utility using on the UK tariff.121
Secondary measures of health outcome for economic analysis included the EQ-VAS, the UK Short Form
Health Survey – 6 Dimensions (SF-6D) and BDI-II, all completed at the same times as the EQ-5D. The
EQ-VAS is a vertical 20-cm visual analogue scale for recording participants’ rating of their current
health-related quality of life. The SF-6D derives an alternative preference-based utility from SF-12 responses
using weights estimated from a sample of the general population by the standard gamble technique.122
For the cost-effectiveness analysis, we calculated the number of weeks free from moderate or severe
depression (deﬁned as a BDI-II score < 13)123 by statistical inference from the observed distribution of BDI-II
scores, assuming linear interpolation between time points (baseline, 4, 12 and 25 weeks).Data analysis
We combined data on costs and outcomes in the ‘treatment allocated’ population (see Statistical methods,
Imputation of missing date for analysis by treatment allocated, Missing items within a subscale, above)
over 25 weeks to estimate an incremental cost-effectiveness ratio (ICER) for comparison against accepted
thresholds. Primary analysis was on the data set in which we had imputed missing data in the manner
described above (see Statistical methods, Trial populations).Analysis of costs
We estimated costs over 25 weeks for each participant by aggregating across resource categories. To draw
inferences from this skewed distribution, we used ‘bootstrapping’, that is resampling with replacement
and re-estimating sample means for each replicate. We used 10,000 replicates, corrected for bias and
skewness by the technique known as ‘bias correction and acceleration’, and generated 95% CIs. We
inferred whether differences in mean costs between treatment and control groups were statistically
signiﬁcant from those bootstrapped CIs.124 To adjust for differences at baseline and in duration of
follow-up, we used the regression model:125
LnðCostiÞ ¼ β0 þ β1gi þ β2lnðCiÞ þ β3T i ð2Þ
where patient i in treatment group gi has a pre-baseline cost of Ci and a time between randomisation and
ﬁnal follow up of Ti and β1 represents the difference in costs after adjusting for imbalance in mean costs
before baseline. We used the logarithmic transformation to address the natural skewness of costs, and
transformed the results of the regression back to recover the differential cost. As there were essentially no
differences in demographic variables between groups, we did not need to adjust for any other variable.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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While the AUC average Uav is the measure analysed in effectiveness tables (see Methods for analysing
outcomes: Continuous outcomes with baseline and more than one follow-up above), economic analysis
uses QALY: the area under the utility curve over the participant’s follow-up period in years. Hence:
QALY ¼ Uav T365
 
ð3Þ
where Uav is the participant’s AUC average utility and T is the duration in days of the participant’s study
period. However, as this period may vary from 21 to 29 weeks, we adjusted QALYs, like costs, for duration
as well as baseline.
To adjust QALYs for differences in baseline utility and duration of follow-up, we used the regression model:126
QALYi ¼ β0 þ β1gi þ β2Bi þ β3T i ð4Þ
where patient i in treatment group gi has baseline utility of Bi [equal to U0 in equation (1) above] and time
between randomisation and ﬁnal follow-up of Ti; and β1 represents the difference in QALYs after adjusting
for imbalance in mean utility at baseline. As again there were essentially no differences in demographic
variables between the two groups, we did not need to adjust for any other variable. We applied the same
procedure to other measures of health outcome.
For all economic measures of health outcome we used 10,000 replicates to generate non-parametric
bootstrapped 95% CIs, again corrected for bias and skewness, for the differences in means between
treatment and control groups.Cost–utility analysis
Comparing two treatments results in one of four scenarios. The intervention ‘dominates’ if it saves costs
and improves health outcomes. The intervention ‘is dominated’ if it increases costs and outcomes
deteriorate. More commonly the intervention improves outcomes at greater cost, or saves costs at the
expense of outcomes. Then one must estimate an incremental cost-effectiveness ratio (ICER) by dividing
the difference in adjusted mean costs (ΔC) by the difference in adjusted mean beneﬁts (ΔB). NICE is more
likely to recommend an intervention for use by the NHS if the ICER falls below the threshold for
cost-effectiveness, which ranges from £20,000 to £30,000 per QALY.112
We used non-parametric bootstrapping to map the joint distribution of costs and outcomes on the
cost-effectiveness plane and generate cost-effectiveness acceptability curves to show the probability that
the intervention was cost-effective across a range of thresholds of cost-effectiveness.Sensitivity analysis
To examine the extent to which the ICERs are sensitive to basic assumptions, we used two alternative
approaches to measuring utility – the EQ-VAS and the SF-6D, and restricted analysis to all participants who
gave complete EQ-5D responses. We used R software111 for all analyses.Genetic methodsOur aim was to test whether genetic polymorphisms affect the efﬁcacy of folic acid in combination with
ADM, with a view to using them as predictive markers of adjuvant folic acid efﬁcacy. There is strong
evidence to suggests that folic acid can play a role in the treatment and prevention of depression.60 It is
the effect of genetic variability on this role that we aim to investigate. This study focuses on variability in
genes encoding proteins and enzymes implicated in the carbon folate and methionine synthesis pathways,17
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18rather on genome-wide analysis.127 We justify this approach by the folic acid intervention in this study and
the weight of evidence to suggest decreased folate is associated with depressive illness.41,77,128
Given the level of complexity of the one-carbon folate pathway,127 the genetic characteristics of FolATED
trial participants span a comprehensive set of folate pathway genes beyond the commonly analysed
methylenetetrahydrofolate reductase (MTHFR) polymorphisms. Similar pathway-wide candidate gene
approaches to genotyping have previously successfully identiﬁed genetic risk factors for several clinical
phenotypes including colorectal,129,130 breast,131 and bladder cancers,132 and cleft lip or palate.133DNA isolation
We extracted genomic DNA from 5ml of whole blood using the Chemagic Magnetic Module (MSM) 1
system according to the manufacturer’s protocol (Chemagen Biopolymer-Technologie AG, Baesweiler,
Germany). We eluted samples in 500 µl of the manufacturer’s elution buffer.Single nucleotide polymorphism selection
We compiled a list of 25 candidate genes127 associated with either the one-carbon folate or methionine
synthesis pathways. We identiﬁed 48 non-synonymous single nucleotide polymorphisms (SNPs) within
these genes from the Single Nucleotide Polymorpism Database [dbSNP;134 www.ncbi.nlm.nih.gov/SNP
(accessed May 2008)] and selected for analysis those with minor allele frequency greater than 5%. We
included a further 100 SNPs from the HapMap (http://hapmap.ncbi.nlm.nih.gov) population of Utah
residents with ancestry from northern and western Europe which, when analysed by Haploview software
version 402 (www.broadinstitute.org/haploview/haploview), tagged at least one other SNP. We added a
19 base pair (bp) deletion polymorphism of intron 1 of the dihydrofolate reductase gene (DHFR) and a
28 base pair double or triple tandem repeat polymorphism of the thymidylate synthase (TYMS) gene
because both have been extensively characterised in clinical studies.127Genotyping
We designed multiplex assays for the MALDI-TOF-based Sequenom iPLEX system (Sequenom Inc.,
San Diego, CA, USA) using the software at https://mysequenom.com/default.aspx. We included 140 SNPs
in ﬁve-assay plexes ranging from 11 to 35 SNPs in size. We excluded ﬁve SNPs which we could not
incorporate in assays because of proximal nucleotide sequence constraints and another three SNPs which
we could not include at a minimum plexing level of > 10 SNPs per assay (see Appendix 6, Table 35).
We genotyped patients for these 140 SNPs according to the manufacturer’s protocol using 40 ng/reaction
genomic DNA. We obtained sequence-speciﬁc polymerase chain reaction (PCR) and extension reaction
oligonucleotides from Metabion GmbH (Martinsried, Germany). Table 36 of Appendix 6 deﬁnes the
corresponding primer and probe sequences.
We typed the 19 bp deletion polymorphism from the dihydrofolate reductase gene (DHFR) and the 28 bp
tandem repeat polymorphism from the thymidylate synthase (TYMS) gene using previously published
protocols and PCR primer sequences21,22 with minor modiﬁcation. Brieﬂy the 25-µl PCR reaction consisted
of 20 ng genomic DNA, 5 pmol each of primer and 18 µl 1.1× ReddyMix™ PCR mastermix (Abgene Ltd,
Epsom, UK).
We resolved all PCR products with ethidium bromide staining on a 3% agarose gel. For the DHFR 19 bp
deletion, a 92 bp product identiﬁed the deletion allele and a 113 bp product identiﬁed the insertion allele.
For the TYMS tandem repeat a 144 bp product distinguished the triple repeat allele from the double
(116 bp).
We undertook all genotyping with 10% of DNA samples duplicated as well as positive and negative
controls to conﬁrm genotype calling accuracy and concordance.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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For this genetic sub-study, the primary outcome was self-rated symptom severity on the Beck Depression
Inventory (BDI-II) at baseline, and 4, 12 and 25 weeks, consistent with the trial’s primary outcome.
Secondary outcomes were:
1. symptom severity rated by clinicians on the MADRS and the CGI of change (also at baseline and 4, 12
and 25 weeks)
2. mental and physical aspects of self-reported health status on the SF-12 (ditto)
3. side effects assessed by the UKU side effects scale and reported AEs (ditto), and
4. proportion of patients with self-rated moderate or severe depression (i.e. BDI-II score ≥ 19) at 25 weeks.Genetics statistical methods
Before the analyses of association, we tested each SNP for Hardy–Weinberg Equilibrium, and excluded
those found to deviate at a signiﬁcance level of 0.1%. We also excluded SNPs which did not meet all our
genotype quality criteria:
a. minor allele frequency greater than 1%
b. genotyping rate greater than 95% per SNP, and
c. samples more than 90% of SNPs called.
We ﬁtted three mixed models to all ﬁve outcomes for each included SNP. The ﬁrst (‘baseline model’)
included the baseline value of the outcome, covariates representing the three time points (4, 12 and
25 weeks), three validated stratifying variables – centre, type of antidepressant, new or continuing
patient – and treatment received, that is whether participants supplemented their medication with folic
acid or not. We also tested non-genetic factors known to be generally associated with outcome (age,
gender, marital status, employment status, number of dependents, smoking and alcohol consumption,
previous counselling and treatment adherence as assessed by the Morisky scale) for univariate association
with each outcome and included them in the model if the signiﬁcance level was less than 10%.
The second (‘SNP’) model was identical to the ﬁrst with the addition of the SNP as covariate. The third
(‘interaction’) model was identical to the second with the addition of interaction between SNP and
treatment received. To test for statistical signiﬁcance of SNP main effects, we used likelihood ratio tests to
compare the speciﬁc SNP model with the baseline model. To test for statistical signiﬁcance of the
SNP-folated interaction, we again used the likelihood ratio test to compare the speciﬁc interaction model
with the speciﬁc SNP model. Each test tried two models – one making no assumption about the
underlying mode of inheritance, the other assuming an additive mode of inheritance – and used the lower
signiﬁcance level for each SNP.
To take account of the multiple comparisons due to four tests on each of more than 100 SNPs, we
estimated the false discovery rate (‘FDR’) for each comparison, and treated FDRs less than 5% as
statistically signiﬁcant associations. We used the statistical software packages: R;111 PLINK version 1.07
from http://pngu.mgh.harvard.edu/~purcell/plink/; and PASW version 18135,136 for these analyses.Systematic review of the effectiveness of folate in augmenting
antidepressant medication
Introduction
At the start of the FolATED trial understanding of the beneﬁts of folate augmentation of ADM stemmed
from a recent Cochrane systematic review.50,64 The authors concluded that there was limited evidence that
adding folate to ADM was helpful, and recommended larger trials to test this hypothesis thoroughly.
That recommendation led directly to the funding of FolATED.19
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20Method
Data sources and study selection
We updated the current Cochrane systematic review50 following analysis of the FolATED trial. The authors
of that review searched the Cochrane Central Register of Controlled Trials and MEDLINE from 1966 until
May 2005. In August 2012 we reran their search for randomised trials evaluating folate in any form to
augment ADM in treating depression. We followed the Cochrane systematic review search strategy in
PubMed until December 2011 but without language restrictions. Consistent with the design of FolATED
we selected randomised trials evaluating folate to augment antidepressants in treating depressive disorder
rather than folate as sole therapy.Data extraction and synthesis
Two of us (BRC and ITR) independently assessed potential trials for eligibility and quality, and extracted
data. The Cochrane systematic review had used the Hamilton Depression Rating Scale (HDRS) as primary
outcome.50 In contrast the FolATED trial used the Beck Depression Index (BDI-II). To compare these
instruments we converted both to standard Normal distributions with a SD of 1 and mean equal to the
trial effect size, namely the mean difference between trial groups divided by trial SD. We gave each trial a
weight inversely proportional to the variance with which it estimated that difference. We used a
random-effects model to estimate the standardised mean difference and associated 95% CI. We assessed
the heterogeneity of ﬁndings by the I2-statistic.137NIHR Journals Library www.journalslibrary.nihr.ac.uk
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randomisations took place in North West Wales in July 2007, in Swansea in August 2007, and in North
East Wales in October 2007. We randomised the ﬁnal participant in November 2010 and completed
follow-up in May 2011.
Figure 2 shows that FolATED received 1488 referrals; screened 863, of whom 635 consented to take part;
randomised 479, of whom four were in error and removed from analysis; and analysed 440 (92% of the
475 valid randomisations). Though the four randomised in error had BDI-II scores of at least 19 at –2 weeks,
these had fallen below 17 at randomisation, so they should have been excluded. The reasons why
625 referred patients did not reach screening were: 44% did not wish to take part; 26% did not respond
to the research team; 16.5% were ineligible; and 13.5% did not attend the screening appointment.
At screening to assess eligibility for the trial, the primary reason for exclusion was that people did not meet
the trial speciﬁed criteria for moderate to severe depression (54%). The other criteria that excluded more
than 5% of those screened were: presence of malignancy or similar disorder (10%); not currently taking
antidepressants (9%); and taking anticonvulsants (7%).
Randomisation interviews took place 2 weeks after screening when blood test results were available to
verify eligibility to enter the trial. Of the 635 people who had consented to take part, we could not
randomise 156: 68 people dropped out between screening and randomisation and a further 42 at the
randomisation interview, of whom 36 scored too low on the BDI-II. Forty-six people entered the
comprehensive cohort and 20 who were eligible to do so declined. Table 3 cross-tabulates reasons for
losses by stage of recruitment and Appendix 7 does so by centre.
Centre differences in recruitment patterns
North West Wales received 47% of the referrals to the trial and randomised 50% of the ﬁnal sample.
North East Wales and Swansea received and randomised very similar proportions of the total – 27% and
26% respectively of referrals received and 25% of the randomised sample each). Table 4 summarises these
ﬂows by centre.
Loss to follow-up
We randomised 475 participants (excluding four randomised in error): 237 to receive folic acid and 238 to
receive placebo. In the folic acid group 15 people withdrew and 26 were lost to follow-up by 25 weeks.
In the placebo group 18 people withdrew and 32 were lost to follow-up by 25 weeks. Table 5 shows the
reasons for loss at each stage.
Participant drop-out and missing data
There were no follow-up data for 35 randomised participants; 18 withdrew before the 4-week follow-up
(8 folic acid group, 10 placebo group) and 17 did not attend any appointments (6 folic acid group,
11 placebo group). Thus 14 dropped out of the folic acid group and 21 out of the placebo group.
We removed these from further analysis. Therefore 440 entered the main analysis, 223 from the folic acid
group and 217 from the placebo group. If these evaluable participants missed follow-up appointments,
we imputed their data in accordance with Chapter 2, Statistical methods, Trial populations, above
(Table 6). However we imputed no baseline measures.21
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Screened for eligibility (n = 863)
Excluded (n = 228)
Not eligible (n = 212)
Declined to participate (n = 16)
Further details in Table 41
Randomised (n = 479)
Allocated to placebo (n = 238)Allocated to folic acid (n = 237)
Week 4 follow-up (n = 217)
Completed (n = 196)
Did not complete and were imputed (n = 21)
Week 4 follow-up (n = 223)
Completed (n = 208)
Did not complete and were imputed (n = 15)
Referred (n = 1488) Not screened (n = 625)
Not eligible (n = 103)
Declined to participate (n = 277)
DNA screening (n = 84)
Unable to contact (n = 161)
Further details in Table 40
Consented (n = 635)
Not randomised (n = 156)
Not eligible (n = 78)
Comprehensive cohort (n = 46)
DNA randomisation (n = 15)
Refused (n = 17)
Further details in Table 42
Randomised in error
[BDI-II < 18 at baseline]
(n = 4)
Week 12 follow-up (n = 223)
Completed (n = 201)
Withdrawn and were imputed (n = 6)
Lost to follow-up and were imputed (n = 11)
Did not compete and were imputed (n = 5)
Week 12 follow-up (n = 217)
Completed (n = 199)
Withdrawn and were imputed (n = 5)
Lost to follow-up and were imputed (n = 10)
Did not complete and were imputed (n = 3)
Week 25 follow-up (n = 223)
Completed (n = 196)
Withdrawn and were imputed (n = 7)
Lost to follow-up and were imputed (n = 20)
Week 25 follow-up (n = 217)
Completed (n = 188)
Withdrawn and were imputed (n = 8)
Lost to follow-up and were imputed (n = 21)
Lost to follow-up
before week 4
(n = 14)
Lost to follow-up
before week 4
(n = 21)
FIGURE 2 ‘CONSORT diagram’ of flow of participants through trial. Note: Hence we included 223 + 217 = 440
participants in primary analysis.
RESULTS
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TABLE 3 Reasons for losses between referral and randomisation by stage
Reason for not randomising
Between referral
and screening Screening Randomisation Total
Pre-speciﬁed exclusion criteria
Are under 18 years 4 0 0 4
Not depressed by ICD – 10 criteria 0 122 36 158
Folate deﬁcient 0 1 15 16
B12 deﬁcient 2 0 8 10
Have taken folate supplementation 14 8 2 24
Suffered from psychosis 3 2 0 5
Bipolar disorder 2 4 0 6
Are already in another research trial 2 0 0 2
Are pregnant or planning to be so 9 0 0 9
Taking anticonvulsants 5 16 1 22
Serious, advanced or terminal illness 0 0 0 0
Treatment for a medical condition not yet stabilised 1 2 0 3
Taking lithium 1 0 0 1
Have had diagnosis of malignant disease 19 22 2 43
Subtotal 62 177 64 303
Other exclusions
Not on antidepressants 36 21 9 66
Other 5 14 5 24
Subtotal 41 35 14 90
Refusal 277 16 17 310
Did not attend appointment 84 0 15 99
Could not contact 161 0 0 161
Subtotal 522 16 32 570
Comprehensive cohort 0 0 46 46
Total 625 228 156 1009
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TABLE 4 Participant ﬂow from referral to randomisation by centre
Reason for not randomising North East Wales North West Wales Swansea Total
Number referred 400 698 390 1488
Trial exclusion criteria 15 31 16 62
Other exclusions 15 17 9 41
Refusal 91 128 58 227
Did not attend 21 29 34 84
Could not contact 26 75 60 161
Number screened 232 418 213 863
Trial exclusion criteria 57 75 45 177
Other exclusions 7 25 3 35
Refusal 4 12 0 16
Other loss 0 0 0 0
Number consented 164 306 165 635
Trial exclusion criteria 6 42 16 64
Other exclusions 1 9 4 14
Refusal 9 4 4 17
Did not attend 3 6 6 15
To comprehensive cohort 24 7 15 46
Number randomised 121 238 120 479
RESULTS
24Of the 440 evaluable participants 36 (8%) missed follow-up at 4 weeks, 40 (9%) at 12 weeks, and
56 (13%) at 25 weeks. Thus 10% of follow-up assessments were missing. Sixty-two participants
missed one assessment: 33 at 4 weeks, 6 at 12 weeks and 23 at 25 weeks. Thirty-ﬁve participants missed
two assessments: 2 at 4 and 12 weeks; 1 at 4 and 25 weeks; and 32 at 12 and 25 weeks. Thus
343 (78%) participants undertook all three assessments.
For the eight main outcome measures (BDI-II, MADRS, CGI, SF-12, EQ-5D, EQ-VAS, MINI and Morisky) a
full data set over the four times would have comprised 102,520 data items. Only 2572 (2.5%) were
missing, of which 2476 (2.4%) items were in missing subscales or times while 96 (0.1%) items were
isolated missing values within otherwise complete subscales. Reassuringly there was no hint of signiﬁcant
differences between trial groups in either respect.
The missing item rate for seven of these measures is fairly consistent: BDI-II, EQ-5D, EQ-VAS, and MINI all
2.3%; MADRS 2.4%; SF-12 3.2% and CGI 3.3%. In contrast the Morisky data had a missing item rate of
10%, not explained by being collected only at 12 weeks. Predictably the pattern of missing data differed
very signiﬁcantly between centres: North West Wales, the best recruiting centre, missed more 4-week data
than other centres, but fewer at 25 weeks. This pattern was due to heavy workload early in the trial when
several 4-week appointments were missed; fortunately routine monitoring recognised and rectiﬁed the
problem. Reassuringly there was no signiﬁcant difference between centres in the proportion followed up.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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TABLE 6 Number of participants with complete and imputed data by time point
Follow-up
Folate (n = 223) Placebo (n = 217)
Completed Imputed Completed Imputed
4 weeks 208 15 196 21
12 weeks 201 22 199 18
25 weeks 196 27 188 29
RESULTS
26Validation of stratification variables
The trial used ﬁve variables to balance allocation between treatment groups during dynamic
randomisation: centre; sex; antidepressant type; whether the participant was new or continuing on
treatment; and whether the participant had ever received counselling for depression. Not surprisingly
given the speed of the recruitment process, data validation identiﬁed a few inconsistencies in these data.
However we found no misclassiﬁcation of centre, sex or counselling, and minimal misclassiﬁcation of
antidepressant type or new patient (Table 7).
Baseline characteristics of participants
Table 8 compares the baseline characteristics of those included in the trial analysis with those excluded for
lack of follow-up data. Those who dropped out were signiﬁcantly younger, less likely to have a current
partner and more likely to exceed safe limits of alcohol consumption, and had a higher mean BDI-II score.
All of these are consistent with these participants having worse depression. However the systematic
exclusion of these 35 (7.4%) consented participants from 475 created little risk of bias since they were
equally distributed across the arms of the trial. Nevertheless this may have removed those who could have
beneﬁted most from the intervention.TABLE 7 Stratiﬁcation variables by group – at randomisation and after validation
Stratiﬁcation variable or category
Recorded at
randomisation, no. (%)
Amended following
validation, no. (%)
Folate Placebo Folate Placebo
Type of antidepressant
SSRI 157 (70) 145 (67) 155 (70) 143 (66)
Other 66 (30) 72 (33) 68 (30) 74 (34)
Previous treatment?
No – new ADM 56 (25) 52 (24) 45 (20) 42 (19)
Yes – continuing ADM 167 (75) 165 (76) 178 (80) 175 (81)
Previous counselling?
Yes 101 (45) 97 (45) No change
No 122 (55) 120 (55)
Gender
Male 79 (35) 81 (37) No change
Female 144 (65) 136 (63)
Centre
North East Wales 57 (26) 53 (24)
North West Wales 110 (49) 113 (52) No change
Swansea 56 (25) 51 (24)
NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 8 Baseline characteristics of participants by whether included in ﬁnal analysis
Characteristic Included (n = 440) Excluded (n = 35) Signiﬁcance test
Age
Range 19–81 20–66
Mean (SD) 45 (13) 39 (14)
Median (IQR) 46 (36 to 54) 40 (26 to 47) U = 6200, p = 0.005
Gender, no. (%)
Male 160 (36) 11 (31) χ2 = 0.34, df = 1, p = 0.56
Female 280 (64) 24 (69)
Ethnicity, no. (%)
White 427 (97) 34 (97) Fisher’s: p = 0.46
Other 5 (1) 1 (3)
Not stated 8 (2) 0 (0)
Marital status, no. (%)
Single 109 (25) 13 (37) χ2 = 7.0, df = 2, p = 0.031
Had a partner 91 (21) 11 (31.5)
Have a partner 240 (54) 11 (31.5)
Number of dependent children, no. (%)
0 269 (61) 22 (63) Fisher’s: p = 1
1 70 (16) 5 (14)
2 61 (14) 5 (14)
3 or more 40 (9) 3 (9)
Employment, no. (%)
Full time employed 121 (28) 11 (31) χ2 = 1.1, df = 2, p = 0.58
Part time or in education 124 (28) 7 (20)
Smoking status, no. (%)
Inactive 195 (44) 17 (49) χ2 = 0.093, df = 2, p = 0.96
Smoker 162 (37) 14 (40)
Non smoker 194 (44) 15 (43)
Ex-smoker 77 (17) 6 (17)
Not stated 7 (2)
Alcohol consumption per week, no. (%)
None 177 (40) 10 (29) χ2 = 7.1, df = 2, p = 0.029
Within safe limita 215 (49) 16 (45)
Above safe limita 48 (11) 9 (26)
Centre, no. (%)
Bangor 223 (51) 15 (43) χ2 = 1.1, df = 2, p = 0.59
Wrexham 110 (25) 9 (26)
Swansea 107 (24) 11 (31)
continued
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TABLE 8 Baseline characteristics of participants by whether included in ﬁnal analysis (continued )
Characteristic Included (n = 440) Excluded (n = 35) Signiﬁcance test
Baseline BDI-II score
Range 17–61 18–57
Mean (SD) 34 (10) 39 (11) t = –2.793, df = 461, p = 0.005
Median (IQR) 33 (26 to 41) 39 (31 to 48)
Missing 10 2
Group allocated
Folate 223 14 χ2 = 1.5, df = 1, p = 0.22
Placebo 217 21
IQR, interquartile range.
a Safe limits: females = 14 units per week; males = 21 units per week.
RESULTS
28Differences between centres at baseline
The management of the FolATED trial included a monthly telephone conference between the three clinical
centres and NWORTH, the coordinating Clinical Trials Unit. These conferences soon identiﬁed substantial
differences between centres, notably in psychiatric practice and recruitment policy. Judging that these
differences would enhance the generalisability of the trial provided the conduct of the research was
consistent across centres, we pursued such consistency, notably by maintaining a rigorous ﬁeldwork
handbook and arranging regular inter-centre training.
Table 9 shows that participants differed signiﬁcantly between centres, notably in:
(a) Mean age Those in North West Wales were on average more than 3 years younger than those in the
other centres.
(b) Numbers of dependent children Half of those in North West Wales had children, but only 30% of
those elsewhere.
(c) Employment status Swansea had many more students, while North East Wales had more unemployed.
(d) Smoking rates Nearly half of those in Swansea smoked, but only 30% of those elsewhere.
However there was no signiﬁcant difference in mean BDI-II scores across centres; or in alcohol
consumption.
Another difference between centres identiﬁed by our monthly management conferences is that one centre
did more to optimise medication than the other two, notably by using reboxetine (Edronax®, Pﬁzer) to
augment basic ADM. Though we plan to analyse the process and outcome of optimisation in detail, we
have conﬁrmed that this reboxetine augmentation did not differ between allocated groups; hence there
was no danger of bias from differential optimisation.Baseline demographic profile
Predictably our randomisation algorithm generated similar treatment groups (Tables 10 and 11).NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 9 Baseline demographic characteristics of trial participants by centre
Characteristic
North East
Wales (n = 110)
North West
Wales (n = 223)
Swansea
(n = 107)
Total
(n = 440)
Age
Range 19–75 19–81 19–75 19–81
Mean (SD) 46 (11) 44 (12) 47 (14) 45 (13)
Gender, no. (%)
Male 30 (27) 90 (40) 40 (37) 160 (36)
Female 80 (73) 133 (60) 67 (63) 280 (64)
Ethnicity, no. (%)
White 107 (97) 220 (99) 100 (94) 427 (97)
Other 1 (1) 2 (1) 2 (2) 5 (1)
Not stated/missing 2 (2) 1 (0) 5 (4) 8 (2)
Marital status, no. (%)
Single 18 (16) 62 (28) 29 (27) 109 (25)
Had a partner 27 (25) 40 (18) 24 (22) 91 (21)
Have a partner 65 (59) 121 (54) 54 (51) 240 (54)
Number of dependent children, no. (%)
0 72 (65) 117 (52) 80 (75) 269 (61)
1 15 (14) 40 (18) 15 (14) 70 (16)
2 18 (16) 37 (17) 6 (5.5) 61 (14)
3 or more 5 (5) 29 (13) 6 (5.5) 40 (9)
Employment status,a no. (%)
Full time employed 38 (35) 59 (26) 24 (22) 121 (28)
Part time or in education 31 (28) 48 (22) 45 (42) 124 (28)
Inactive 41 (37) 116 (52) 38 (36) 195 (44)
Smoking status, no. (%)
Smoker 27 (24) 97 (44) 38 (35) 162 (37)
Non smoker 57 (52) 94 (42) 50 (47) 201 (46)
Ex-smoker 26 (24) 32 (14) 19 (18) 77 (17)
BDI-II
Mean (SD) 33.7 (9.3) 34.3 (9.2) 33.1 (10.8) 33.7 (9.6)
Range 18–61 19–58 17–60 17–61
a Appendix 9 elaborates on this table and describes how we recorded these variables.
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TABLE 10 Baseline demographic characteristics of trial participants by treatment allocated
Characteristic Folate (n = 223) Placebo (n = 217)
Age
Range 19–81 20–75
Mean (SD) 45 (14) 45 (12)
Median (IQR) 47 (35 to 55) 45 (36 to 53)
Gender, no. (%)
Male 79 (35) 81 (37)
Female 144 (65) 136 (63)
Ethnicity, no. (%)
White 215 (97) 212 (98)
Other 5 (2) 0 (0)
Not stated 3 (1) 5 (2)
Marital status, no. (%)
Single 60 (27) 49 (23)
Had a partner 124 (56) 116 (53)
Have a partner 39 (17) 52 (24)
Number of dependent children, no. (%)
0 146 (66) 123 (56)
1 29 (13) 41 (19)
2 27 (12) 34 (16)
3 or more 21 (9) 19 (9)
Employment status, no. (%)
Full time employment 49 (22) 72 (33)
Part time employment or education 69 (31) 55 (25)
Inactive 105 (47) 90 (42)
Smoking status, no. (%)
Smoker 82 (37) 80 (37)
Non smoker 98 (44) 103 (47)
Ex-smoker 43 (19) 34 (16)
Smoking consumption, no. (%)
Non-smoker 141 (63) 137 (63)
Low (≤ 10) 30 (14) 34 (16)
Medium (between 10 and 20) 43 (19) 32 (15)
High (≥ 20) 9 (4) 14 (6)
Alcohol consumption per week, no. (%)
None 86 (39) 82 (38)
Below safe limit 106 (47) 101 (46)
Above safe limit 31 (14) 34 (16)
IQR, interquartile range.
RESULTS
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DOI: 10.3310/hta18480 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 48Baseline clinical profileTABLE 11 Baseline clinical measures and blood results by treatment allocated
Measure or scale Folate (n = 223) Placebo (n = 217)
Symptom severity instruments
BDI-II Range 17 to 60 17 to 61
Mean (SD) 33 (9) 34 (10)
MADRS Range 1 to 50 13 to 53
Mean (SD) 28 (7) 29 (7)
CGI: Severity of illness, no. (%) Normal to mild 3 (1) 0 (0)
Mild to moderate 148 (67) 147 (68)
Moderate to severe 72 (32) 70 (32)
Health status and utility
EQ-5D Range –0.2 to 1.0 –0.3 to 1.0
Mean (SD) 0.48 (0.30) 0.51 (0.30)
EQ-VAS Range 0 to 100 0 to 95
Mean (SD) 45 (20) 44 (20)
SF-12: Physical component scale Range 17 to 69 17 to 71
Mean (SD) 44 (12) 44 (13)
SF-12: Mental component scale Range 4 to 50 –1 to 57
Mean (SD) 26 (9) 26 (10)
Biochemistry
Serum folate level Range 2 to 20 2 to 20
Mean (SD) 7.1 (4.2) 7.2 (4.2)
B12 level Range 142 to 1019 150 to 928
Median (IQR) 300 (228 to 391) 306 (248 to 402)
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RESULTS
32Clinical effectiveness results
Is folic acid clinically effective?
Primary clinical effectiveness outcomes
The primary clinical effectiveness outcome measure was self-rated symptom severity as measured by BDI-II
scores over 25 weeks, as summarised by the AUC of mean BDI-II scores from randomisation till 25 weeks.
This provided no evidence that folic acid was effective (Figure 3). The adjusted difference in AUC between
folic acid and placebo was 1.09 (95% CI from –0.48 to 2.66; p = 0.17). The adjusted difference between
folic acid and placebo at 25 weeks was 1.27 (95% CI from –0.99 to 3.54; p = 0.27). Similarly there was no
signiﬁcant difference in the proportion of patients who were depressed at 25 weeks (at least moderately,
i.e. BDI-II ≥ 19): there were 126/223 (57%) depressed participants in the folate group and 118/217 (54%)
in the placebo group. The adjusted OR of being depressed in the folate group compared with placebo
group was 1.09 (95% CI from 0.75 to 1.59; p = 0.65).
Secondary clinical effectiveness outcomes
Table 12 shows the unadjusted AUC results for all the main outcome measures, together with two-sample
t-tests. The only signiﬁcant result favoured the placebo in the SF-12 mental component. By convention
generic outcome measures like EQ-5D and SF-12 show good health by high scores, while condition-speciﬁc
outcome measures like BDI-II, CGI and MADRS show good health by scores that are low, if not zero. Thus
ﬁve of the non-signiﬁcant differences favoured placebo and seven favoured folate. Table 42 of Appendix 10
elaborates on Table 12 by showing the results of unadjusted two-sample t-tests for each variable at each
time point separately.
Area under the curve analysis adjusted for stratiﬁcation variables and baseline score of the variable in
question gave a very similar picture. Table 13 shows these results and reports all signiﬁcant stratiﬁcation
and baseline variables. For most variables the baseline score and antidepressant type were signiﬁcant
covariates, but allocated treatment was not. As for the unadjusted AUCs the only outcome on which the
allocated treatment had a statistically signiﬁcant effect was the SF-12 mental component, again favouring
the placebo.Baseline
34
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FIGURE 3 Estimated mean BDI-II scores over time adjusted for baseline score and stratification variables – by
treatment allocated. Baseline score = observed population mean BDI-II score.
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TABLE 12 Unadjusted AUC average (using values at baseline and 4, 12 and 25 weeks) of main outcomes by
treatment allocated
Folate Placebo Difference (folate minus placebo)
Outcome variable Mean (SD) Mean (SD) Mean (SE) 95% CI Signiﬁcance
BDI-II 25.70 (10.83) 25.64 (11.43) 0.06 (1.06) 2.02 to 2.15 0.953
MADRS 22.17 (7.59) 22.39 (8.34) 0.22 (0.76) 1.71 to 1.27 0.771
Euroqol
EQ-5D 0.573 (0.259) 0.591 (0.262) 0.018 (0.025) 0.067 to 0.031 0.476
EQ-VAS 54.58 (18.38) 54.34 (17.85) 0.25 (1.73) 3.15 to 3.64 0.887
SF-12
SF-12 PCS 44.89 (11.13) 44.28 (11.48) 0.61 (1.08) 1.51 to 2.73 0.571
SF-12 MCS* 31.99 (9.34) 34.09 (9.01) –2.09 (0.88) –3.81 to –0.37 0.017
CGI
CGI: Severity 3.60 (0.87) 3.61 (0.94) 0.00 (0.09) 0.17 to 0.17 0.980
CGI: Improvement 3.11 (0.86) 3.09 (0.95) 0.02 (0.09) 0.15 to 0.19 0.794
CGI: Efﬁcacya 0.29 (0.49) 0.30 (0.50) 0.01 (0.05) 0.10 to 0.08 0.826
Estimated CGI 1.34b (–) 1.35b (–) 0.99c (–) 0.90 to 1.08c
UKU
UKU: Psychic 8.21 (3.86) 8.16 (4.01) 0.05 (0.38) 0.68 to 0.79 0.894
UKU: Neurologicd 0.73 (0.67) 0.79 (0.71) 0.06 (0.07) 0.19 to 0.07 0.371
Estimated UKU 0.53e (–) 0.62e (–) (–) (–) (–)
UKU: Autonomic 2.93 (2.22) 2.85 (2.51) 0.08 (0.23) 0.37 to 0.52 0.723
UKU: Other 3.62 (2.68) 4.06 (3.11) 0.44 (0.28) 0.98 to 0.11 0.114
a After logarithmic transformation.
b Estimated CGI scale scores in each group from the transformed model.
c Ratio of estimated CGI scores and CI for the ratio.
d After square-root transformation.
e Estimated UKU scale scores in each group from the transformed model.
* Difference signiﬁcant at 5% level with effect size = 0.23.
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TABLE 13 Area under curve average of main outcomes adjusted for stratiﬁcation variables and their own
baselines – by treatment allocated
Outcome variable
Difference (folateminus placebo)
Signiﬁcant covariates SigniﬁcanceMean (SE) 95% CI Signiﬁcance
BDI-II 1.09 (0.86) –0.48 to 2.66 0.173 Baseline scores < 0.001
Type of antidepressant 0.028
Centre 0.025
MADRS 0.71 (0.62) –0.51 to 1.93 0.252 Baseline scores < 0.001
Type of antidepressant 0.002
Centre 0.026
EQ-5D 0.00 (0.017) –0.034 to 0.033 0.982 Baseline scores < 0.001
EQ-VAS –0.48 (1.36) –3.16 to 2.20 0.726 Baseline scores < 0.001
Type of antidepressant 0.001
SF-12 PCS 0.40 (0.60) –0.78 to 1.59 0.501 Baseline scores < 0.001
Previous treatment 0.002
SF-12 MCS* –1.97 (0.78) –3.49 to –0.44 0.012 Baseline scores < 0.001
Type of antidepressant 0.001
CGI: Severity 0.05 (0.08) –0.11 to 0.2 0.553 Baseline scores < 0.001
Type of antidepressant 0.001
Centre < 0.001
CGI: Improvement 0.04 (0.08) –0.13 to 0.21 0.649 Type of antidepressant 0.002
Centre 0.009
CGI: Efﬁcacya 0.98b (0.04) –0.89 to 1.07 0.604 Type of antidepressant < 0.001
Centre < 0.001
UKU: Psychic 0.31 (0.31) –0.3 to 0.92 0.319 Baseline scores < 0.001
Type of antidepressant 0.001
Centre 0.029
UKU: Neurologic –0.01 (0.04) –0.10 to 0.07 0.738 Baseline scores < 0.001
Centre 0.008
UKU: Autonomic –0.11 (0.15) –0.42 to 0.19 0.458 Baseline scores < 0.001
UKU: Other –0.38 (0.20) –0.78 to 0.02 0.065 Baseline scores < 0.001
Centre 0.002
a Ratio (folate/placebo) and its CI.
* Difference signiﬁcant at 5% level with effect size = 0.24.
RESULTS
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DOI: 10.3310/hta18480 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 48Figures 4–11 display the remaining adjusted analyses, except those relating to the UKU, by individual
time points. Though receiving folic acid or placebo does not affect the outcome of treatment in the trial,
the pattern of results over time is consistent across measures: ADM achieves major beneﬁt over the
ﬁrst 4 weeks, and continuing though reducing improvement over 25 weeks. In particular Figure 11 shows
how the adjusted SF-12 MCSs differ between arms, with the difference favouring placebo: the mean
scores diverge by 4 weeks, achieve a substantial gap by 12 weeks, and converge a little by 25 weeks.
Table 14 records the statistical analyses underpinning these nine ﬁgures, together with the corresponding
analyses from the UKU side effects scale.28
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FIGURE 4 Estimated mean MADRS scores over time adjusted for baseline score and stratification variables – by
treatment allocated. Baseline score = observed population mean MADRS score.
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FIGURE 5 Estimated mean CGI severity scores over time adjusted for baseline score and stratification variables – by
treatment allocated. Baseline score = observed population mean CGI severity score.
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IGURE 7 Estimated mean CGI efficacy scores at follow up adjusted for stratification variables – by
reatment allocated.
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FIGURE 6 Estimated mean CGI improvement scores at follow up adjusted for stratification variables – by
treatment allocated.
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FIGURE 8 Estimated mean EQ-5D scores over time adjusted for baseline score and stratification variables – by
treatment allocated. Baseline score = observed population mean EQ-5D score.
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FIGURE 9 Estimated mean EQ-VAS scores over time adjusted for baseline score and stratification variables – by
treatment allocated. Baseline score = observed population mean EQ-VAS score.
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FIGURE 10 Estimated mean SF-12 Physical Component Scale scores over time adjusted by baseline score and
stratification variables – by treatment allocated. Baseline score = observed population mean SF-12 Physical
Component Scale score.
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FIGURE 11 Estimated mean SF-12 Mental Component Scale scores over time adjusted for baseline score and
stratification variables – by treatment allocated. Baseline score = observed population mean SF-12 Mental
Component Scale score.
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38The absence of the binary variable ‘Previous treatment?’ from the signiﬁcant covariates in all but the SF-12
Physical Component Score of the 13 rows of Table 13, and from all but four non-psychiatric rows of the
39 rows of Table 14, conﬁrms that this does not seem to predict the clinical outcome of ADM or of
adjunctive folate.
Tables 43–46 of Appendix 10 complement Table 14, speciﬁcally the BDI-II row, by reporting the analogous
logistic regression analyses for two levels of response to treatment – 50% or full improvement – both at
12 and at 25 weeks, thus illustrating the primary analysis in clinical terms.Side effects, adverse events and suicidality
Side effects
There were 33 reported AEs in the folic acid arm of the trial and 45 in the placebo arm – difference not
statistically signiﬁcant (χ2 = 2.66; df = 1; p = 0.10; OR = 0.66; 95% CI from 0.40 to 1.09). We adjudged six ofNIHR Journals Library www.journalslibrary.nihr.ac.uk
ABLE 14 Outcomes over time adjusted for signiﬁcant stratiﬁcation variables and their own baselines by
reatment allocated
Outcome variable and
time point
Difference (folate minus placebo)
Signiﬁcant
covariates SigniﬁcanceMean (SE) 95% CI Signiﬁcance
BDI-II
BDI-II (4 weeks) 0.45 (0.91) –1.34 to 2.23 0.623 Baseline scores < 0.001
BDI-II (12 weeks) 1.52 (1.10) –0.64 to 3.69 0.168 Baseline scores < 0.001
Centre 0.013
BDI-II (25 weeks) 1.27 (1.15) –0.99 to 3.54 0.270 Baseline scores < 0.001
Type of antidepressant 0.004
Centre 0.011
MADRS
MADRS (4 weeks) 1.02 (0.75) –0.45 to 2.49 0.174 Baseline scores < 0.001
MADRS (12 weeks) 1.14 (0.89) –0.62 to 2.89 0.204 Baseline scores < 0.001
Type of antidepressant 0.012
MADRS (25 weeks) 0.02 (0.95) –1.84 to 1.88 0.981 Baseline scores < 0.001
Type of antidepressant 0.003
EQ-5D
EQ-5D (4 weeks) –0.028 (0.024) –0.074 to 0.017 0.247 Baseline scores < 0.001
Previous treatment 0.005
EQ-5D (12 weeks) 0.010 (0.024) –0.037 to 0.057 0.681 Baseline scores < 0.001
EQ-5D (25 weeks) 0.019 (0.024) –0.027 to 0.065 0.450 Baseline scores < 0.001
EQ-VAS
EQ-VAS (4 weeks) 0.15 (1.74) –3.28 to 3.58 0.932 Baseline scores < 0.001
Type of antidepressant 0.004
EQ-VAS (12 weeks) –1.83 (1.90) –5.57 to 1.91 0.337 Baseline scores < 0.001
Type of antidepressant 0.026
EQ-VAS (25 weeks) 1.11 (2.01) –2.85 to 5.07 0.582 Baseline scores < 0.001
Type of antidepressant 0.002
Previous treatment 0.018
SF12 PCS
SF-12 PCS (4 weeks) 1.45 (0.78) –0.08 to 2.98 0.064 Baseline scores < 0.001
Previous treatment 0.008
SF-12 PCS (12 weeks) –0.28 (0.83) –1.91 to 1.35 0.733 Baseline scores < 0.001
Previous treatment 0.019
Centre 0.063
SF-12 PCS (25 weeks) 0.76 (0.83) –0.87 to 2.38 0.360 Baseline scores < 0.001
Previous counselling 0.080
Previous treatment 0.009
continued
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ABLE 14 Outcomes over time adjusted for signiﬁcant stratiﬁcation variables and their own baselines by
reatment allocated (continued )
Outcome variable and
time point
Difference (folate minus placebo)
Signiﬁcant
covariates SigniﬁcanceMean (SE) 95% CI Signiﬁcance
SF-12 MCS
SF-12 MCS (4 weeks) –1.28 (0.99) –3.22 to 0.67 0.198 Baseline scores < 0.001
SF-12 MCS (12 weeks)* –2.95 (1.12) –5.16 to –0.75 0.009 Baseline scores < 0.001
Type of
antidepressant
0.002
SF-12 MCS (25 weeks) –1.93 (1.21) –4.30 to 0.45 0.112 Baseline scores < 0.001
Type of antidepressant 0.005
Previous counselling 0.02
CGI: Severity
CGI: Severity (4 weeks) 0.06 (0.09) –0.12 to 0.23 0.517 Baseline scores < 0.001
Type of antidepressant 0.008
CGI: Severity (12 weeks) 0.12 (0.11) –0.09 to 0.32 0.276 Baseline scores < 0.001
Type of antidepressant 0.035
Centre < 0.001
CGI: Severity (25 weeks) –0.06 (0.12) –0.30 to 0.18 0.616 Baseline scores < 0.001
Type of antidepressant < 0.001
Centre < 0.001
CGI: Improvement
CGI: Improvement (4 weeks) 0.14 (0.10) –0.05 to 0.33 0.139 Type of antidepressant 0.030
CGI: Improvement (12 weeks) 0.06 (0.11) –0.16 to 0.28 0.594 Type of antidepressant 0.052
CGI: Improvement (25 weeks) –0.07 (0.13) –0.32 to 0.18 0.596 Type of antidepressant 0.005
Centre 0.012
CGI: Efficacy
CGI: Efﬁcacy (4 weeks)a –0.10 (0.05) –0.20 to 0.01 0.079 Type of antidepressant 0.003
Centre < 0.001
CGI: Efﬁcacy (12 weeks)a 0.04 (0.06) –0.08 to 0.15 0.560 Type of antidepressant 0.007
Centre 0.005
CGI: Efﬁcacy (25 weeks)a –0.07 (0.06) –0.19 to 0.05 0.272 Type of antidepressant 0.004
Centre < 0.001
RESULTS
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ABLE 14 Outcomes over time adjusted for signiﬁcant stratiﬁcation variables and their own baselines by
reatment allocated (continued )
Outcome variable and
time point
Difference (folate minus placebo)
Signiﬁcant
covariates SigniﬁcanceMean (SE) 95% CI Signiﬁcance
UKU: psychic
UKU: psychic (4 weeks) 0.81 (0.47) –0.11 to 1.73 0.084 Baseline scores < 0.001
UKU: psychic (12 weeks) 0.08 (0.47) –0.84 to 1.00 0.869 Baseline scores < 0.001
Type of antidepressant 0.005
Centre 0.003
UKU: psychic (25 weeks) 0.37 (0.46) –0.54 to 1.28 0.426 Baseline scores < 0.001
Type of antidepressant 0.002
Centre 0.013
UKU: neurologic
UKU: neurologic (4 weeks)b –0.00 (0.06) –0.12 to 0.12 0.989 Baseline scores < 0.001
Centre < 0.001
UKU: neurologic (12 weeks)b –0.03 (0.06) –0.16 to 0.10 0.642 Baseline scores < 0.001
Centre 0.039
UKU: neurologic (25 weeks)b –0.02 (0.07) –0.15 to 0.12 0.821 Baseline scores < 0.001
UKU: autonomic
UKU: autonomic (4 weeks) –0.13 (0.22) –0.55 to 0.30 0.565 Baseline scores < 0.001
Centre 0.004
UKU: autonomic (12 weeks) –0.17 (0.23) –0.63 to 0.28 0.460 Baseline scores < 0.001
UKU: autonomic (25 weeks) 0.03 (0.24) –0.43 to 0.49 0.907 Baseline scores < 0.001
UKU: other
UKU: other (4 weeks) –0.11 (0.28) –0.65 to 0.44 0.694 Baseline scores < 0.001
Centre < 0.001
UKU: other (12 weeks)** –0.63 (0.30) –1.22 to –0.04 0.037 Baseline scores < 0.001
UKU: other (25 weeks) –0.39 (0.30) –0.98 to 0.20 0.195 Baseline scores < 0.001
Previous treatment 0.047
Gender 0.018
a After logarithmic transformation.
b After square-root transformation.
* Difference signiﬁcant at 5% level with effect size = 0.25 in favour of placebo.
**Difference signiﬁcant at 5% level with effect size = 0.44 in favour of folic acid.
DOI: 10.3310/hta18480 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 48T
t41
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Bedson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
RESULTS
42the AEs in the intervention arm to be serious, compared with 14 in the control arm – difference also not
statistically signiﬁcant (χ2 = 3.59; df = 1; p = 0.058; OR = 0.40; 95% CI from 0.15 to 1.06). We classiﬁed
seven of the 78 AEs as adverse reactions because folic acid (if prescribed) was a possible cause; unblinding
revealed that four had received folic acid and three not – difference again not statistically signiﬁcant
(χ2 = 0.12; df = 1; p = 0.73; OR = 1.30; 95% CI from 0.29 to 5.89). None of these was serious or unexpected.Suicidality using the MINI and UKU
We measured side effects by the UKU side effects scale. Comparison of the areas under subscale curves
over 25 weeks showed no signiﬁcant differences between treatment groups (Table 15). When we
examined differences at each of the three follow-up times for each of the four subscales, we found a
marginally signiﬁcant difference at 12 weeks in the ‘other’ subscale, which includes mostly sexual side
effects (p = 0.037). As this is one of many comparisons for the UKU, we treat this ﬁnding with caution.
Table 16 tabulates the numbers and percentages of patients classiﬁed in each of three suicidal risk
categories from the MINI suicidality scale by follow-up time and treatment arm. All four differences are
small and non-signiﬁcant.
Adherence to trial medication
We assessed adherence to the trial medication at 12 weeks in four ways: scores on the Morisky
Questionnaire; counting returned trial medication; serum folate levels; and homocysteine levels. We followed
the published instructions for calculating respondents’ scores on the Morisky Questionnaire. We deﬁned the
biochemical criteria for adherence to folic acid treatment as: serum folate at 12 weeks greater than 15 µg/ml,
and reduction of at least 15% in serum homocysteine between baseline and 12 weeks. Table 17 shows no
signiﬁcant difference between randomised groups in Morisky score or tablet count. Of the biochemical
criteria, serum folate shows better adherence than homocysteine.TABLE 15 Area under UKU curve adjusted by stratiﬁcation variables and their own baselines – by
treatment allocated
UKU subscale
Difference (folate minus placebo)
Mean (SE) 95% CI Signiﬁcance
Psychic 0.31 (0.31) –0.30 to 0.92 0.319
Neurologica –0.01 (0.04) –0.10 to 0.07 0.738
Autonomic –0.11 (0.15) –0.42 to 0.19 0.458
Other (mostly sexual) –0.38 (0.20) –0.78 to 0.02 0.065
a After square-root transformation.
TABLE 16 Suicide risk on MINI suicidality scale by treatment allocated
Week
Folate (n = 223) Placebo (n = 217)
Suicide risk: number (%) Suicide risk: number (%)
None Low Medium High None Low Medium High
0 0 (0) 138 (62) 36 (16) 49 (22) 0 (0) 143 (66) 34 (16) 40 (18)
4 0 (0) 169 (76) 21 (9) 33 (15) 0 (0) 155 (71) 32 (15) 30 (14)
12 0 (0) 152 (68) 35 (16) 36 (16) 0 (0) 168 (77) 21 (10) 28 (13)
25 0 (0) 163 (73) 35 (16) 25 (11) 0 (0) 156 (72) 33 (15) 28 (13)
NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 17 Measures of adherence at 12 weeks by treatment allocated
Adherence at 12 weeks Folate (n = 223) Placebo (n = 217)
Morisky score – no. (%)
0 (best) 4 (2) 6 (3)
1 18 (8) 17 (8)
2 43 (19) 36 (17)
> 2 (worst) 158 (71) 158 (73)
Missing Nil Nil
Tablet count – median (IQR) 14 (7 to 20) 14 (7 to 20)
Missing 43 45
Serum folate > 15 µg/ml – no. (%) 163 (73) Not applicable
Missing 29 (13)
Homocysteine reduction of 15% – no. (%) 103 (46) Not applicable
Missing 51 (23)
IQR, interquartile range.
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Table 18 comparing the main and complete case analyses of BDI-II found no essential differences between
the alternative estimates of the AUC of folic acid minus placebo: in particular the complete case analysis’s
estimate of the adjusted AUC was 1.26 (95% CI from –0.56 to 3.08; p = 0.18), very close to that of the
main analysis.
Multi-level repeated-measures analysis
We ﬁtted a mixed-effects multi-level model with the same covariates as the AUC analysis. Table 19 shows
that both analyses reported the same general ﬁndings; in particular the repeated measures analysis’s
estimate of the AUC was 0.67 (95% CI from –1.00 to 2.34; p = 0.429), close to that of the main analysis.TABLE 18 Estimated effectiveness on BDI-II of folic acid vs. placebo – sensitivity to missing data
BDI-II scores
Difference (folate minus placebo)
Main analysis (imputing missing) (n=440) Complete case analysis (n = 323)
Mean 95% CI Signiﬁcance Mean 95% CI Signiﬁcance
AUC average: unadjusted –0.06 –2.02 to 2.15 0.953 0.11 –2.30 to 2.52 0.930
AUC average: adjusted 1.09 –0.48 to 2.66 0.173 1.26 –0.56 to 3.08 0.175
ANCOVA: adjusted
4 weeks 0.45 –1.34 to 2.23 0.623 0.91 –1.14 to 2.96 0.384
12 weeks 1.52 –0.64 to 3.69 0.168 1.75 –0.68 to 4.19 0.157
25 weeks 1.27 –0.99 to 3.54 0.270 1.24 –1.44 to 3.91 0.364
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TABLE 19 Estimated effectiveness of folic acid vs. placebo – sensitivity to analysis by AUC
Outcome variable
Difference (folate minus placebo)
Main analysis (AUC) Repeated measures analysis
Mean 95% CI Signiﬁcance Mean 95% CI Signiﬁcance
BDI-II 1.09 –0.48 to 2.66 0.173 0.67 –1.00 to 2.34 0.429
MADRS 0.71 –0.51 to 1.93 0.252 0.49 –0.80 to 1.78 0.452
EQ-5D 0.001 –0.033 to 0.031 0.982 0.013 –0.062 to 0.087 0.760
EQ-VAS –0.48 –3.16 to 2.20 0.726 0.03 –0.02 to 0.08 0.230
SF-12 PCS 0.40 –0.78 to 1.59 0.501 0.64 –0.61 to 1.90 0.313
SF-12 MCS* –1.97 –3.49 to –0.44 0.012 –1.83 –3.48 to –0.19 0.029
CGI: Severity 0.05 –0.11 to 0.20 0.553 0.00 –0.16 to 0.16 0.995
CGI: Improvement 0.04 –0.13 to 0.21 0.649 0.01 –0.15 to 0.16 0.942
CGI: Efﬁcacya –0.02 –0.11 to 0.07 0.604 –0.05 –0.17 to 0.08 0.482
Estimated CGI 0.98b 0.90b 1.07b 0.95b 0.84 to 1.08b
a After logarithmic transformation.
b Ratio of estimated CGI scores and CI for the ratio.
*Differences signiﬁcant at 5% level.
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44Analysis reweighted to adjust for participants who did not respond
after baseline
Table 20 comparing the main and reweighted analyses of BDI-II found no essential differences between
the alternative estimates of the AUC of folic acid minus placebo: in particular the reweighted analysis’s
estimate of the adjusted AUC was 1.17 (95% CI from –0.36 to 2.69; p = 0.135), very close to that of the
main analysis. Table 47 in Appendix 10 shows that the 35 participants completely lost to follow-up were
very similar to their ‘nearest neighbours’ in the analysed population. For 30 participants the matches were
unambiguous; we resolved the ambiguity for the remaining ﬁve participants by matching them with the
candidate with the closest BDI-II at baseline.ABLE 20 Estimated effectiveness of folic acid compared with placebo – sensitivity to non-response
BDI-II
Folate minus placebo
Main analysis (responders) (n = 440) Reweighted analysis (n = 475)
Mean 95% CI Signiﬁcance Mean 95% CI Signiﬁcance
AUC: unadjusted –0.06 –2.02 to 2.15 0.953 1.02 –1.83 to 2.18 0.864
AUC: adjusted 1.09 –0.48 to 2.66 0.173 1.17 –0.36 to 2.69 0.135
ANCOVA: adjusted
4 weeks
0.45 –1.34 to 2.23 0.623 0.52 –1.19 to 2.22 0.554
12 weeks 1.52 –0.64 to 3.69 0.168 1.51 –0.59 to 3.62 0.158
25 weeks 1.27 –0.99 to 3.54 0.270 1.36 –0.83 to 3.55 0.222TNIHR Journals Library www.journalslibrary.nihr.ac.uk
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Table 21 shows that baseline BDI-II was a powerful predictor of subsequent BDI-II scores, to the exclusion
of all biochemical covariates in stepwise linear regression.
The alternative repeated measures analysis adjusted for baseline biochemistry but still found no consistent
evidence of differences between folate and placebo groups in any outcome (Table 22). For example after
adjustment for serum folate the estimated difference between the folate and placebo groups in the
BDI-II after treatment was 0.68 (95% CI from –0.96 to 2.32; p = 0.413). Again only the SF-12 mental
health component score (MCS) showed statistical signiﬁcance with an estimated difference adjusted for
baseline serum folate of –1.85 (95% CI from –3.48 to –0.21; p = 0.027).
The estimated change in BDI-II after a unit increase in baseline serum folate was –0.07 (95% CI from
–0.24 to 0.10; p = 0.431). Only in the CGI Improvement scale did any baseline biochemical variables
predict clinical outcome. There was some evidence that red cell folate predicts outcome and strong
evidence for homocysteine: a single unit of baseline homocysteine increased CGI improvement by 0.05
(95% CI from 0.03 to 0.08; p < 0.001).
The repeated measures analysis adjusted for biochemical measures while on treatment in week 12 found
no evidence of difference between folate and placebo groups in any instrument (Table 23). However there
was clear evidence across most instruments except SF-12 showing that homocysteine measured in week
12 while on treatment predicted clinical outcomes like MADRS, CGI (severity and improvement) and
EQ-5D. In particular a unit increase in homocysteine at week 12 increased BDI-II by 0.34 (95% CI from
0.15 to 0.52; p = 0.001). Tables 48 and 49 of Appendix 10 elaborate on Tables 22 and 23 by reporting
more extensive models in more detail.
Biochemistry outcomes
Despite the lack of clinical response to folic acid, it was effective in increasing participants’ folate. Table 24
shows that the folate group had higher serum folate by 15.1 (95% CI from 12.4 to 17.8) at 12 weeks, and
by 15.6 (95% CI from 13.3 to 17.8) at 25 weeks. The difference in red cell folate was 272 (95% CI from
210 to 334) at 12 weeks, but only 82 (95% CI from 26 to 139) at 25 weeks. Baseline scores enhanced the
prediction of all four biochemical outcomes. Each unit of baseline serum folate increased serum folate on
treatment by 0.49 (95% CI from 0.30 to 0.68); each unit of baseline red cell folate increased red cell folate
on treatment by 0.34 (95% CI from 0.22 to 0.45). Age was another good predictor for red cell folate: eachABLE 21 Beck Depression Inventory at 12 and 25 weeks by treatment allocated
Difference (folate minus placebo)
Signiﬁcant covariates SigniﬁcanceMean (SE) 95% CI
Unadjusted
BDI-II (12 weeks) 1.21 (1.14) –1.02 to 3.44 Baseline BDI-II score < 0.001
BDI-II (25 weeks) 0.71 (1.20) –1.65 to 3.07 Baseline BDI-II score < 0.001
Adjusted by stratification variables and allocated treatment
BDI-II (12 weeks) 1.43 (1.12) –0.79 to 3.65 Baseline BDI-II score < 0.001
Centre 0.019
BDI-II (25 weeks) 0.90 (1.18) –1.42 to 3.22 Baseline BDI-II score < 0.001
Type of ADM 0.007
Centre 0.012T45
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TABLE 22 Clinical effectiveness by repeated measures analysis adjusting for baseline biochemistry
Outcome variable Covariate
Difference (folate minus placebo)
Mean (SE) 95% CI Signiﬁcance
BDI-II Serum folate 0.682 (0.833) –0.96 to 2.32 0.413
Red cell folate –0.045 (0.990) –1.99 to 1.90 0.964
MADRS Serum folate 0.530 (0.649) –0.75 to 1.81 0.415
Red cell folate 0.351 (0.744) –1.11 to 1.82 0.638
EQ-5Da Serum folate 0.012 (0.038) –0.064 to 0.068 0.763
Red cell folate 0.028 (0.022) –0.015 to 0.070 0.202
EQ-VASa Serum folate 1.019 (0.850) –0.65 to 2.69 0.231
Red cell folate –0.026 (1.016) –2.03 to 1.97 0.980
MCS Serum folate –1.848 (0.832) –3.48 to –0.21 0.027
Red cell folate –0.610 (0.991) –2.56 to 1.34 0.538
PCS Serum folate 0.657 (0.635) –0.59 to 1.91 0.302
Red cell folate 0.996 (0.743) –0.47 to 2.45 0.181
CGI: Severity Serum folate 0.003 (0.082) –0.16 to 0.16 0.971
Red cell folate –0.085 (0.095) –0.27 to 0.10 0.368
CGI: Improvement Serum folate 0.059 (0.109) –0.15 to 0.27 0.586
Red cell folate –0.022 (0.124) –0.27 to 0.22 0.859
a Raw scores rather than QALYs.
RESULTS
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TABLE 23 Clinical effectiveness by repeated measures analysis adjusting for biochemistry ‘on treatment’
Outcome variable Covariate
Difference (folate minus placebo)
Mean (SE) 95% CI Signiﬁcance
BDI-II Serum folate 0.107 (1.093) –2.04 to 2.26 0.922
Red cell folate –1.794 (1.490) –4.73 to 1.14 0.230
MADRS Serum folate 0.260 (0.894) –1.50 to 2.02 0.772
Red cell folate –0.623 (1.188) –2.97 to 1.72 0.601
EQ-5D Serum folate 0.021 (0.022) –0.011 to 0.074 0.363
Red cell folate 0.059 (0.031) –0.003 to 0.121 0.060
EQ-VAS Serum folate 0.107 (1.093) –2.04 to 2.26 0.922
Red cell folate –1.794 (1.490) –4.73 to 1.14 0.230
MCS Serum folate –1.172 (1.146) –3.42 to 1.08 0.307
Red cell folate 0.096 (1.565) –2.99 to 3.18 0.951
PCS Serum folate 1.136 (0.825) –0.49 to 2.76 0.170
Red cell folate 1.502 (1.114) –0.69 to 3.70 0.179
CGI: Severity Serum folate –0.042 (0.112) –0.26 to 0.18 0.706
Red cell folate –0.233 (0.144) –0.52 to 0.05 0.107
CGI: Improvement Serum folate –0.063 (0.119) –0.30 to 0.17 0.597
Red cell folate –0.116 (0.165) –0.44 to 0.21 0.480
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TABLE 24 Biochemistry outcomes at 12 weeks – by treatment allocated
Outcome variable
Difference (folate minus placebo) Statistical signiﬁcance of other variables
Mean (SE) 95% CI Signiﬁcance Covariate Signiﬁcance
Serum folate 15.1 (1.4) 12.4 to 17.8 < 0.001 Centre 0.034
Time < 0.001
Baseline serum folate < 0.001
Type of antidepressant 0.209
Previous treatment 0.856
Red cell folate at 12 weeks < 0.001
Allocated treatment by time < 0.001
Red cell folate 272.4 (31.4) 210.5 to 334.3 < 0.001 Centre 0.504
Time 0.004
Baseline red cell folate < 0.001
Type of antidepressant 0.914
Previous treatment 0.118
Age 0.008
Serum folate at 12 weeks < 0.001
Allocated treatment by time 0.066
Homocysteine 0.93 (0.37) 0.19 to 1.66 0.014 Centre 0.726
Time 0.703
Baseline homocysteine < 0.001
Type of antidepressant 0.285
Previous treatment 0.773
Age 0.002
Gender < 0.001
Serum folate at 12 weeks < 0.001
Vitamin B12 6.20 (8.28) –10.1 to 22.5 0.454 Centre 0.005
Time 0.036
Baseline B12 < 0.001
Type of antidepressant 0.017
Previous treatment 0.998
Homocysteine at 12 weeks 0.005
Note: Threshold signiﬁcance level for main effects to be included in the model is p < 0.05, and for interactions is p < 0.10.
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DOI: 10.3310/hta18480 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 48year increased mean red cell folate by 2.17 (95% CI from 0.58 to 3.75). The reduction in homocysteine
caused by folic acid was –0.93 (95% CI from –1.66 to –0.19). Prediction of homocysteine improved after
adjustment for baseline homocysteine and serum folate at 12 weeks. Age and gender were also good
predictors for homocysteine: for every year of life homocysteine reduced by 0.048 (95% CI from 0.021 to
0.076); and females had higher homocysteine by 1.64 (95% CI from 0.91 to 2.34).
Many expected that patients deﬁcient in folate and randomised to the folated group would achieve
improvements in biochemical and clinical outcomes. So we analysed the subset of patients who at baseline
had a serum folate concentration of less than 3 µg/l, a red cell folate less than 200 µg/l, or homocysteine
greater than 15.3 µmol/l. Table 25 found no clinical or statistical difference between folate and placeboTABLE 25 Participants with baseline deﬁciency in biochemistry – by treatment allocated
Outcome variable Deﬁciency n
Difference (folate minus placebo)
Mean (SE) 95% CI Signiﬁcance
BDI-II Serum folate < 3 µg/l 27 –1.67 (3.99) –9.85 to 6.51 0.679
Red cell folate < 200 µg/l 9 –18.4 (8.2) –36.8 to 0.2 0.052
Homocysteine > 15.3 µmol/l 53 3.51 (2.63) –1.77 to 8.78 0.188
MADRS Serum folate < 3 µg/l 27 2.51 (2.40) –2.42 to 7.43 0.305
Red cell folate < 200 µg/l 9 –7.49 (3.66) –15.8 to 0.79 0.071
Homocysteine > 15.3 µmol/l 53 1.04 (1.94) –2.85 to 4.94 0.593
EQ-5D Serum folate < 3 µg/l 27 –0.080 (0.074) –0.226 to 0.072 0.281
Red cell folate < 200 µg/l 9 0.189 (0.131) –0.109 to 0.488 0.179
Homocysteine > 15.3 µmol/l 53 0.03 (0.07) –0.11 to 0.17 0.661
EQ-VAS Serum folate < 3 µg/l 27 0.5 (6.0) –11.8 to 12.8 0.937
Red cell folate < 200 µg/l 9 34.5 (15.5) –0.6 to 69.6 0.054
Homocysteine > 15.3 µmol/l 53 –1.9 (5.9) –13.6 to 9.9 0.753
MCS Serum folate < 3 µg/l 27 0.83 (3.69) –6.75 to 8.40 0.824
Red cell folate < 200 µg/l 9 15.9 (6.2) 2.0 to 29.9 0.029
Homocysteine > 15.3 µmol/l 53 –0.38 (2.47) –5.33 to 4.56 0.877
PCS Serum folate < 3 µg/l 27 2.26 (2.65) –3.18 to 7.69 0.402
Red cell folate < 200 µg/l 9 –1.88 (3.94) –10.8 to 7.02 0.644
Homocysteine > 15.3 µmol/l 53 –3.13 (2.04) –7.21 to 0.94 0.129
CGI: Severity Serum folate < 3 µg/l 27 –0.19 (0.34) –0.88 to 0.50 0.581
Red cell folate < 200 µg/l 9 –1.40 (0.52) –2.57 to –0.23 0.024
Homocysteine > 15.3 µmol/l 53 –0.14 (0.23) –0.61 to 0.33 0.549
CGI: Improvement Serum folate < 3 µg/l 27 0.09 (0.32) –0.56 to 0.73 0.787
Red cell folate < 200 µg/l 9 –1.35 (0.63) –2.75 to 0.05 0.058
Homocysteine > 15.3 µmol/l 53 –0.06 (0.23) –0.52 to 0.40 0.802
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RESULTS
50groups among those with deﬁciency in serum folate or homocysteine. For example the estimated
difference in BDI-II in patients who had less than 3 µg/l serum folate was –1.67 (95% CI from –9.85 to
6.51; p = 0.68). In contrast the few patients who were deﬁcient in baseline red cell folate (RCF) yielded
necessarily weak but consistent evidence across multiple instruments that augmenting ADM with folic acid
improved clinical outcome. Since high scores in EQ-5D and SF-12, and low scores in depression scales are
all good, folic acid achieved (near) signiﬁcant improvements in six of the eight criteria, speciﬁcally in the
RCF-deﬁcient group.
Cost-effectivenessResource use
Table 26 presents participants’ use of NHS and PSS resources over their 25 weeks in the trial. The majority
of participants, 78% and 81% in folic acid and placebo groups respectively, visited their GP on at least
one occasion. The mean number of visits was 3.3 and 3.9. Many participants reported telephone contact
with their GPs – 21% of those in the folic acid group and 27% in the placebo group; and visits to practice
nurses – 35% and 39% respectively. Despite the NICE recommendation that people with moderate to
severe depression should receive psychological therapy, only 7% of intervention participants and 6% of
controls did so (0.4 times on average). However 22% of those randomised to folic acid consulted
psychiatrists at hospital clinics (0.6 times on average), compared with 29% of control participants
(0.8 times on average). Other hospital visits were reported by similar numbers of participants – 22% and
25% respectively; and only 6% of patients in each group were admitted to hospital. All patients received
prescribed medication during the trial, with a mean of 6.5 and 7.2 antidepressant items in folic acid and
placebo groups respectively. Total prescribing was comparable at 21.0 and 21.9 items respectively.
Participants’ use of social services was low. Thus there were no signiﬁcant differences in resource use
between the two groups.
The mean percentage of responses missing from the resource use questionnaire, across all questions and
time points, was 10.1% in the folic acid group and 11.0% in the control group. The level of missing data
was not related to the treatment allocation at any time point (Student’s t-test: p > 0.1 for each point).
The lowest rate of missing data was in response to consultations at general practices (8.1% across both
treatment groups) while the highest rate of missing data related to contact with health visitors (23.5%).
The high response rate is in marked contrast to the AHEAD study, which used the same questionnaire, but
required patients to return their completed forms by mail, leaving 73.8% of questionnaires incomplete.138Costs
Table 27 presents unadjusted costs incurred during the 25 weeks of follow-up. There were no statistically
signiﬁcant differences in categorised or total cost between treatment groups, although there was a
tendency towards lower costs in the control group for all categories. Psychiatric services in hospital or
community services took more than half the total cost – £797 in the folic acid group, and £886 in the
placebo control group. Participants’ attendances at hospital clinics for consultations with psychiatrists was
the main driver of this. The costs of prescribed medicines were the second highest cost category at £240
and £257 in intervention and control groups respectively. Antidepressants accounted for around 30%
of total medication costs.
There were differences in baseline costs, evident from the resource use questionnaire relating to the
3 months before baseline visits. Baseline costs in the folic acid group were £514 compared with £746 in
the placebo group (a difference of £232, 95% CI from –£9 to £487). Although baseline costs do not
contribute to the total costs, imbalances at baseline may reﬂect an imbalance in patient or diseaseNIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 26 Resource use over 25 weeks – by treatment allocated
Type of resource
Folate (n = 223) Placebo (n = 217)
Mean (SD)
Non-zero responses
Mean (SD)
Non-zero responses
no. (%) [Median]a no. (%) [Median]a
General practice, community pharmacy, and nursing services
GP surgery visits 3.3 (3.3) 173 (78) [3] 3.9 (4.1) 176 (81) [3]
GP home visits 0.1 (0.6) 11 (5) [2] 0.0 (0.2) 3 (1) [1]
GP telephone contacts 0.4 (1.3) 46 (21) [1] 0.6 (1.4) 59 (27) [1]
Visits to practice nurse 0.7 (1.2) 79 (35) [1] 1.3 (3.9) 84 (39) [2]
District nurse home visits 0.0 (0.1) 1 (0) [2] 0.0 (0.2) 2 (1) [2]
Counsellor at surgery 0.6 (1.8) 31 (14) [3] 0.4 (1.5) 27 (12) [2]
Vitamin B12 testing 1.0 (0) 223 (100) [1] 0.0 (0) 0 (0) [0]
Folic acid dispensing fee 1.0 (0) 223 (100) [1] 0.0 (0) 0 (0) [0]
Antidepressant items
dispensed
6.5 (3.9) 223 (100) [6] 7.2 (5.7) 217 (100) [6]
All prescription items
dispensed
21.0 (17.8) 223 (100) [17] 21.9 (27.3) 217 (100) [14]
Other 0.2 (0.9) 19 (9) [3] 0.1 (0.6) 11 (5) [2]
Health visitor 0.2 (2.6) 4 (2) [4] 0.1 (0.5) 7 (3) [1]
Social services
Social worker 0.3 (1.4) 15 (7) [2] 0.3 (1.4) 14 (6) [3]
Home help 0.2 (3.2) 1 (0) [48] 1.8 (19.1) 3 (1) [162]
Care assistant 0.3 (3.3) 3 (1) [8] 0.9 (10.0) 5 (2) [6]
Day centre visits 0.1 (0.8) 2 (1) [6.5] 0.2 (1.8) 5 (2) [12]
Other (social services) 0.0 (0.4) 5 (2) [2] 0.1 (1.3) 6 (3) [2.5]
Psychiatric hospital and community services
Psychiatrist at hospital clinic 0.6 (1.7) 50 (22) [2] 0.8 (1.9) 63 (29) [2]
Psychiatrist at home 0.0 (0.2) 3 (1) [2] 0.0 (0.3) 2 (1) [2.5]
Psychologist 0.4 (2.2) 15 (7) [4] 0.4 (2.3) 14 (6) [2]
Community psychiatric nurse 0.5 (2.0) 25 (11) [3] 1.4 (4.0) 35 (16) [5]
Other (psychiatric services) 0.4 (1.6) 25 (11) [2] 0.3 (2.2) 16 (7) [2.5]
Other services
Day hospital 0.2 (0.9) 18 (8) [1.5] 0.3 (1.3) 17 (8) [2]
Accident and Emergency 0.2 (0.6) 31 (14) [1] 0.3 (1.1) 38 (18) [1]
Hospital clinic 0.5 (1.5) 48 (22) [1] 0.6 (1.5) 55 (25) [2]
Nights spent on hospital ward 0.8 (5.2) 13 (6) [6] 0.4 (2.5) 13 (6) [3]
Occupational or employment
health services
0.1 (0.5) 12 (5) [1.5] 0.3 (1.0) 21 (10) [2]
Other (hospital) 0.2 (0.9) 14 (6) [1] 0.1 (0.7) 9 (4) [1]
NHS Direct 0.2 (1.7) 19 (9) [1] 0.1 (1.0) 12 (6) [1.5]
Ambulance or paramedic 0.1 (0.4) 14 (6) [1] 0.1 (0.5) 11 (5) [1]
a Median of non-zero responses.
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TABLE 27 Unadjusted costs through 25 weeks – by treatment allocated
Type of cost
Folate Placebo
Difference
(folate minus placebo)
Mean (95% CI) Mean (95% CI) Mean (95% CI)
GP costs 164.20 (144.72 to 185.02) 186.46 (163.60 to 210.61) –22.26 (–53.61 to 8.64)
Social care costs 148.46 (84.63 to 233.98) 324.86 (144.51 to 569.11) –176.40 (–428.14 to 19.63)
Psychiatric hospital
and community
services costs
797.37 (562.94 to 1090.52) 886.40 (712.65 to 1089.37) –89.03 (–404.23 to 249.42)
Antidepressant drug
costs
72.93 (62.39 to 84.47) 75.30 (63.84 to 88.44) –2.37 (–19.37 to 13.96)
All medication costs 239.95 (206.94 to 275.14) 256.79 (201.15 to 324.42) –16.84 (–91.66 to 49.17)
Other costs 60.72 (44.60 to 78.85) 66.44 (48.50 to 86.49) –5.72 (–31.42 to 19.50)
Total cost 1410.21 (1147.28 to 1729.31) 1719.12 (1398.10 to 2088.25) –308.94 (–764.14 to 155.18)
RESULTS
52characteristics. Hence they may bias cost estimates, particularly if previous use of health and social care
predicts future use. The primary cost analysis therefore corrected for baseline differences by regression.125
Adjusting for these differences at baseline reduced the mean difference in total costs from £309 (95% CI
from –£155 to £764) to £48 (95% CI from –£292 to £389), still not signiﬁcant.Health outcomes
Figure 12 shows the distribution of EQ-5D scores by time, treatment group and dimension. At baseline the
majority of patients described themselves as having either moderate or severe problems in relation to
anxiety or depression (97% in both groups), pain or discomfort (61% and 59% for folic acid and placebo
groups respectively), and usual activities (77% and 80% respectively). Improvements in the states of
anxiety or depression (to 75% in both groups), and ability to perform usual activities (to 62% and 55%
respectively) were evident between baseline and 25 weeks. The corresponding changes in unadjusted
mean utilities from baseline to 25 weeks were 0.481 to 0.605 for folic acid and 0.514 to 0.607
for placebo.
Table 28 presents the numbers of gross and net QALYs gained, as measured by the EQ-5D (primary
analysis), EQ-VAS and SF-6D. There were no statistically signiﬁcant differences between treatment groups.
Similarly there were no differences in either outcome measure in the cost-effectiveness analyses – the AUC
for BDI-II scores and the number of ‘depression-free weeks’ (when participants’ BDI-II scores were less
than 13). The number of participants reporting time free from depression was low – 18 (11%) in the folate
group and 23 (15%) in the placebo group at 4 weeks, rising to 56 (33%) and 63 (41%), respectively,
at 25 weeks.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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FIGURE 12 Participants responding to each dimension of the EQ-5D – by time and treatment allocated.
n shows the number of completed responses within each treatment group. Level 3 represents the most
severe problems. (continued)
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FIGURE 12 Participants responding to each dimension of the EQ-5D – by time and treatment allocated.
n shows the number of completed responses within each treatment group. Level 3 represents the most
severe problems.
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TABLE 28 Unadjusted health outcomes over 25 weeks – by treatment allocated
Outcome
measure
Full responses no. (%) Mean (95% CI) including inputed response
Folate Placebo Folate (n = 223) Placebo (n = 217) Difference
QALYs (EQ-5D) 172 (77.1) 165 (76.0) 0.290
(0.270 to 0.308)
0.298
(0.279 to 0.316)
–0.0079
(–0.0346 to 0.0191)
QALYs (EQ-5D –
complete cases)
0.294a
(0.274 to 0.314)
0.290b
(0.269 to 0.309)
0.0046
(–0.0254 to 0.0328)
QALYs (EQ-VAS) 173 (77.6) 162 (74.7) 0.276
(0.262 to 0.290)
0.275
(0.262 to 0.288)
0.0008
(–0.0187 to 0.0197)
QALYs (SF-6D) 157 (70.4) 141 (65.0) 0.292
(0.273 to 0.311)
0.303
(0.284 to 0.322)
–0.0113
(–0.0378 to 0.0156)
AUC (BDI-II)c 169 (75.8) 154 (71.0) 12.91
(12.19 to 13.66)
12.95
(12.16 to 13.76)
–0.030
(–1.12 to 1.06)
a n = 172.
b n = 165.
c True area under curve, not ‘AUC average’.
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In the primary analysis after baseline adjustment following Manca et al.,126 folic acid is on average £48 less
expensive than the placebo group, and more effective by 0.0012 QALYs. As those ﬁndings put folic acid in
the south-east quadrant of the cost-effectiveness plane (Figure 13) it is therefore the dominant strategy.
However there is considerable uncertainty surrounding these estimates, shown by the distribution of costs
and QALYs over all four quadrants of the cost-effectiveness plane. The estimated probability of folic acid
saving costs is 64%, and that of it gaining QALYs is 55% (Table 29). The resulting cost-effectiveness– 0.03 – 0.02 – 0.01 0.00 0.01 0.02 0.03
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FIGURE 13 Cost-effectiveness plane showing joint distribution of costs and QALYs. Note: Confidence ellipses
represent the 5%, 50% and 95% levels of confidence.
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cacceptability curve (Figure 14) shows that the probability of folic acid being cost-effective is 0.62 at the
threshold of £20,000 per QALY and 0.61 at the £30,000 threshold (see Table 29).
As this ICER is close to the origin of the cost-effectiveness plane, comparison with other QALY outcomes is
labile. For example QALYs derived from both the EQ-VAS and SF-6D located the ICER in the south-west
quadrant, where folic acid is both less effective and less expensive than placebo.
The interpretation of cost-effectiveness results suffers from lack of a benchmark for economic efﬁciency.
The unstable direction of differences in mean effect exacerbates this. The primary clinical outcome of area
under the BDI-II curve shows folic acid dominating placebo, being more effective and less costly. However
the cost per depression-free week averted suggests that folic acid is less effective by an average of 6
depression-free days over 25 weeks, though less expensive. In short the proximity of all possible criteria to
the origin of the cost-effectiveness plane, and associated uncertainty suggests that folic acid is no more
effective, but no more expensive than placebo.Genetics
Introduction
Of the 440 patients included in the main analysis by treatment allocated, we excluded from genetic
analysis: ﬁve with low genotype call rates; 14 non-Caucasians; and 38 who did not consent to the genetic
study. Thus we included 383 patients in genetic analysis.
Of the 142 variants genotyped, 38 were omitted as they failed to meet minimum inclusion criteria. These
included 19 SNPs owing to quality controls issues with the call rate of the speciﬁc SNP assay; 13 SNPs
due to a minor allele frequency < 0.01, and six with a Hardy–Weinberg p-value of < 0.0001. In total
104 genetic variants were carried forward for analysis.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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RESULTS
58Results of the analysis of association between each SNP and each of the seven outcome measures (BDI-II,
MADRS, CGI1 severity of illness, EQ-5D, EQ-5D visual analogue score (VAS), SF-12 mental, and SF-12
physical) are given in Table 30. Two associations gave a FDR < 0.05. Results of assessing for the statistical
signiﬁcance of a SNP-treatment group interaction term for each SNP and each outcome are given in
Table 31 – for this only one SNP gave a FDR < 0.05.
Statistically significant main single nucleotide polymorphism effects
The rs11627525 SNP in the methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1 (MTHFD1)
gene was associated with MADRS (p = 0.0004, FDR = 0.0467). This association was not replicated with any
of the other six outcome measures analysed (p > 0.05; FDR > 0.05).
A plot of mean MADRS at each study time point compared with rs11627525 genotype, stratifying by
genotype [CC wild-type group and a combined CT and TT group since the homozygote variant allele
frequency was so low (n = 4)], is given in Figure 15. At baseline, there was no difference observed
[28.3 ± 0.4 (CC) compared with 29.0 ± 0.7 (CT/TT)]. The data suggest a more dramatic reduction in
MADRS between baseline and 12 weeks between CC individuals (mean difference between baseline and
12 weeks: 6.11) and the combined CT/TT group (mean difference between baseline and 12 weeks: 9.82).
The rs588458 SNP in the folate hydrolase 1 (FOLH1) gene was associated with EQ-5D (p = 0.0003,
FDR = 0.0337). This association was not replicated with any of the other six outcomes (FDR > 0.05),
although both EQ-VAS (p = 0.0414) and SF-12 mental (p = 0.0140).
A plot of mean EQ-5D scores at baseline, 4 12 and 25 weeks, stratiﬁed into the three genotype groups, is
given in Figure 16a. At baseline, TT carriers had a mean EQ-5D of 0.534 (± 0.024) – the mean scores for
heterozygotes (TC carriers) were 0.049 lower, while they were 0.102 points lower for CC carriers. Similar
differences were observed at 4 weeks with TC carriers being 0.078 lower than TT (0.625 ± 0.023) with
CC carriers being 0.140 lower than TT. A signiﬁcant difference in score was apparent at 12 weeks
where the mean score (± SE) for TT carriers was 0.645 (± 0.023) compared with 0 for TC genotype (0.058
lower) and (0.140 lower than baseline) for individuals with the CC genotype. Similarly, at 25 weeks, mean
EQ-5D for TT individuals (0.673 ± 0.023) was signiﬁcantly higher (0.09 points) than TC which, in turn, was
signiﬁcantly higher (0.192 points) than for CC genotype). The overall trajectory of improvement
(by EQ-5D) appears to stabilise ﬁrst in the CC group (at around 4 weeks); then the TC group at around
12 weeks; whilst the wild-type TT group appear to continue to improve.
Plots for EQ-VAS and SF-12 Mental Component Scale (MCS) against rs588458 genotype are also provided
(see Figure 16b and c, respectively) since the associations with rs588458 in the main SNP effect model
gave p < 0.05. For mean EQ-VAS, there was a signiﬁcant divergence between genotypes at 12 weeks
with TT genotype (62.2 ± 1.9) signiﬁcantly higher (difference of means = 4.5) than CT (57.7 ± 1.8) and
CC (52.6 ± 2.8) (difference in means = 9.6). No difference was observed at any earlier time points. Mean
SF-12 did not show an obvious divergence between genotypes at any of the time points though a
moderate difference was seen at 12 weeks between TT (37.1 ± 1.0) and TC (34.3 ± 1.0).NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 30 Signiﬁcant associations between folate pathway gene polymorphisms and seven outcome measures
SNP Gene symbol Associated outcome measure Signiﬁcance
rs10380 MTRR PCS 0.0491
rs1051266 SLC19A1 EQ-VAS 0.0103
rs10640 AMT1 MCS 0.0023
rs1127717 ALDH1L1 EQ-5D 0.0064
rs11545078 GGH EQ-VAS 0.0162
rs11627525 MTHFD1 MADRS 0.0004*
rs11995525 GGH BDI-II 0.0382
MADRS 0.0337
EQ-VAS 0.0383
rs12347 MTRR CGI1 0.0329
rs1532268 MTRR PCS 0.0489
rs16837178 ALDH1L1 BDI-II 0.0493
MADRS 0.0460
CGI1 0.0356
rs1801133 MTHFR PCS 0.0297
MCS 0.0481
rs2236225 MTHFD1 MADRS 0.0354
MCS 0.0322
rs2273026 SHMT1 MADRS 0.0147
rs2273028 SHMT1 BDI-II 0.0431
MADRS 0.0195
rs2330183 SLC19A1 EQ-VAS 0.0060
rs2461838 SHMT1 BDI-II 0.0159
MADRS 0.0338
rs2853532 TYMS PCS 0.0494
rs3772426 ALDH1L1 MADRS 0.0407
MCS 0.0180
rs383028 FOLH1 MADRS 0.0303
EQ-VAS 0.0143
rs4817577 GART MCS 0.0181
rs4920037 CBS MADRS 0.0361
EQ-5D 0.0195
rs4933327 MAT1A MADRS 0.0071
rs588458 FOLH1 EQ-5D 0.0003*
EQ-VAS 0.0414
MCS 0.0140
rs6435899 ATIC BDI-II 0.0202
MADRS 0.0046
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TABLE 30 Signiﬁcant associations between folate pathway gene polymorphisms and seven outcome measures
(continued )
SNP Gene symbol Associated outcome measure Signiﬁcance
CGI1 0.0275
EQ-5D 0.0212
EQ-VAS 0.0023
MCS 0.0488
rs6494509 MTFMT PCS 0.0077
rs6668344 MTR BDI-II 0.0489
rs6800400 ALDH1L1 PCS 0.0035
EQ-5D 0.0090
rs7010484 GGH BDI-II 0.0423
CGI1 0.0087
MCS 0.0342
rs7553194 MTHFR PCS 0.0138
rs8012229 MTHFD1 MADRS 0.0023
TSER TYMS PCS 0.0088
MCS 0.0369
* False discovery rate of < 0.05.
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TABLE 31 Signiﬁcant interactions between folate pathway gene polymorphisms, treatment and seven outcomes
SNP Gene Interacting outcome measure Signiﬁcance
rs1004474 TYMS BDI-II 0.0456
EQ-VAS 0.0369
rs1127717 ALDH1L1 EQ-5D 0.0368
rs13268472 GGH PCS 0.0100
rs16837171 ALDH1L1 MADRS 0.0402
MCS 0.0038
rs17102596 MAT1A BDI-II 0.0135
MADRS 0.0151
CGI1 0.0086
MCS 0.0002*
rs1801394 MTRR MCS 0.0336
rs1950902 MTHFD1 CGI1 0.0097
rs2236225 MTHFD1 PCS 0.0023
EQ-5D 0.0164
EQ-VAS 0.0224
rs2276726 ALDH1L1 EQ-5D 0.0175
rs2372536 ATIC EQ-5D 0.0069
MCS 0.0016
rs2586154 MTHFS BDI-II 0.0371
rs2586183 MTHFS BDI-II 0.0073
CGI1 0.0111
EQ-VAS 0.0179
MCS 0.0026
rs2733107 MTHFS CGI1 0.0347
rs2853532 TYMS MCS 0.0491
rs3862534 MAT1A MADRS 0.0443
MCS 0.0022
rs4779165 MTHFS PCS 0.0057
rs4920037 CBS BDI-II 0.0246
CGI1 0.0333
MCS 0.0315
rs535112 CTH EQ-VAS 0.0350
rs7010484 GGH MADRS 0.0025
rs8042012 MTHFS CGI1 0.0262
MCS 0.0061
TSER TYMS MCS 0.0182
* False discovery rate of < 0.05.
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RESULTS
62Statistically significant single nucleotide polymorphism–treatment interaction
For the model incorporating the treatment interaction term, the association of the rs17102596 SNP in the
methionine adenosyltransferase I alpha (MAT1A) gene and SF-12 mental status was statistically signiﬁcant
(p = 0.0002, FDR = 0.0255).
A plot of mean SF-12 Mental Component Score at each study time point stratiﬁed by genotype and
treatment group (folic acid or placebo) is given in Figure 17. At baseline, no difference in SF-12 is observed
between TT (25.0 ± 0.8) and TC + CC (25.2 ± 1.2) groups in the folate arm of the trial. In the placebo arm,
there was a modest difference at baseline between TT (25.8 ± 0.9) and TC + CC (28.2 ± 1.3). In both arms
of the trial, wild-type (TT) individuals showed a similar trajectory for increase in SF-12 with similar mean
SF-12 at 25 weeks (folic acid = 25.0 ± 0.8; placebo = 25.8 ± 0.9). In individuals with TC or CC genotypes in
the placebo group, there was a marginally steeper trajectory of the ΔSF-12 resulting in a signiﬁcantly
higher mean value at 12 weeks (39.6 ± 1.7) compared with TT individuals though much of this difference
could be explained by the variability in baseline measure. This is considerably higher than those individuals
with TC or CC genotype receiving folic acid (31.2 ± 1.7) (difference in mean = 8.4) whose Δ mean SF-12
trajectory stabilises after 4 weeks. The SNP effect model was run on the two arms of the trial separately
(data not shown) with resulting statistically signiﬁcant difference in both the folate group (p = 0.02) and
the placebo group (p = 0.00006).
As three other outcomes measure (BDI-II, MADRS, and CGI severity of illness) gave p < 0.05 for tests of
association with rs17102596-treatment interaction (see Table 31), these too were plotted (not shown).
In all three instances the pattern demonstrated with SF-12 was not replicated and no clear distinction in
the trajectory of the improvement determined by each outcome was seen.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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FIGURE 17 SF-12 Mental Component Scores by MAT1A rs17102596 genotype – by treatment allocated.
Note: Graphs plot mean SF-12 MCS scores at each point with vertical bars denoting standard error of the mean.
RESULTS
64Comprehensive cohortWe recruited participants to this cohort as part of the basic trial process until screening results were
known. During the screening appointment the screener took a blood sample to assess B12 and serum
folate status, and arranged a further research appointment within 14 days to conﬁrm these results. As we
then needed to treat patients who were B12 or folate deﬁcient, we had to exclude them from the main
trial. Nevertheless we invited them to continue in the ‘comprehensive cohort’ of recruited patients. Though
they could not contribute to our evaluation of folic acid as adjunct to ADM, they help us to describe the
experiences of the entire cohort of patients invited to join FolATED.Recruitment and baseline characteristics of the comprehensive cohort
Of the 635 people who originally consented to take part, we could not randomise 156 (see Figure 2).
Of these 68 dropped out between screening and randomisation, and another 42 at the randomisation
interview, 36 because their BDI-II scores were too low for the trial. The remaining 46 people continued as
‘residual’ members of the comprehensive cohort alongside the 475 properly randomised into the trial.
Table 3 tabulates the reasons for losses by stage of recruitment; and Appendix 7 does so by centre.
Table 32 compares the baseline characteristics of the ‘residual’ cohort with those of trial completers:
though residual members included more economically inactive females, the most notable difference is
that, while Bangor recruited most to the trial, Wrexham recruited most to the residual cohort.
Methods of analysis and results from the residual cohort
We followed the residual cohort like trial participants, but limited data collection to BDI-II at baseline, 4,
12 and 25 weeks. We also used similar methods of analysis. As the ﬁndings of fully imputed and complete
case analyses were very similar, Table 33 displays the former. Though both residual and control groups
show steady improvement in BDI-II scores from baseline over 25 weeks, the residual members start slower
but ﬁnish with greater net improvement. We attribute this to the delayed effects of therapy to correct
known deﬁciencies in B12 or folate.NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 32 Baseline characteristics – residual cohort vs. trial completers
Participant characteristic Residual cohort (n = 46) Trial completers (n = 440)
Age: mean (SD) in years 47 (12) 45 (13)
Gender: female 35 (76%) 280 (64%)
Race: white 44 (96%) 427 (97%)
Marital status
Single 9 (20%) 109 (25%)
Had a partner 18 (39%) 91 (21%)
Have a partner 19 (41%) 240 (54%)
No dependent children 30 (65%) 269 (61%)
Employment
Full time employed 7 (15%) 121 (28%)
Part time or in education 10 (22%) 124 (28%)
Inactive 29 (63%) 195 (44%)
Smoker? Never 17 (37%) 194 (44%)
Alcohol? None 14 (30%) 177 (40%)
Centre
Bangor 7 (15%) 223 (51%)
Wrexham 24 (52%) 110 (25%)
Swansea 15 (33%) 107 (24%)
Baseline BDI-II score
Mean (SD) 34 (13) 34 (10)
TABLE 33 Changes in BDI-II – residual cohort vs. control group
Patient sample Time of analysis n
Change from baseline
Mean (SD) 95% CI Signiﬁcance
Residual cohort (imputed) 4 weeks 45 4.33 (10.82) 1.00 to 7.65 0.012
12 weeks 45 7.22 (9.41) 4.08 to 10.40 < 0.001
25 weeks 45 14.53 (13.50) 9.67 to 19.40 < 0.001
Control participants (imputed) 4 weeks 217 6.06 (9.96) 4.72 to 7.39 < 0.001
12 weeks 217 9.54 (11.81) 7.96 to 11.12 < 0.001
25 weeks 217 11.33 (12.56) 9.65 to 13.01 < 0.001
Patient sample Time of analysis
Change in residual cohort minus change in control
Mean (SE) 95% CI Signiﬁcance
Residual cohort (imputed)
minus control participants
(imputed)
4 weeks 1.73 (1.75) 5.18 to 1.72 0.323
12 weeks 2.32 (1.62) 5.50 to 0.86 0.151
25 weeks 3.20 (2.19) 1.11 to 7.51 0.143
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RESULTS
66Systematic review of the effectiveness of folate in augmenting
antidepressant medication
Introduction
There is general consensus in current clinical guidelines for depression that the augmentation of ADM with
folate improves patient symptoms. However the supporting evidence is little more than biochemical theory
and two small trials.65,66 Indeed the authors of the current Cochrane systematic review concluded that
there was limited evidence that adding folate to ADM was helpful, and recommended a trial like FolATED
to test this hypothesis thoroughly.50Effects of interventions
Our updated search found no additional trials that met the criteria of the Cochrane review.50 Hence our
updated review analysed three trials – FolATED with 440 analysable participants, Coppen and Bailey with
100,65 and Godfrey et al. with 24.66 As the primary analysis of the much larger FolATED trial favours the
placebo (Figure 18), our updated review reverses the ﬁndings of the Cochrane review. As higher scores on
both alternative outcomes – HDRS and BDI-II – show more depression, the resulting standardised mean
difference of 0.05 (95% CI from –0.11 to 0.22; p = 0.52) also favours placebo. Furthermore there was no
heterogeneity between studies. Hence there is no evidence to support the use of folic acid as an adjunct
to ADM.Study or subgroup
Raw statistics
Godfrey 199066
Coppen 200065 
Folated 2013
Subtotal (95% CI)
Heterogeneity: τ 2 = 0.00; χ 2 = 0.62, df = 2 (p = 0.73); I 2 = 0%
Test for overall effect: z = 0.64 (p = 0.52)
Mean
1.291
1.5
1.422
SD
1
1
1
1
1
1
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13
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285
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1.339
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11
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Weight Year
4.2%
17.7%
78.0%
100.0%
– 0.22 (– 1.02 to 0.59)
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FIGURE 18 Updated systematic review of the effectiveness of folic acid augmentation of antidepressants.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Clinical effectiveness
FolATED shows that on average routinely adding 5mg of folic acid to antidepressants prescribed at
therapeutic dosages has no clinical beneﬁts. The lack of any mean treatment effect is highly consistent
across all outcome measures and time points. The trajectory of response across time is also consistent
between measures. The one exception to this is the MCS of the SF-12, which shows a signiﬁcant
difference favouring placebo, especially at 12 weeks. It is not immediately clear whether this single
statistically signiﬁcant adverse result in a secondary outcome measure has any clinical signiﬁcance. As we
used many secondary measures in the trial, this may be a statistical artefact of multiple testing. Given high
levels of correlation between the MCS and measures of depression;139,140 however, it seems unlikely that
the MCS detected a real treatment effect not detected by the other outcome measures.
To put this disappointing ﬁnding into context, we record that the biochemical outcomes conﬁrmed that
folic acid was delivered successfully, as in other studies.141 Fortunately the few patients who were deﬁcient
in baseline red cell folate yielded consistent evidence that augmenting ADM with folic acid improved their
clinical outcomes. Furthermore folic acid appeared well tolerated, resulting in no more reports of side
effects, AEs or SAEs than placebo.Cost-effectiveness
The FolATED trial showed no signiﬁcant clinical effect of 5 mg folic acid once daily for 12 weeks in new
or existing users of antidepressants. The economic analysis suggested that folic acid might save costs of
about £48 per patient (equivalent to about two-thirds of the cost of antidepressants). According to
economic theory, one might therefore conclude that folic acid has positive net beneﬁts, and should be
recommended for use. However it seems unlikely that the prescribing of an additional, ineffective
medicine would result in reduced costs, since the probability of folic acid being cost saving was not high.
A more appropriate conclusion, therefore, is that the economic evaluation was unable to demonstrate
cost-effectiveness. We interpret results suggestive of dominance in the primary analysis with caution, as
the mean difference in effect was less than half a quality-adjusted day (or six depression-free days) over
the 25 weeks of the trial. Furthermore complete case analysis and alternative methods of calculating
QALYs did not contradict the principal ﬁndings given the small differences in costs and effects, and their
associated uncertainty.
Although it is not generally possible for an intervention to be cost-effective when clinical effectiveness has
not been established, the application of a cost minimisation analysis would be inappropriate for several
reasons.142,143 First, lack of signiﬁcant effects does not conﬁrm equivalence.144 Second, equivalence in one
clinical end point does not necessarily mean equivalence in others. Third, preference-based measures of
outcome may reveal differences unrelated to the effect of the intervention on depression. Finally it is
arguable that hypothesis testing is arbitrary and irrelevant to decision making because the intervention
with the highest net beneﬁt should be adopted whether or not difference in beneﬁt reach conventional
levels of statistical signiﬁcance.145
We considered it inappropriate to extend the economic analysis to evaluate the cost-effectiveness of
pharmacogenetic testing, as the evidence had not supported the clinical utility of testing in relation to the
predicting patients’ responsiveness to folic acid.67
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68Genetics
Our study has identiﬁed two polymorphisms within genes of the one-carbon folate and methionine
metabolism pathways associated with outcome regardless of treatment arm (a main SNP effect), and one
polymorphism–treatment interaction which is associated with outcome. However the well characterised
c.677C > T (rs1801133) polymorphism of the MTHFR associated in previous studies with depression risk or
outcome76,77,79,128 did not modify the effect of either the antidepressant therapy or the folic acid
supplementation. This seems to correlate with the study ﬁnding that folic acid and modiﬁcation of
homocysteine levels does not inﬂuence antidepressant outcome in treatment of moderate to
severe depression.MTHFD1 genetic variation association with outcome measures
Our data suggest an association between the rs11627525 SNP of the MTHFD1 gene locus and outcome.
Though statistically signiﬁcant only for the MADRS outcome, the trend was also present in the BDI-II and
CGI measures of severity of illness. The main difference in MADRS between genotypes appears to
occur between 4 and 12 weeks with the trajectory of improvement similar after the end of folic acid
supplementation at 12 weeks. Given that the effect is seen in the study cohort as a whole regardless of
arm, however, any relationship to folic acid supplementation is questionable. Further support comes from
the lack of an association of the SNP with any outcome when analysed using the model incorporating the
treatment interaction term.
The MTHFD1 gene encodes an enzyme which catalyses three sequential reactions in the inter-conversion
of derivatives of one-carbon tetrahydrofolate, key substrates for methionine, thymidylate, and purine
synthesis de novo. Given its function within the one-carbon folate metabolism, MTHFD1 is a very good
candidate. As only one outcome measure reached statistical signiﬁcance, however, this ﬁnding does
not provide compelling evidence that the SNP in question might be a reliable predictive marker of
antidepressant therapy outcome. Furthermore a difference of three points on MADRS scale after 12 weeks
between the two genetics groups, as well as a decrease of 10.5 (variant carriers) and 7.3 (wild-type) is
not clinically signiﬁcant; so prognostic utility is debatable. However previous studies have estimated the
minimal clinically relevant change in the MADRS as 1.6 to 1.9.146FOLH1 genetic variation association with outcome measures
In addition to the MTHFD1 SNP, our data suggest that the rs588458 SNP in the FOLH1 gene locus is
signiﬁcantly associated with outcome, particularly the SF-12 mental component score (MCS) well-being
tool. This is an intronic variant with no obvious consequence for the functionality of the FOLH1 protein.
Within the HapMap (http://hapmap.ncbi.nlm.nih.gov) CEPH population of Utah residents with ancestry
from northern and western Europe, however, rs588458 is in high linkage disequilibrium (D″ = 1) with
rs202676, a c.484T>C polymorphism, encoding a tyrosine to histidine substitution at amino acid residue
60 (p.Y60H). This variant has recently been identiﬁed as a potential risk factor for anencephaly, a neural
tube defect, in a Chinese population.147
FOLH1 acts as a glutamate carboxypeptidase which performs the initial hydrolysis of glutamate residues
of the main dietary form of folates, folylpoly-γ-glutamates. Thus FOLH1 is a key regulator of intestinal
absorption of dietary folate. Studies have demonstrated that the presence of a p.H475Y amino acid
substitution polymorphism in FOLH1 is associated with impaired absorption of dietary folate, with
associated low blood levels and hyperhomocystinuria.148 Indeed studies have identiﬁed an association
between the c.1561C>T (rs61886492) polymorphism and depressive symptoms on the Center for
Epidemiologic Studies Depression scale (CES-D),149 and cognitive function.150
The association with rs588458 is seen in our study group as a whole regardless of treatment arm. Folic
acid is likely to neutralise any effect of FOLH1 genetic variation on folate levels, and subsequent
improvement in outcome measures. As folic acid supplementation will swamp dietary folate levels, any
effect of FOLH1 variation is likely to occur before or after administration of folic acid or placebo. From our
data, baseline EQ-5D, as well as the trajectory of increase after baseline is greatest in wild-type (TT) and isNIHR Journals Library www.journalslibrary.nihr.ac.uk
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appear to plateau. It is plausible that the difference between genotypes is due to variability in the
availability of dietary folates. Observations for two other outcome measures (EQ-VAS and SF-12 mental)
appear to support the differences in outcome trajectory, particularly between 12 and 25 weeks.
However these observations need caution. Analysis of correlation between serum and red cell folate levels
and genotype suggested that there was no effect on folate levels driven by FOLH1 genetic variation.
It is possible that the association with outcome is independent of folate status. FOLH1, or GCPII as it is
also known, is expressed in brain tissue and hydrolyses extracellular, N-acetylaspartylglutamate,
N-acetylaspartate and glutamate thus affecting glutamatergic transmission. Protein expression and
functionality of FOLH1 may therefore play an important role in the pathophysiology of psychiatric
disorders.151 It is possible that worse outcomes in patients with variant FOLH1 may be due to a GCPII
functionality in the brain and its effect on the depressive symptoms rather than the FOLH1 effect on folate
levels. So this is an encouraging observation that requires considerable further investigation.MAT1A genetic variation and treatment group interaction with
outcome measures
A single interaction between SNP rs17102596 and treatment group was associated with the SF-12 Mental
Scale. This SNP lies within an intronic region of the MAT1A gene. MAT1A encodes the enzyme,
methionine adenosyltransferase I alpha, which catalyses the transfer of adenosyl moiety of ATP to
methionine, forming S-adenosylmethionine, the source of methyl groups for most biological methylations.
Mutations of the MAT1A have been identiﬁed in patients with methionine adenosyltransferase deﬁciency,
also known as hypermethionaemia.152,153 So it is unlikely that variability in this gene would have any direct
effect on either folate or homocysteine levels. This requires further investigation.
Curiously this association suggests that participants with the variant for the MAT1A polymorphism have
better outcomes on the SF-12 Mental Component Scale when receiving placebo, and worse outcomes
when receiving folate. However no other outcome analysed was able to demonstrate a similar effect. Thus
we suspect this is a spurious observation. As such it should be viewed with caution until such time as it is
independently validated.Strengths and limitations of FolATEDFolATED is by far the largest trial to evaluate the clinical effectiveness and cost-effectiveness of folic acid to
augment ADM for depression. We powered it to detect a clinically small difference between treatment
groups, and followed rigorous procedures for randomisation and blinding. We recruited a wide range of
patients being treated for moderate or severe depression in primary or secondary care. There were few
exclusion criteria, and our sample included common comorbidities like substance misuse, often excluded
from less pragmatic trials.
The reported response to ADM was within the range expected from a mixed study of new and continuing
treatment episodes. After 25 weeks 36% of our sample had achieved ‘response to treatment’ deﬁned as a
50% reduction in BDI-II score from baseline; this is consistent with clinical response rates of about 50%
reported in the literature for new patients.18 Also after 25 weeks 27% had achieved ‘remission’, deﬁned as
a BDI-II score less than or equal to 12;123 this is consistent with remission rates between 35% and 50%
reported in the literature for new patients.18 Again after 25 weeks 46% had improved to the point where
they reported BDI-II scores less than 19 (i.e. depression so mild that they would not have been eligible for
FolATED), also consistent with reported recovery rates.
This suggests that the lack of treatment effect for folic acid is not attributable to unusual treatment
resistance to antidepressants in our sample. Indeed the trajectory of response to ADM in our sample, with
a clear reduction in depressive symptoms over the ﬁrst few weeks followed by slower improvement up to69
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7025 weeks, is entirely consistent with the model reported in the large GENDEP sample of 807 patients with
major depressive disorder treated with escitalopram or nortriptyline.154
Also in line with the published literature, baseline severity of depressive symptoms predicted greater
response to ADM.155 Treatment with SSRIs also led to better outcomes over 25 weeks than treatment with
other antidepressants. This supports previous reviews suggesting better practical outcomes for SSRIs are
due to much better completion of therapeutic courses for SSRIs compared with other antidepressants like
TCAs.156 Other ﬁndings also accord with observations from antidepressant trials, with both continuing,
rather than new, antidepressant treatment, and economic inactivity like unemployment or long-term
sickness, leading to poorer response. In short FolATED was both robust and representative.Interpretation
Clinical effectiveness
Our negative outcomes contrast with positive ﬁndings in two small, selective trials. Coppen and Bailey
reported a signiﬁcantly greater reduction in HDRS scores in females treated with ﬂuoxetine and 400µg of
folic acid, compared with ﬂuoxetine and placebo.65 They suggested that males required higher doses of
folic acid. In response we selected 5 mg of folic acid for FolATED to cover the entire dose–response curve
They achieved very high clinical response rates – 82% in the folic acid arm and 62% in the placebo
arm – surpassing those in the general literature, because their sample was much less representative than
that recruited by FolATED. For example they excluded patients with continuing episodes of depression,
previous poor response to ﬂuoxetine, or comorbid substance use. One must also question the robustness
of their blinding, especially in handling blood results, whereas FolATED took great care at all stages to
avoid unblinding clinicians, patients and researchers. While females treated with folic acid by Coppen
showed a 21% reduction in homocysteine levels, similar to the FolATED sample, the males did not. In
FolATED, however, there was no gender difference in homocysteine levels following treatment with folic
acid, suggesting that we covered the dose–response curve, yet without treatment effect.
In contrast Godfrey and colleagues recruited only from secondary care, speciﬁcally patients with folate
deﬁciency (viz. red cell folate less than 200 µg) but suffering from a wide range of psychiatric disorders
including depression and schizophrenia; hence they had to adapt clinical outcomes to diagnosis.66 This
makes comparison difﬁcult as FolATED examined the routine use of folic acid augmentation in depressed
patients recruited predominantly from primary care. Though Godfrey used 15mg of the biologically active
MTHF, the gross differences between studies generate no evidence for the superiority of MTHF over
folic acid.
Hence, after updating the systematic review50 by including FOLATED, we found no evidence to support the
previous suggestion that folic acid could improve the clinical beneﬁts of ADM.Cost-effectiveness
Our economic evaluation showed that folic acid, clinically ineffective, could not be a cost-effective use of
resources. With no other economic evaluations of folic acid in managing depression, we assessed external
validity in comparison with other studies of depression. For example the AHEAD trial pragmatically
compared TCAs, SSRIs and lofepramine in UK primary care, and provided the prototype for our resource
use questionnaire. Though AHEAD followed patients for 12 months, their rates of contact with healthcare
professionals was comparable pro rata with FolATED ﬁndings. AHEAD trial participants visited GPs on 9.1
occasions over 12 months, compared with 3.6 over 25 weeks in FolATED; the mean length of inpatient
stay was 1.05 days in AHEAD, compared with 0.58 in FolATED. With one exception we consider our
participants’ use of NHS and PSS resources to be generally representative of UK practice, and typical of
locations other than the recruiting sites. The exception lies in divergence from the NICE recommendation
that people with moderate to severe depression receive psychological therapy, as only 6.5% of participants
did so. Fortunately there is no evidence that greater use of psychotherapy, engendered for example by theNIHR Journals Library www.journalslibrary.nihr.ac.uk
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insigniﬁcant ﬁndings. As our genetic analysis found no support for pharmacogenetic testing in this ﬁeld,
that too could not be a cost-effective use of resources.Genetic implications
Our study has identiﬁed three polymorphisms associated with modiﬁcation of depression outcomes.
For MTHFD1 rs11627525 and FOLH1 rs588458 this association was independent of treatment allocated;
in particular the new link between EQ-5D and the rs588458 genotype needs further study. The MAT1A
rs17102596 SNP modiﬁed the SF-12 Mental Component Scale through interaction between SNP
and treatment.
In general, however, there is little evidence that any of the variants analysed can predict patients’ response
to ADM or the efﬁcacy of folic acid. Even the three SNPs showing association could not replicate this with
any other outcome measure. Above all none of the polymorphisms analysed could achieve statistically
signiﬁcant modiﬁcation of BDI-II, the primary outcome measure.
However we limited the variants analysed to genes within the one-carbon folate or methionine synthesis
pathways. It is possible that other factors, genetic or otherwise, may inﬂuence patient response to ADM or
folic acid. Thus it is conceivable that in future a whole-genome approach to the FolATED data set could
identify markers of efﬁcacy beyond those already analysed.Biochemical interpretation
Folate is a naturally occurring B vitamin, needed in the brain to synthesise serotonin, noradrenaline and
dopamine. In humans the biologically active form is 5-methyltetrahydrofolate (5-MTHF), which is derived
from ingested folates and is the form taken up by cells and transported to the cerebrospinal ﬂuid (CSF) via
folate receptors. Folic acid is an inactive, stable, synthesised, oxidised form of folate, not naturally found in
the human body; it has to undergo transformation to 5-MTHF – an inefﬁcient process as unmetabolised
folic acid remains in the blood even after an intake of only 400 µg, the recommended daily intake of
folate. Folinic acid (calcium folinate) is a stable reduced form of 5-MTHF that needs no transformation
before entering the CSF.157 There is evidence that commercial preparations of folic acid can compete with
5-MTHF for the folate receptor and thus exacerbate a folate deﬁciency in the central nervous system
(CNS).158 Hence we wonder whether our ﬁnding that folic acid had a statistically signiﬁcant negative effect
on the widely used SF-12 MCS was a manifestation of such a folate deﬁciency rather than the type 1 error
that we ﬁrst supposed.
Thus better understanding of the one-carbon folate and methionine biosynthesis pathways have raised
questions about the most appropriate formulation of folate to use clinically for functional folate deﬁciency.
Stahl argues that 5-MTHF is therapeutically better than folic acid as it bypasses conversion of folic acid to
the biologically active 5-MTHF, which may be difﬁcult for some patients.159 Furthermore high doses of
inactive folic acid may compete with 5-MTHF for transport across the blood–brain barrier, potentially
reducing active 5-MTHF in the brain. Other reasons why 5-MTHF synthesis may be difﬁcult include
inhibition of the enzyme by anticonvulsants. Fortunately we avoided this potential confounding factor by
excluding patients on anticonvulsant medication.
Against this biomedical background our rigorous and powerful trial has established that folic acid has no
general role as adjunct in antidepressant therapy. However studies in patients with cardiovascular disease
have shown that higher doses of folic acid produce greater concentrations of 5-MTHF in plasma.160
Moreover the reductions in homocysteine in FolATED participants on folic acid relative to those on placebo
suggests that they were successfully metabolising folic acid to 5-MTHF. Nevertheless we suspect that the
beneﬁcial increase in 5-MTHF was masked by the excess folic acid that competed with 5-MTHF for the
folate receptors and led to the negative results.
71
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72Recommendations for research
Folate and depression
Our inclusive multi-disciplinary trial has shown beyond doubt that folic acid is an ineffective adjunct in
antidepressant therapy. Furthermore better understanding of the one-carbon pathway offers a plausible
explanation why.158 Before we can write off folic acid entirely, however, we recommend updating the
Cochrane systematic review and meta-analysis,64 and summarising the systematic review data more
thoroughly than was possible in Chapter 3 (see Systematic review of the effectiveness of folate in
augmenting antidepressant medication).
At the time of our initial grant proposal little information was available on the use of 5-MTHF or folinic
acid in patients with depression. Now there is evidence that 5-MTHF given as adjunct or monotherapy
reduces depressive symptoms in patients with low folate levels or alcoholism, and improves cognitive
function and reduces depressive symptoms in elderly patients with dementia and folate deﬁciency.161
Furthermore there are long-standing concerns that folate may increase cancer risk, mask B12 deﬁciency and
exacerbate depressive symptoms. As 5-MTHF may reduce some of these risks, we judge that that is now a
candidate for a large multi-centre trial. There is also evidence that adjunctive 5-MTHF reduces depressive
symptoms in patients who were partially responsive or non-responsive to a selective SSRI.161
In that context we offer the design of FolATED as a proven model. With the beneﬁt of hindsight, however,
we judge that a trial recruiting for 1 year in 10 centres would yield better value for money than one
recruiting for 3 years in three centres.Recruitment
Like many trials FolATED recruited more slowly than expected. We based the original target of randomising
550 participants in three centres over 2 years – slightly less than 24 per month across all three centres – on
experience with a previously successful trial in one of the three centres. Initially, however, the complex
design of FolATED, designed to exclude patients suffering from folate or B12 deﬁciency while allowing
psychiatric teams to optimise antidepressant treatment in normal clinical practice (Figure 1), restricted
randomisation across all three centres to eight a month. We attribute our success in eventually increasing
these initial rates by 50% to 12 a month across all three centres to a lot of hard work, a combination of
creative protocol changes summarised in Appendix 4, and the mutual support engendered by joint training
and joint monthly telephone conferences about management and recruitment.
Late in the conduct of FolATED we used a qualitative reﬂective data collection tool to undertake a
retrospective study of recruitment and retention issues (see Appendix 11). We sought, not to evaluate
which methods were the most effective in increasing recruitment and retention, but rather to gain insights
into problems we faced and methods we used to overcome recruitment and retention problems within
FolATED. We found little research into participants’ preferences between different approaches. This leads
us to recommend that future large trials include smaller trials or qualitative studies or both to assess the
effectiveness of materials used in recruitment such as posters, leaﬂets, patient information sheets and
newsletters to participating practitioners.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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This rigorous and adequately powered trial has established that folic acid is not an effective adjunct toantidepressant therapy. The NIHR Health Technology Assessment programme commissioned FolATED at
a time when there was considerable scientiﬁc interest in the role of folate in the aetiology of depression
and in treating depression. During the lifetime of FolATED this interest has grown, with increasing
international pressure to use folate as an adjunct to antidepressants and in algorithms for
treating depression.
The unequivocally negative ﬁndings of FolATED demand reappraisal of this consensus and associated
treatment guidelines. Thus there is a strong case for research to investigate whether future trials of
5-MTHF would yield value for money.73
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approved by DMEC, TSC, MHRA, MREC and NCCHTAReferralsInitially we accepted referrals from GPs and psychiatrists only. To be more inclusive, and to improve
recruitment into the trial, on 15 May 2009 we started to accept referrals from other healthcare
professionals including primary care liaison workers, social workers and mental health nurses.
To improve recruitment in the Swansea centre, we amended our protocol to accept self referrals from
people already taking antidepressants. From 26 June 2010 we recruited participants through
advertisements in the community, including posters, local newspapers, pharmacies, clinics and general
practices. To help with the expected increase in referrals we gained permission for registered mental health
nurses to screen people who refer themselves to the study.
Our original protocol stated that we would reimburse general practices £50 to cover administration costs
for every patient recruited. In November 2010 we gained permission to extend reimbursement to
secondary care teams.RecruitmentWe initially planned to complete all randomisations by August 2008. However unforeseen delays in
research governance delayed the start of recruitment by 6 months for reasons including: change of
sponsor; delays in appointing researchers; delays in obtaining regulatory approval; and delays in obtaining
honorary contracts. We also encountered obstacles to recruitment including: shortage of psychiatrists to
screen patients; fewer referrals from secondary care than expected; fewer referrals of newly diagnosed
patients than expected; limited space in general practices for screening; and difﬁculty in contacting
referred patients. The NIHR HTA programme therefore granted us a 24-month costed extension to extend
recruitment by 18 months.
On 25 June 2009 we gained permission to extend the Wrexham centre to include Conwy
and Denbighshire.Exclusion criteriaIn July 2007 we removed substance misuse from the list of exclusion criteria for three reasons:
1. to make the trial more pragmatic and inclusive
2. to increase recruitment, and
3. because we could detect folate deﬁciency from alcohol use through blood tests at screening.
We added malignancy and related conditions like intestinal polyposis as exclusion criteria, following advice
from the TSC in January 2007 based on evidence from rat studies that high folate intake may increase
growth of existing tumours.
In response to our original application for a CTA the MHRA asked us to add taking lithium as an exclusion
criterion, which we did. However we found no evidence of adverse interactions between lithium and
folate. Furthermore we identiﬁed that this exclusion criterion was impeding recruitment into the trial,103
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104particularly from secondary care. In April 2008, we therefore amended the exclusion criterion for taking
lithium to exclude patients with bipolar disorder whether taking lithium or not. This ensured that only
patients with unipolar depression entered the trial.Data collectionIt had been our intention for the FolATED trial to be paperless. However IT constraints led us had to
substitute a rigorous paper-based system to collect data and we amended the protocol accordingly.
We identiﬁed a need for researchers to make home visits to conduct the research assessments. Depression
can often make it difﬁcult for patients to attend hospital and many potential participants had requested
that researchers go to their homes for appointments. In May 2009 we amended the protocol to allow
researchers to visit homes when needed.Assessment and follow-upFollowing the initial application for approval in October 2006, we received further requests from the
MREC, local R&D Departments and Trial Management Group to amend the protocol, including:
1. taking extra samples of blood for homocysteine analysis, to guard against losing samples in the post
2. collecting red cell folate at screening to ensure that we did not randomise patients with
folate deﬁciency
3. collecting serum folate at weeks 12 and 25 to check for compliance
4. measuring plasma vitamin B12 concentrations at minus 2, 12 and 25 weeks, to guard against
participants becoming B12 deﬁcient during treatment with folic acid and resulting in a neuropathy, and
5. asking patients at each follow-up whether they are taking additional supplements.
We found that the initial screening appointment with patients took longer than expected owing to the
number of assessments. In April 2008 we gained permission to remove the majority of the assessments
including the MADRS, UKU, SF12, EQ5D and CGI from this appointment. The full battery of assessments
at randomisation, which provided the true baseline, continued as planned. This increased the number of
patients be screened by psychiatrists and reduced the burden on participants.
After the MHRA recommended following up any pregnancy that occurs during a trial, we gained
permission in April 2008 to alter the information sheet to allow us to track any such pregnancy.
On 17 September 2008, the TSC identiﬁed the need to ask participants explicitly about attempts at
self-harm. Though we deﬁne self-harm as a SAE, this relies on participants reporting it without prompts.
We therefore added the question: ‘Since we last saw you, have you tried to harm yourself? For example,
have you taken any extra tablets or cut yourself or done anything else to injure yourself?’Additional analysesIn December 2009 we gained permission to investigate the interaction between folic acid and MMA, a
metabolic marker of the enzymatic function of vitamin B12 and a more sensitive marker of B12 status.
High-dose folate is generally considered safe, provided that B12 deﬁciency is excluded.162 However, there is
evidence that high folate levels combined with low B12 levels are associated with signiﬁcant cognitive
impairment in the elderly.163 Furthermore the US National Health and Nutrition Examination Survey
observed a relationship between folic acid and MMA (57). The FolATED trial offers a rare opportunity to
observe the effects of folic acid supplementation on MMA concentration (not reported in this monograph).NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18480 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 48To ensure the safety of participants in the trial ﬁeldworkers informed their Principal Investigator (PI) of any
participant who attempted suicide or was at high risk. For this purpose they completed the MINI suicidality
scale at the end of the MADRS. If there was a marked increase in suicidal risk, they reported this as a SAE.
Though we had approval to monitor suicidality through our safety reporting system, we did not name the
MINI suicidality explicitly in our protocol. The MREC therefore asked us not to analyse these data. However
our TSC were concerned that not to report fully on the safety of our intervention would be unscientiﬁc.
So they recommended that we seek permission to publish this information in the public domain.
We therefore gained permission in May 2011 to publish analyses comparing differences between the
two treatment groups in MINI suicidality scores at follow-up.Clariﬁcation of protocolFollowing meetings of TSC and Data Monitoring Committee early in 2007 we replaced the lay summary
with a technical abstract at the beginning of the protocol.81 We elaborated on screening, informed
consent, randomisation, withdrawal and safety reporting. We improved clarity, not least by integrating the
ﬂow diagram and outcome measures table into the main text of the protocol.81,82Review of power calculation (approved by DMEC, TSC
and NCCHTA)We originally powered FolATED to detect a difference between the two treatment groups of three points
on the Beck Depression Inventory (BDI-II) at 25 weeks, judging that a clinically important difference. As we
estimated the SD of BDI-II scores in the trial population at 10.7, our protocol proposed a completed sample
size of 400 at 25 weeks to yield 80% power to detect this difference using a signiﬁcance level of 5%.
As interim analysis of baseline BDI-II scores showed that their SD was about 10, we revised the target
completed sample size to 358 at 25 weeks. The original protocol allowed 10% loss at each of the
three follow-up assessments, thus requiring a randomised sample of 549 to achieve 400 completers at
25 weeks. As interim analysis also showed that retention at 25 weeks was 79% rather than the
73% expected, the new target of 358 completers needed a randomised sample of 453 participants.105
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Trial design
FolATED is a three-centred, double-blind, placebo-controlled, pragmatic randomised trial of folic acid
augmentation of moderate-to-severe depression. It investigates the effect of augmentation on new and
continuing ADM. Assessments take place 2 weeks before randomisation (‘week –2’) to screen for eligibility
and initiate antidepressant if required; 1 week before randomisation (‘week –1’) by telephone to check for
tolerability of antidepressant; baseline (‘week 0’) to randomise to folate or placebo; and at weeks 4, 12
and 25 to assess outcomes. To estimate the effectiveness of folic acid in augmenting ADM, the trial uses
standardised instruments to measure changes in depressive symptoms from two perspectives – clinical
and participants’.Primary outcome measures
The primary clinical effectiveness outcome measure is self-rated symptom severity as measured by the Beck
Depression Inventory (BDI-II). Though BDI-II scores at 25 weeks are useful in assessing participants’
medium-term recovery, the primary outcome is the ‘AUC’ of mean BDI-II scores between randomisation
and the 25-week follow-up, to aggregate participants’ paths to recovery over that timeframe. The primary
economic measure is ICER, namely cost per QALY gained.Secondary outcome measuresa. Symptom severity as measured by clinicians using the MADRS and the CGI of change.
b. Health status (mental and physical components) as measured by SF-12.
c. Health utility as measured by the EuroQoL (EQ-5D).
d. Proportion of patients with moderate depression (deﬁned as BDI-II score ≥ 19) at week 25 – estimated
by statistical inference from observed distribution of BDI-II scores rather than statistically weaker
technique of counting cases.
e. Side effects as measured by the UKU side effects scale and reported AEs – serious examples include
psychiatric inpatient admission, attempted or completed suicide, and other mortality.
f. Compliance and adherence of patients to take the medication as prescribed.
g. Suicidality as measured by the MINI suicidality scale.
h. Folate status as measured by homocysteine derived from blood samples taken at baseline, 12, and
25 weeks; and B12 status as measured by MMA at 12 weeks only.
i. Resource use as measured by the self-completed health and social care resource use questionnaire, and
j. Genetic analysis of SNPs between the two arms.Scope of statistical analysis plan
The statistical analysis plan focuses on clinical effectiveness as measured by its primary outcome and
secondary outcomes a to g. Annexes 2 and 3 summarise the assessment timetable and outcome measures.
Annex 4 outlines the methods for economic analyses; Annex 5 those for genetic analysis; and Annex 6
those for biochemical analysis.Management of analysis of trialThe trial data manager will coordinate the preparation and provision of suitable data sets for the various
analysts, and the transfer of data between them. He will manage all data in accordance with the NWORTH
data management standard operating procedure (SOP) – 6.01.164 Statistical and health economic analysis107
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108will follow the principles set out in the corresponding NWORTH SOPs – 5.02165 and 7.01.166 The genetic
analyses will follow the relevant SOPs in use in Liverpool University.Data collection
Visit windows
Though we aim to complete questionnaires 2 weeks before randomisation and 12 and 25 weeks
thereafter, we have deﬁned an advisory window for each. We monitor reasons for collecting the data
outside these windows.
Mode of data collection
Some of the trial instruments are administered by researcher or clinician, and others by participant. There is
evidence from the MODE-ARTS systematic review that pragmatic changes of administrator ‘at random’ are
unlikely to bias outcomes within placebo-controlled trials.167Allocation concealment and unblinding the data
In principle throughout recruitment to the trial we conceal treatment allocation from participants,
healthcare professionals, investigators, and study team. We shall continue this during data analysis.
The trial report will specify occasions when blinding was broken for speciﬁc participants.
We shall unblind the data at the joint ﬁnal meeting of the TSC and the DMEC meeting on 10 October
2011. The chair of this meeting will have a sealed envelope to unblind the data when the TSC and DMEC
members are content. After correcting errors detected up to, and as a consequence of, the TSC-DMEC
meeting, the trial statistician (RhW) will freeze the database. No longer than a week before that meeting
an independent senior statistician (CJW) will check the allocations and thus become unblinded to the
treatment allocation. However the trial statisticians (RhW, YS as the assistant trial statistician, and BRC as
senior trial analyst responsible for the second, validating analysis) will continue to analyse clinical
effectiveness blind to allocated treatment.Delivery of data sets to biochemistry, genetics and health economics teams
These teams will receive cleaned data from NWORTH. Annexes 4–6 describe the analysis of these data.TABLE 34 Data collection end point windows
Data collection Day due (days since randomisation) Window
Screening for eligibility (week –2) –14 days ± 10 days
Telephone monitoring –7 days ± 3 days
Randomisation (baseline) 0 Origin
4-week follow-up 28 days + 14 days
12-week follow-up 84 days ± 14 days
25-week follow-up 175 days ± 28 days
NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Populations
‘Analysed’ population
This population – the subject of the principal analyses – comprises all randomised participants with at least
one post-baseline BDI-II outcome. If they fail to return any questionnaire or to complete all items for each
instrument, we shall impute these data using the principles and methods described under Missing
Data above.‘Complete case’ population
This population comprises only those participants whose outcome data are complete. It will provide a
useful sensitivity analysis of primary and secondary ﬁndings, especially whether they are sensitive to the
presence of missing data and the methods of imputation we use to augment them.‘Randomised’ population
At ﬁrst sight it is difﬁcult to draw inferences about this population because some contributed no data after
baseline, even on the BDI-II. Because we know the baseline characteristics of all these participants,
however, it is possible to reweight the analysed population so they match the characteristics of the
randomised population, notably allocated treatment, stratifying variables and baseline BDI-II.Instruments
BDI-II
We shall compare the effects of adding folic acid or placebo on self-rated symptom severity by comparing
the total scores of the BDI-II.84
Scoring: This instrument collected data at: screening; baseline; 4; 12; and 25 weeks. We shall score it
according to the validated manual, namely by summing the ratings of the 21 items. Each item is rated on
a four-point scale ranging from 0 to 3, yielding a total possible score of 63. If a participant ticks more than
one category, we shall score the highest.MADRS
We shall compare the effects of adding folic acid or placebo on researcher-rated depression severity by
comparing total MADRS scores.90
Scoring: This instrument collected data at: baseline; 4; 12; and 25 weeks. We shall score it according to
the validated manual by adding the ratings of the 10 items. Each item is rated on a seven-point scale
ranging from 0 to 6, yielding a possible score of 60. If a rater selects more than one category, we shall
score the highest.CGI
We shall compare the effects of adding folic acid or placebo on the researcher-rated CGI.91
Scoring: This instrument collected data at: baseline; 4; 12; and 25 weeks. It comprises three separate
clinician-rated items: an ordinal scale of current severity of illness using a range of responses from 1 to 7;
an ordinal scale of global improvement since recruitment ranging from 1 to 7; and an efﬁcacy index
ranging from 0.25 to 4.0 derived from a 4 × 4 matrix plotting therapeutic effect against side effects.SF-12 version 2
We shall compare the effects of adding folic acid or placebo on self-rated quality of life in the form of
SF-12 scores for mental and physical components.91109
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110Scoring: We collected SF-12 data at baseline 4, 12, and 25 weeks. The SF-12 comprises ten × 5-point
items and three 3-point items. We shall score it according to the validated method, namely by applying
Norm-Based Scoring (NBS) algorithms using the recommended standardisation (mean = 50, SD = 10 in the
1998 general US population) to calculate the physical and mental component scores PCS-12 and MCS-12.
Missing items: We shall use the SF-12 missing data software which uses Missing Data Estimation.EQ-5D
We shall compare the effects of adding folic acid or placebo on self-rated health utility in the form of the
EQ-5D (also known as EuroQol). This consists of a self-reported matrix and a self-rated visual analogue
scale (EQ-VAS).93 The self-reported matrix comprises ﬁve dimensions: mobility, self-care, usual activities,
pain-discomfort and anxiety-depression.
Scoring: This instrument collected data at: 4, 12, and 25 weeks. The ﬁve dimensions use three-point
scales ranging from 0 to 2. If a participant ticks more than one category, we shall score the highest. In the
clinical effectiveness section we shall analyse this as an outcome in its own right, rather than convert it to
QALYs. In contrast the health economics section will convert these data to QALYs.UKU side-effects scale
We shall compare the effects of adding folic acid or placebo on four UKU researcher-rated system-speciﬁc
side-effect scores and their total.94
Scoring: Participants completed the instrument at telephone monitoring 1 week before baseline; baseline;
4; 12; and weeks. The instrument sums scores on 48 distinct side effects – 10 ‘psychic’, 8 ‘neurologic’,
11 ‘autonomic’ and 19 other, of which 11 are gender-free, four are male-speciﬁc and four are
female-speciﬁc. It ﬁnishes with three generic items, of which we used two – global assessments by ‘patient’
and researcher – for imputation. It rates each item on a four-point scale ranging from 0 to 3, yielding
possible system-speciﬁc scores of 30, 24, 33 and 45 (different questions for each sex, but same total).
Missing items: If respondents fail to answer system-speciﬁc items in the instrument, we shall consider
them informative missing items and impute by assuming they did not experience those items If raters score
above the range of the instrument, we shall censor at the upper limit.
Analysis: As the authors developed the UKU scale speciﬁcally for psychotropic drugs, they planned mainly
to analyse speciﬁc side effects, but acknowledged the case for planned analyses of system-speciﬁc scores.93
Believing that folate does not have independent psychotropic properties, however, we shall test whether it
is safe by analysing the four system-speciﬁc scores.Morisky compliance scale
We shall use this four-item instrument to compare the effects of adding folic acid or placebo on self-rated
compliance with medication.95
Scoring: Participants completed the instrument at 12 weeks. We shall score it as the number of ‘yes’
responses, yielding a score between 0 and 4.MINI suicidality scale
We shall use this six-item instrument to compare the effects of folic acid and placebo on self-reported
suicidality.96
Scoring: Participants completed the instrument at all six data collection points: screening; monitoring;
baseline; 4; 12 and 25 weeks. Though we selected it primarily to fulﬁl our duty of care to participants, the
TSC and DMEC asked us to analyse it as an outcome in its own right, and the Wales MREC agreed.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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yielding a total score between 0 and 33.Missing dataWe shall adopt a consistent approach to missing data relating to both effectiveness and cost-effectiveness
except where individual outcome measures require some variation in that approach; for example the SF12
has its own missing data software. In particular we shall exclude participants without follow-up data. Then
for each variable we shall summarise the frequency of missing data by type (e.g. participant withdrew;
questionnaire not returned; page missing; item missing). Where < 10% of data are missing, we shall
assume they are missing completely at random in the sense that there is no systematic reason for absences
(MCAR).108 Where > 10% of data are missing, we shall explore the missing data and tabulate them by
stratiﬁcation variables [namely centre (Swansea, North East Wales or North West Wales); sex (male or
female); new or continuing prescription (where participants in the second category have taken the same
daily antidepressant for at least 2 months with a stable dose in the therapeutic range reported in the BNF
for at least 1 month); type of antidepressant prescribed (SSRI or other) and whether or not they have ever
received counselling for depression], both as reported at randomisation and as validated after quality
assurance; patient demographics; and other important scientiﬁc covariates. If there is no reason to suspect
that the data are not MCAR, we shall impute values to be used in the main analyses by the following
methods. If there is reason to suspect that the missing data are not MCAR, the trial statistician and CI will
discuss the ﬁndings.Missing items within a subscale
If a subscale comprises three or fewer items, we shall treat each as a separate subscale. In addressing
missing items within a subscale thus deﬁned, we shall take account of methodological publications about
the validated instrument. In principle we seek to impute missing items to complete instruments thus:108
a. If < 25% of the items within a subscale are missing for a participant at a time point, we shall impute
them by the weighted mean of the completed items.
b. If > 50% of the items within a subscale are missing for a participant at a time point, we shall treat that
subscale as missing and impute it.Missing subscales
Where between 25% and 50% of the items within a subscale are missing, we shall proceed thus:
1. If < 40% of the subscales for a participant at a time point are missing, we shall impute all missing
subscales by a single application at that point of the SPSS multivariate imputation algorithm that also
takes account of all validated stratiﬁcation variables.
2. If > 40% of the subscales for a participant at a time point are missing, but < 20% of participants
experience that problem, we shall impute all missing subscales by a single multivariate imputation that
also takes account of all validated stratiﬁcation variables across all time points.
3. If > 40% of the subscales for a participant at a time point had been missing, and > 20% of participants
had experienced that problem, we would have used multiple multivariate imputations; in the event,
however, this never happened.111
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112Missing time points1. If < 15% of all time points are missing, we shall impute all subscales within each time point by one
iteration of the SPSS multiple imputation algorithm using all other subscales at all time points, together
with age, gender, centre and group.
2. If > 15% but < 30% of all time points are missing, we shall impute all subscales within each time point
by ﬁve iterations of the SPSS multiple imputation algorithm using all other subscales at all time points,
together with age, gender, centre and group.Preliminary data description
We shall summarise baseline and demographic data by both treatment allocation and centre. Conscious
that our three centres differed in many respects notably psychiatric practice and recruitment policy, we
shall present outcomes believed to follow a Normal distribution in the form: number of responses; mean
and SD. If Normal plots show evidence of non-normality however, we shall them present them in the
form: number of responses; median and ﬁrst and third quartiles.Data transformations
Our analysis plan assumes that residual variation from our statistical models will follow approximately
Normal distributions. This is a robust assumption in the sense that only a substantial deviation would
invalidate each analysis. Hence the trial statistician will plot all residual distributions and discuss any
evidence against normality, as shown for example by Normal plots, with the CI. If necessary we shall seek
an optimal transformation to improve approximation to Normality.Analytical methodsAll tests will be two-sided with a signiﬁcance level of 5% but no correction for multiple testing.Continuous outcomes with baseline and more than one follow-up
(for example BDI-II)
We shall use ‘AUC’ to combine outcomes over all time points to create the primary outcome. As covariates
in the AUC analysis we shall use validated stratiﬁcation variables – centre, gender, new or old patient, type
of antidepressant and previous counselling. For individual time points we shall use analysis of covariance to
adjust for the corresponding baseline score.
As a sensitivity analysis we shall use multi-level modelling with the same covariates, also known as
repeated measures analysis of variance. We shall estimate parameters for three ﬁxed factors – the three
time points (4, 12 and 25 weeks), centre and treatment group. We shall also include interactions between
treatment and both time point and centre. We shall summarise all effects by parameter estimate, standard
error, signiﬁcance level, and 95% conﬁdence level.Continuous outcome with no baseline and only one follow-up
(Morisky scale)
We shall use analysis of covariance, with baseline depression scores and validated stratiﬁcation variables as
covariates, to test whether medication adherence, measured on the Morisky scale, is signiﬁcantly different
between the treatment groups. If so, or if there is other evidence that the Morisky score inﬂuences the
main psychological outcomes, we shall test in secondary analysis whether adding it to the usual covariates
improves the ﬁt of each model and reﬁne those models accordingly. In these circumstances we shall test
whether also to add prescribed medications recorded by GPs to the usual covariates.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18480 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 48Dichotomous outcomes (serious adverse effects and adverse events)
We shall use logistic regression of the binary response of (S)AE or no (S)AE over each participant’s time in
the trial to test whether the proportion of participants who experienced (S)AEs differs between treatment
arms. Covariates will include baseline scores and validated stratiﬁcation variables. We shall transform all
estimated ﬁxed effects back from their logistic form and summarise them by OR; standard error;
signiﬁcance level and 95% CI.Covariates for adjustment within statistical model
We shall keep baseline depression scores and validated stratiﬁcation variables as covariates throughout.
We shall explore covariates of potential scientiﬁc relevance, including: demographic (e.g. age, ethnicity,
marital status, number of dependants and employment status, coded in accordance with usual
demographic practice); and clinical (e.g. referral source, smoking, alcohol consumption and medication
adherence, measured by both Morisky scale and recorded prescriptions). We shall retain these if they
achieve signiﬁcance levels of 10%.Interactions to be tested
Within each analysis we shall test for interaction between treatment and centre, not least because our
three centres differed in many respects, notably psychiatric practice and recruitment policy. Any evidence
of interaction between treatment and centres will lead to exploratory analysis to explain the effects, initially
by covariates within the ‘treatment allocated’ population. Failing that, we shall estimate the treatment
effect for each centre separately. We shall also test interactions with signiﬁcant covariates and include
these interactions within the model if signiﬁcant at the 10% level.Sensitivity analysesIn addition to the planned sensitivity analyses described in Chapter 2 (see Statistical methods, Methods for
analysing outcomes, Sensitivity analyses), we shall use sensitivity analysis ad hoc to test whether the
validity of the trial is at risk, for example to protocol deviations that result in systematic missing data or
potentially differential reasons for withdrawal from the trial and loss to follow-up.113
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Aim
To assess whether the use of folic acid supplementation is cost-effective by estimating the incremental
cost–utility and cost-effectiveness ratios of ADM plus folic acid relative to ADM alone.Data
Healthcare resources: We measure participants’ use of health and social care services by:
a. self-completed questionnaires (collected by research professionals at baseline, and weeks 12 and 25),
which ask patients to recall their use of general practice, community services and social services over
previous 3 months
b. general practice records of prescribed medications over 25 weeks of follow-up, and
c. data on hospitalisations, triggered by notiﬁed SAEs.
Unit costs: We shall derive the cost of most resources used from national sources.114,116,119 We shall
estimate specialised costs like pharmacogenetic testing from appropriate local sources. The cost year will
be 2010 and the perspective will be that of the NHS and PSS.
Health outcomes: Participants completed the EQ5D instrument at: baseline, 4, 12, and 25 weeks. We
shall convert their responses into a single, preference-based utility value based on the UK tariff.168 They
completed the SF12 at: baseline, 4, 12, and 25 weeks. To generate the SF6D utility score from their
responses we shall apply a valuation algorithm using preference weights obtained from a sample of the
general population using the standard gamble technique.122 For the cost-effectiveness analysis, we shall
estimate the number of weeks free from moderate or severe depression from participants’ responses to
the BDI-II.Analysis
Cost analysis: In principle we shall impute missing data on resource use according to the section of the
statistical analysis plan on ‘Missing items within an instrument’. We shall estimate the mean cost per
patient over 25 weeks across both arms of the trial together with their respective bootstrapped 95% CIs
using 10,000 replicates. We shall analyse cost data by assuming that the large samples generate nearly
Normal distributions of sample means, thus justifying Student’s t-test and ordinary least squares (OLS)
linear regression. If quantile–quantile plots,169 and Shapiro-Wilk170 and Shapiro-Francia171 tests for
normality show problems like skewness and excess zeros (at least 20% of samples),124 we shall develop an
appropriate generalised linear model. To gain precision in estimating mean costs, we shall include
covariates in the cost regression models. Selection of covariates will accord with the section of the
statistical analysis plan on ‘Covariates for adjustment within statistical model’.
Analysis of health outcomes: We shall impute data missing from EQ5D responses according to the
section of the statistical analysis plan on ‘Missing items within an instrument’. We shall present descriptive
statistics of fully imputed responses to individual items within the EQ5D (mobility, self-care, usual activity,
pain-discomfort and anxiety-depression) and the derived utility scores and Visual Analogue Scale scores for
each time point across treatment groups. We shall estimate the number of QALYs experienced by each
patient over 25 weeks as the area under the EQ5D utility curve, using the trapezoidal rule and adjusting
for baseline utility score.170 We shall derive non-parametric 95% CIs from 10,000 bootstrapped replicates.
We shall analyse these QALY data by Student’s t-test and OLS linear regression, after testing by
quantile-quantile plots169 and the Shapiro-Wilk170 and Shapiro-Francia171 tests that the large samples
generate Normal distributions. To gain precision in estimating mean QALYs, we shall include covariates in
the QALY regression models. Selection of covariates will include baseline utility score126 and accord with
the section of the statistical analysis plan on ‘Covariates for adjustment within statistical model’).117
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118Cost-effectiveness analysis: We shall estimate the number of weeks free from moderate or severe
depression (when BDI-II scores are less than 13) by statistical inference from the observed distribution of
BDI-II scores and assuming linear interpolation between time points – baseline and at 4, 12 and 25 weeks.
Incremental and uncertainty analysis: We shall derive ICERs by dividing differences in adjusted
mean costs by differences in adjusted mean effects. We shall explore uncertainty around ICERs using
non-parametric bootstrapping. We shall display results on cost-effectiveness planes and as
cost-effectiveness acceptability curves showing when the results fall below given cost-effectiveness
thresholds. We shall conduct sensitivity analyses to test the robustness of our ﬁndings and examine the
extent to which ICERs are sensitive to key assumptions in the analysis, notably on unit costs and SF6D
utilities and through complete case analysis.
Secondary analysis: Depending on the analysis of clinical data, secondary analyses will assess
relationships between cost-effectiveness and potential predictors of response, notably adverse reactions
and high-cost episodes by including them in generalised linear regression models.172 These are likely to
include baseline disease severity and class of prescribed ADM, along with gender, age and genetic factors.
If the results of the genetic analysis suggest clinical value, we shall undertake exploratory analysis of the
cost-effectiveness of pharmacogenetic testing.Annex 5: Genetic analysis planWe shall analyse baseline samples for 140 single nucleotide polymorphisms and two tandem repeat
polymorphisms within the genomic loci of 25 genes related to either one-carbon folate metabolism or
methionine biosynthesis pathways. Initially we shall examine each single nucleotide polymorphism (‘SNP’)
in turn for association with participants’ response to antidepressant medication (ADM).
We shall ﬁt two mixed models. The ﬁrst will include baseline values, the three time points (4, 12 and
25 weeks), centre, genetic factors potentially associated with outcome a priori [age, gender, body mass
index (BMI), co-medications, type of antidepressant and new or continuing patient] as well as an indicator
variable to indicate whether a patient supplemented their treatment with folic acid or not. This indicator
variable will specify treatment received rather than treatment allocated.
The second model will be the same as the ﬁrst except for a covariate representing the SNP. We shall
compare both models by the likelihood ratio test, and record the signiﬁcance level. Initially we shall
assume an additive mode of inheritance for each SNP, with patients having the wild-type genotype coded
‘0’, those having the heterozygous genotype coded ‘1’, and those having the homozygous variant
genotype coded ‘2’. Later sensitivity analysis will test whether a dominant allele model provides a better ﬁt
to the data.
Before the analyses of association, we shall test each SNP for Hardy–Weinberg Equilibrium. We shall ﬂag
those found to deviate at the 1% signiﬁcance level but include them in analysis. We shall include in the
association analyses only SNPs passing the following genotype quality criteria:
a. minor allele frequency > 0.01
b. genotypes call > 95% of SNPs
c. samples call > 90% of SNPs.
In addition we shall exclude any patient samples with > 5% missing genotypes from analysis. Also before
the analyses of association, we shall reduce the number of SNPs investigated by assessing the extent of
linkage disequilibrium (‘LD’) between SNPs. Where the LD is signiﬁcant (r2 > 0.81) for a group of two or
more SNPs, we shall include only the SNP with the least missing data in the analyses.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18480 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 48If the study includes only a small proportion of self-reported non-Caucasian patients (5%), we shall
exclude them from the genetic association analyses. If the proportion exceeds 5%, we shall adjust for
ethnic origin in analysis by including additional covariates in the regression models.
Once all genetic analyses of association with participants’ response to ADMs are complete, we shall
estimate the FDR for each association. We shall treat FDRs less than 0.05 as statistically signiﬁcant
associations. For marginally signiﬁcant SNPs (i.e. FDR < 0.10), we shall ﬁt a further regression model
including a folic acid × SNP interaction term to identify genetic predictors of the efﬁcacy of folic acid
adjuvant to ADM. We shall compare this model with the model without interaction, and re-estimate the
FDR with 5% again the criterion of signiﬁcance.
We shall also undertake exploratory analyses for association between each SNP and changes from baseline
in the biochemical markers speciﬁed in Annex 6 below, following the same format as for the primary
analyses. We shall use the statistical packages R, SPSS and PLINK.111,135,136
Hence the genetic component of the study will need the clinical and biochemical data speciﬁed in Annex 2
including the following stratifying variables: centre, age, gender, BMI (i.e. weight/height2), co-medications,
type of antidepressant, and whether new or continuing patient.Annex 6: Biochemistry analysis plan
Homocysteine
Folate and vitamin B12 concentrations are major determinants of one-carbon metabolism, in which the
essential methyl donor S-adenosylmethionine (SAM) is formed. SAM is essential for neurologic function.
Low plasma folate concentrations are associated with poor response to ADM, and treatment with folic
acid can improve that response. Plasma total homocysteine (tHcy) is a sensitive marker of folate (and B12)
status. We measure this at baseline and following treatment with folic acid or placebo primarily to assess
the response to folate therapy. It will be informative to characterise how response to folate augmentation
depends upon baseline homocysteine levels. We will assay homocysteine by an automated analyser
(Abbott Architect) using one-step immunoassay with chemiluminescence detection (Axis-Shield). This assay
is standardised using the National Institute of Standards and Technology (NIST) Standard Reference
Material. It is used to assess patient samples routinely, and is subject to rigorous internal and external
quality assurance assessments.Biochemistry analysis
As patients with depression have increased homocysteine concentrations, the primary analysis of
homocysteine will follow essentially the same analysis plan as for genetics in Annex 5. We shall compare
the effects of folic acid and placebo on tHcy using the mixed model approach to repeated-measures
analysis of variance. As potential covariates we shall use baseline Hcy, age, gender, BMI (weight/height2),
co-medications, type of ADM, and new or continuing patient. We shall estimate parameters for three ﬁxed
factors – the three time points (4, 12 and 25 weeks), centre (especially important as tHcy sample handling
differs between centres) and treatment group. We shall also include the interaction between treatment
group and time point to test whether differences between treatments vary over time.
We shall add reported compliance with folate therapy or placebo to this model and test whether this leads
to a fall in tHcy. We shall investigate how type of ADM, lifestyle factors (e.g. smoking, BMI and alcohol)
and genetic polymorphisms in the folate pathway affect patients’ baseline homocysteine concentrations;
and how folic acid affects BDI-II scores, the primary outcome measure. We shall also test the interaction
between biochemical variables and the ﬁnal set of genetic polymorphisms analysed by the genetics
analysis plan (see Annex 5). We shall explore the extent to which tHcy and MMA, both baseline and
subsequent, predict BDI-II, MADRS and CGI scores.119
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120Methylmalonic acid
Methylmalonic acid is a sensitive marker of B12 status. Hence the trial affords a unique opportunity to
estimate the effects of folic acid supplementation on MMA concentration speciﬁcally in individuals with
low-to-normal B12 levels, and thus assist in elucidating the nature of the relationship, if any, between folic
acid and MMA. If folic acid is clearly shown to inﬂuence MMA concentrations, this will be of considerable
importance for public health decisions relating to the issue of food folate fortiﬁcation in the UK and
elsewhere. There is evidence from cross-sectional studies that the combination of high plasma folate and
low B12 status is associated with cognitive decline. Hence we shall later explore the extent to which MMA
acts as a prognostic variable for other outcomes.
Thus the non-genetic data required for the biochemical component of the study are the same as those
listed in Annex 2 for the genetic component of the study.Imputing serum folate measurements censored at 20
We shall impute separately for groups A and B without using demographic variables like age or sex.
1. Step 1:
a. Regress log (serum folate) on log (red cell folate – RCF) using raw data where both values are
present; and derive slope and intercept.
b. Replace serum folates recorded as > 20 by 20.
c. Regress log (serum) on log(RCF) after including the extra data points added in step 1b, expecting the
intercept to increase and the slope to decrease.
2. Step 2:
a. Use slope and intercept from step 1c to impute serum folates recorded as > 20.
b. Retain all imputations that yield serum folates > 20; and replace by 20 all imputations that yield
serum folates < 20 in 2.1.
c. Regress log(serum) on log(RCF) after including the extra data points imputed in step 2b, expecting
the intercept to increase and the slope to decrease.
3. Final steps:
a. Repeat steps 2a to 2c till slope changes by < 0.1 × SD of slope or no imputed folates < 20.
b. Impute all serum folates recorded as > 20 using slope and intercept from ﬁnal iteration of step 2c;
add normally distributed residual with mean zero and SD = residual SD of ﬁnal model.
c. Repeat entire process after replacing RCF by B12 to impute missing values when RCF is missing but
B12 is present; however imputation is not possible when folate, RCF and B12 are all missing.
d. Assess imputation process by scatter plots of serum folate against RCF and B12.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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nucleotide polymorphismsTABLE 35 Single nucleotide polymorphisms included in Sequenom genotyping assays or excluded before analysis
for assay design factors
Gene (HUGO) Accession number Chromosome position
AHCY rs866027 chr20:32874310
rs13043752 chr20:32883308
ALDH1L1 rs4646760 chr3:125822871
rs4646756 chr3:125824256
rs1127717 chr3:125826059
rs2276726 chr3:125826287
rs3772426 chr3:125829830
rs1868130 chr3:125837819
rs12106789 chr3:125838351
rs4646739 chr3:125844079
rs6763254 chr3:125848067
rs6799991 chr3:125856916
rs6800400 chr3:125857342
rs11923466 chr3:125859367
rs10934751 chr3:125868513
rs16837171 chr3:125871773
rs16837178 chr3:125872293
rs3796191 chr3:125872384
rs6774807 chr3:125883082
rs4679102 chr3:125885196
rs9842910 chr3:125896572
AMD1 rs7768897 chr6:111212283
AMT1 rs10640 chr3:49454277
rs1464568 chr3:49458266
ATIC rs7585489 chr2:216181868
rs2372536 chr2:216190020
rs10932606 chr2:216198374
rs6737407 chr2:216207121
rs6435899 chr2:216207271
rs4672768 chr2:216214124
BHMT rs6875201 chr5:78410564
rs506500 chr5:78414337
continued
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TABLE 35 Single nucleotide polymorphisms included in Sequenom genotyping assays or excluded before analysis
for assay design factors (continued )
Gene (HUGO) Accession number Chromosome position
rs3733890 chr5:78421959
CBS CTH rs12613 chr21:44473691
rs4920037 chr21:44481891
rs234706 chr21:44485350
rs535112 chr1:70889476
rs525276 chr1:70893391
rs17131305 chr1:70896165
rs473334 chr1:70896967
rs1021737 chr1:70904800
DHFR rs1677692 chr5:79937014
rs10072026 chr5:79945140
DNMT1 rs10407514 chr19:10255112
rs8111085 (merged with rs2228612) chr19:10273372
rs6511677 chr19:10277799
FOLH1 rs16906158 chr11:49170774
rs383028 chr11:49174141
rs202687 chr11:49180269
rs7126892 chr11:49198799
rs202712 chr11:49198924
rs588458 chr11:49214048
FPGS rs2230270 chr9:130570894
rs34354111 chr9:130575702
FTCD rs17004505 chr21:47571209
rs28941768 chr21:47571859
GART rs8971 chr21:34883618
rs6517178 chr21:34888621
rs2834234 chr21:34894623
rs4817577 chr21:34894797
GGH rs11995525 chr8:63934988
rs7010484 chr8:63937675
rs11545078 chr8:63938764
rs3780130 chr8:63940776
rs13268472 chr8:63942016
rs10957267 chr8:63944251
rs17194931 chr8:63944344
rs13270305 (merged with rs11545077) chr8:63951237
rs1800909 chr8:63951312
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TABLE 35 Single nucleotide polymorphisms included in Sequenom genotyping assays or excluded before analysis
for assay design factors (continued )
Gene (HUGO) Accession number Chromosome position
MAT1A rs4933327 chr10:82033683
rs17102596 chr10:82035173
rs2236568 chr10:82035923
rs873395 chr10:82037215
rs1143693 chr10:82040484
rs3862534 chr10:82048978
MTFMT rs34507711 chr15:65295441
rs6494509 chr15:65307463
rs35302908 chr15:65308791
rs11638255 chr15:65321037
MTHFD1 rs8006686 chr14:64868671
rs1950902 chr14:64882380
rs10133855 chr14:64890227
rs34181110 chr14:64892470
rs11627525 chr14:64894362
rs10498514 chr14:64899055
rs2236225 chr14:64908845
rs8012229 chr14:64911562
rs2281603 chr14:64926097
MTHFR rs2184226 chr1:11847436
rs35737219 chr1:11850750
rs2274974 chr1:11851319
rs13306556 chr1:11852110
rs1801131 chr1:11854476
rs1801133 chr1:11856378
rs4846052 chr1:11857951
rs17367504 chr1:11862778
rs2066472 chr1:11862971
rs7553194 chr1:11864149
rs2244976 chr8:19122545
MTHFS rs8923 chr15:80137560
rs4779165 chr15:80151013
rs2586154 chr15:80165368
rs12899781 chr15:80168282
rs7166189 chr15:80172385
rs2733107 chr15:80178612
continued
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ABLE 35 Single nucleotide polymorphisms included in Sequenom genotyping assays or excluded before analysis
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124T
for assay design factors (continued )
Gene (HUGO) Accession number Chromosome position
rs8042012 chr15:80179847
rs2586183 chr15:80180106
rs12898642 chr15:80182050
rs8040104 chr15:80183342
MTR rs12749581 chr1:236966848
rs6668344 chr1:237001326
rs4659727 chr1:237006914
rs1805087 chr1:237048500
rs10158222 chr1:237050682
rs1252252 chr1:237056002
rs11799647 chr1:237060921
MTRR rs1801394 chr5:7870973
rs326124 chr5:7877178
rs161869 chr5:7877831
rs1532268 chr5:7878179
rs10380 chr5:7897191
rs12347 chr5:7897283
rs716537 chr5:7899419
rs8659 chr5:7900833
SHMT1 rs1979277 chr17:18232096
rs2273028 chr17:18239012
rs9910090 chr17:18250399
rs2273026 chr17:18256979
rs2461838 chr17:18265264
SLC19A1 rs1051296 chr21:46934861
rs12659 chr21:46951556
rs2330183 chr21:46953292
rs1051266 chr21:46957794
rs3177999 (merged with rs1131596) chr21:46957916
rs35789560 chr9:130575515
TYMS rs1004474 chr18:660383
rs11540152 chr18:662215
rs596909 chr18:669087
rs11540153 chr18:669117
rs2853532 chr18:670414
NIHR Journals Library www.journalslibrary.nihr.ac.uk
ABLE 35 Single nucleotide polymorphisms included in Sequenom genotyping assays or excluded before analysis
or assay design factors (continued )
Gene (HUGO) Accession number Chromosome position
Unable to plex owing to sequence constraints
Gene (HUGO) rs number Chromosome position
ALDH1L1 rs4646750 chr3:125826003
CBS rs1801181 chr21:44480616
DNMT1 rs8112801 chr19:10253099
MTHFR rs3927589 chr1:11854493
TYMS rs2853542 chr18:657685
SNPs excluded as incompatible with assay containing ≤ 10 SNP plex
MTHFS rs16971449 chr15:80152997
SLC19A1 rs35786590 chr21:46935675
SLC19A1 rs7278825 chr21:46935942
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DOI: 10.3310/hta18480 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 48Appendix 7 Loss between referral and
randomisationTABLE 37 Withdrawals after referral and before screening – by centre
Exclusion criteria
North East
Wales
North West
Wales Swansea Total
Aged under 18 years 0 4 0 4
B12 deﬁcient 0 0 2 2
Have taken folate supplementation 4 6 4 14
Suffered from psychosis 1 1 1 3
Bipolar disorder 1 0 1 2
Already in another research trial 1 1 0 2
Pregnant or planning to be 3 4 2 9
Taking anticonvulsants 1 2 2 5
Treatment for medical condition not yet stabilised 0 1 0 1
Taking lithium 0 0 1 1
Diagnosed with malignant disease 4 12 3 19
Subtotal 15 31 16 62
Not on antidepressants 13 16 7 36
Other 2 2 1 5
Subtotal 15 17 9 41
Self exclusion: refused 91 128 58 277
Did not attend screening 21 29 34 84
Could not be contacted 26 75 60 161
Subtotal 138 235 152 522
Total 168 280 177 625
Note: When recruiters reported more than one exclusion criterion, we tabulated the ﬁrst criterion in this list.
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TABLE 38 Withdrawals and exclusions at screening – by centre
Exclusion criteria
North East
Wales
North West
Wales Swansea Total
Aged under 18 years 0 0 0 0
Not depressed by ICD-10 criteria or low BDI-II 42 45 35 122
Folate deﬁcient 0 1 0 1
Have taken folate supplementation 4 3 1 8
Suffered from psychosis 1 0 1 2
Bipolar disorder 1 3 0 4
Taking anticonvulsants 6 6 4 16
Treatment for medical condition not yet stabilised 1 0 1 2
Diagnosis with malignant disease 2 17 3 22
Subtotal 57 75 45 177
Not on antidepressants 1 20 0 21
Other 6 5 3 14
Subtotal 7 25 3 35
Self exclusion: refused 4 12 0 16
Did not attend or could not be contacted 0 0 0 0
Subtotal 4 12 0 16
Total 68 112 48 228
Note: When recruiters reported more than one exclusion criterion, we tabulated the ﬁrst criterion in this list.
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TABLE 39 Withdrawals and exclusions at randomisation – by centre
Exclusion criteria
North East
Wales
North West
Wales Swansea Total
Not depressed by ICD-10 criteria or low BDI-II 6 23 7 36
Folate deﬁcient 0 8 7 15
B12 deﬁcient 0 7 1 8
Have taken folate supplementation 0 1 1 2
Taking anti convulsants 0 1 0 1
Diagnosed with malignant disease 0 2 0 2
Subtotal 6 42 16 64
Not on antidepressants 0 7 2 9
Other 1 2 2 5
Subtotal 1 9 4 14
Self exclusion: refused 9 4 4 17
Did not attend or could not be contacted 3 6 6 15
Subtotal 12 10 10 32
Randomised in error 2 0 2 4
Recruited to comprehensive cohort 24 7 15 46
Subtotal 26 7 17 50
Total 45 68 47 160
Note: When recruiters reported more than one exclusion criterion, we tabulated the ﬁrst criterion in this list.
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DOI: 10.3310/hta18480 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 48Appendix 8 Follow-ups completed and imputedTABLE 40 Participants lost to follow up or imputed – by centre and randomisation group
North East
Wales
North West
Wales Swansea Total
Group no. (%)a no. (%)a no. (%)a no. (%)a
Total randomised 119 238 118 475
No follow-up (n = 35) Folate 3 2.5 8 3.4 3 2.5 14 2.5
Placebo 6 6.8 7 2.9 8 6.8 21 5.0
Analysed (n = 440) Folate 57 47.5 110 46.2 56 47.5 223 47.9
Placebo 53 43.2 113 47.5 51 43.2 217 44.5
4 weeks imputed Folate 2 3.5 10 9.1 3 5.4 15 6.7
Placebo 1 1.9 16 14.2 4 7.8 21 9.7
12 weeks imputed Folate 4 7.0 5 4.5 13 23.2 22 9.9
Placebo 7 13.2 6 5.3 5 9.8 18 8.3
25 weeks imputed Folate 8 14.0 6 5.5 13 23.2 27 12.1
Placebo 12 22.6 12 10.6 5 9.8 29 13.4
Two time points imputed Folate 4 8.5 4 1.7 10 8.5 18 3.4
Placebo 8 2.5 6 2.5 3 2.5 17 6.7
a Denominator for analysed and no follow up = total randomised. Denominator for imputed = number analysed for folate
or placebo.137
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DOI: 10.3310/hta18480 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 48Appendix 9 Elaborated demographic dataTABLE 41 Full baseline demographic characteristics of trial participants by centre
Participant characteristic
North East
Wales (n = 110)
North West
Wales (n = 223)
Swansea
(n = 107)
number (%) number (%) number (%)
Ethnicitya White 8 (7) 88 (40) 14 (14)
White British 89 (81) 123 (55) 79 (74)
White Irish 1 (1) 5 (2)
Other white background 9 (8) 4 (2) 7 (6)
White and black Caribbean 1 (0)
Black (British) 1 (1) 1 (1)
Caribbean 1 (1)
Other Asian background 1 (0.5)
Not stated 2 (2) 1 (0.5) 5 (5)
Marital statusb Single (never married) 17 (16) 60 (27) 24 (24)
Married (ﬁrst marriage) 43 (39) 73 (33) 42 (41)
Divorced 19 (17) 27 (12) 16 (16)
Separated 4 (4) 6 (3) 4 (4)
Widowed 4 (4) 7 (3) 4 (4)
Cohabiting 12 (11) 37 (17) 5 (5)
Remarried 10 (9) 11 (5) 7 (7)
Number of dependent childrenc 0 51 (57) 87 (45) 31 (53)
1 15 (17) 40 (21) 15 (26)
2 18 (20) 37 (19) 6 (10)
3 3 (3) 13 (7) 4 (7)
4 1 (1) 7 (4) 2 (3)
5 1 (1) 2 (1)
6 3 (2)
7 3 (2)
8 1 (1)
Employment statusd Full time employed 35 (32) 52 (23) 22 (22)
Part time employed 14 (13) 22 (10) 7 (7)
Self-employed full time 3 (3) 7 (3) 2 (2)
Self-employed part time 4 (4) 4 (2) 1 (1)
Unemployed 8 (7) 47 (21) 14 (14)
Retired 10 (9) 16 (7) 22 (22)
Student 2 (2) 5 (2) 10 (10)
continued
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TABLE 41 Full baseline demographic characteristics of trial participants by centre (continued )
Participant characteristic
North East
Wales (n = 110)
North West
Wales (n = 223)
Swansea
(n = 107)
number (%) number (%) number (%)
Looking after family/home 4 (4) 10 (5) 4 (4)
Permanently sick/disabled 18 (17) 32 (14) 11 (11)
Temporarily sick/disabled 11 (10) 27 (12) 9 (9)
Smoking statuse Smoker 27 (25) 97 (44) 38 (37)
Non-smoker 56 (51) 93 (42) 45 (44)
Ex-smoker 26 (24) 32 (14) 19 (19)
Drinking (units/week)f None 52 (48) 78 (35) 38 (38)
1–7 30 (28) 79 (36) 27 (27)
8–14 16 (15) 20 (9) 15 (15)
15–21 6 (6) 12 (5) 10 (10)
22–35 3 (3) 12 (5) 7 (7)
36–50 2 (2) 6 (3) 1 (1)
51 or more 14 (6) 3 (3)
a We did not use ethnicity in the analysis because it provides no useful discrimination and threatens anonymity.
b For analysis, recoded as single or missing (109) vs. have a partner (240) vs. had a partner (91).
c For analysis, recoded as zero (269) vs. one (70) vs. two (61) vs. three or more (40).
d For analysis, recoded as full time (121) vs. part time or in education (124) vs. none (195).
e For analysis, recoded as smoking status as non-smoker (201) vs. smoker (162) vs. ex-smoker (77).
f For analysis,recoded as none (168) vs. safe (201) vs. less safe or missing (71).
APPENDIX 9
140
NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18480 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 48Appendix 10 Elaborated clinical effectiveness
results141
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Bedson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
ce
APPENDIX 10
142TA
B
LE
42
U
n
ad
ju
st
ed
re
su
lt
s
b
y
ti
m
e
p
o
in
t
O
u
tc
o
m
e
va
ri
ab
le
Fo
la
te
Pl
ac
eb
o
D
if
fe
re
n
ce
(f
o
la
te
m
in
u
s
p
la
ce
b
o
)
Fa
vo
u
rs
Si
g
n
iﬁ
ca
n
M
ea
n
(S
D
)
M
ea
n
(S
D
)
M
ea
n
(S
D
)
95
%
C
I
BD
I-I
I(
4
w
ee
k)
27
.3
0
(1
1.
56
)
27
.8
4
(1
2.
83
)
–
0.
54
(1
2.
20
)
–
2.
83
to
1.
75
FO
LA
TE
0.
64
3
BD
I-I
I(
12
w
ee
k)
25
.1
3
(1
3.
56
)
24
.6
6
(1
3.
6)
0.
47
(1
3.
58
)
–
2.
07
to
3.
02
PL
A
C
EB
O
0.
71
4
BD
I-I
I(
25
w
ee
k)
22
.6
1
(1
3.
53
)
22
.3
3
(1
4.
09
)
0.
28
(1
3.
81
)
–
2.
31
to
2.
87
PL
A
C
EB
O
0.
83
2
M
A
D
RS
(4
w
ee
k)
23
.2
9
(8
.9
2)
23
.2
4
(9
.4
9)
0.
05
(9
.2
1)
–
1.
67
to
1.
78
PL
A
C
EB
O
0.
95
3
M
A
D
RS
(1
2
w
ee
k)
21
.8
3
(1
0.
06
)
21
.6
2
(1
0.
73
)
0.
21
(1
0.
39
)
–
1.
74
to
2.
16
PL
A
C
EB
O
0.
83
2
M
A
D
RS
(2
5
w
ee
k)
19
.7
7
(9
.9
9)
20
.5
4
(1
1.
24
)
–
0.
77
(1
0.
62
)
–
2.
76
to
1.
22
FO
LA
TE
0.
44
9
EQ
-5
D
(4
w
ee
k)
0.
54
(0
.3
1)
0.
59
(0
.3
1)
–
0.
04
(0
.3
1)
–
0.
10
to
0.
01
PL
A
C
EB
O
0.
13
3
EQ
-5
D
(1
2
w
ee
k)
0.
58
(0
.3
)
0.
59
(0
.3
)
–
0.
01
(0
.3
0)
–
0.
06
to
0.
05
PL
A
C
EB
O
0.
80
7
EQ
-5
D
(2
5
w
ee
k)
0.
60
(0
.3
)
0.
6
(0
.3
1)
0.
00
(0
.3
0)
–
0.
05
to
0.
06
EQ
U
A
L
0.
94
9
EQ
-V
A
S
(4
w
ee
k)
52
.5
0
(2
1.
69
)
51
.6
6
(2
0.
41
)
0.
84
(2
1.
07
)
–
3.
11
to
4.
79
FO
LA
TE
0.
67
7
EQ
-V
A
S
(1
2
w
ee
k)
54
.6
1
(2
3)
55
.7
6
(2
2.
2)
–
1.
15
(2
2.
61
)
–
5.
39
to
3.
09
PL
A
C
EB
O
0.
59
4
EQ
-V
A
S
(2
5
w
ee
k)
59
.9
8
(2
2.
71
)
58
.1
3
(2
3.
57
)
1.
85
(2
3.
14
)
–
2.
48
to
6.
19
FO
LA
TE
0.
40
1
SF
-1
2
PC
S
(4
w
ee
k)
45
.3
9
(1
2.
56
)
43
.7
1
(1
2.
49
)
1.
68
(1
2.
52
)
–
0.
66
to
4.
03
FO
LA
TE
0.
15
9
SF
-1
2
PC
S
(1
2
w
ee
k)
44
.6
7
(1
2.
03
)
44
.7
8
(1
3.
05
)
–
0.
11
(1
2.
54
)
–
2.
46
to
2.
24
PL
A
C
EB
O
0.
92
5
SF
-1
2
PC
S
(2
5
w
ee
k)
45
.2
0
(1
2.
05
)
44
.2
1
(1
2.
34
)
0.
98
(1
2.
20
)
–
1.
30
to
3.
27
FO
LA
TE
0.
39
8
SF
-1
2
M
C
S
(4
w
ee
k)
30
.6
1
(1
1.
35
)
32
.1
3
(1
1.
61
)
–
1.
52
(1
1.
48
)
–
3.
67
to
0.
63
PL
A
C
EB
O
0.
16
5
SF
-1
2
M
C
S
(1
2
w
ee
k)
*
32
.6
6
(1
2.
34
)
35
.6
4
(1
2.
19
)
–
2.
97
(1
2.
27
)
–
5.
27
to
–
0.
68
PL
A
C
EB
O
0.
01
1
SF
-1
2
M
C
S
(2
5
w
ee
k)
34
.5
6
(1
3.
18
)
36
.4
7
(1
2.
87
)
–
1.
90
(1
3.
03
)
–
4.
34
to
0.
54
PL
A
C
EB
O
0.
12
6
C
G
I:
Se
ve
rit
y
(4
w
ee
k)
3.
79
(0
.9
8)
3.
78
(1
.0
1)
0.
01
(0
.9
9)
–
0.
17
to
0.
20
PL
A
C
EB
O
0.
87
5
C
G
I:
Se
ve
rit
y
(1
2
w
ee
k)
3.
59
(1
.1
3)
3.
52
(1
.2
4)
0.
07
(1
.1
8)
–
0.
16
to
0.
29
PL
A
C
EB
O
0.
55
5
C
G
I:
Se
ve
rit
y
(2
5
w
ee
k)
3.
21
(1
.3
4)
3.
33
(1
.3
5)
–
0.
12
(1
.3
4)
–
0.
37
to
0.
14
FO
LA
TE
0.
36
3
C
G
I:
Im
pr
ov
em
en
t
(4
w
ee
k)
3.
30
(1
.0
2)
3.
17
(1
.0
1)
0.
13
(1
.0
1)
–
0.
06
to
0.
32
PL
A
C
EB
O
0.
17
9
C
G
I:
Im
pr
ov
em
en
t
(1
2
w
ee
k)
3.
14
(1
.1
6)
3.
09
(1
.2
1)
0.
05
(1
.1
8)
–
0.
17
to
0.
27
PL
A
C
EB
O
0.
67
8
NIHR Journals Library www.journalslibrary.nihr.ac.uk
tc
o
m
e
va
ri
ab
le
Fo
la
te
Pl
ac
eb
o
D
if
fe
re
n
ce
(f
o
la
te
m
in
u
s
p
la
ce
b
o
)
Fa
vo
u
rs
Si
g
n
iﬁ
ca
n
ce
M
ea
n
(S
D
)
M
ea
n
(S
D
)
M
ea
n
(S
D
)
95
%
C
I
I:
Im
pr
ov
em
en
t
(2
5
w
ee
k)
2.
95
(1
.3
1)
3.
04
(1
.4
)
–
0.
09
(1
.3
5)
–
0.
34
to
0.
16
FO
LA
TE
0.
48
2
I:
Ef
ﬁ
ca
cy
(4
w
ee
k)
a
0.
09
(0
.5
9)
0.
17
(0
.5
9)
–
0.
08
(0
.5
9)
–
0.
19
to
0.
03
FO
LA
TE
0.
15
9
I:
Ef
ﬁ
ca
cy
(1
2
w
ee
k)
a
0.
22
(0
.6
4)
0.
17
(0
.6
4)
0.
05
(0
.6
4)
–
0.
07
to
0.
17
PL
A
C
EB
O
0.
44
7
I:
Ef
ﬁ
ca
cy
(2
5
w
ee
k)
a
0.
27
(0
.6
6)
0.
32
(0
.7
)
–
0.
05
(0
.6
8)
–
0.
18
to
0.
08
FO
LA
TE
0.
42
5
U
:
PS
Y
C
H
IC
(4
W
EE
K
)
8.
98
(5
.4
3)
8.
38
(5
.2
8)
0.
60
(5
.3
6)
–
0.
40
to
1.
61
PL
A
C
EB
O
0.
23
8
U
:
PS
Y
C
H
IC
(6
W
EE
K
)
7.
91
(5
.2
)
8.
09
(5
.5
)
–
0.
18
(5
.3
5)
–
1.
18
to
0.
82
FO
LA
TE
0.
72
8
U
:
PS
Y
C
H
IC
(1
2
w
ee
k)
6.
83
(5
.1
1)
6.
72
(5
.3
8)
0.
11
(5
.2
4)
–
0.
87
to
1.
09
PL
A
C
EB
O
0.
82
5
U
:
N
eu
ro
lo
gi
c
(4
w
ee
k)
b
0.
63
(0
.8
5)
0.
68
(0
.8
3)
–
0.
04
(0
.8
4)
–
0.
20
to
0.
12
FO
LA
TE
0.
60
5
U
:
N
eu
ro
lo
gi
c
(1
2
w
ee
k)
b
0.
55
(0
.7
8)
0.
62
(0
.8
3)
–
0.
07
(0
.8
0)
–
0.
22
to
0.
08
FO
LA
TE
0.
38
1
U
:
N
eu
ro
lo
gi
c
(2
5
w
ee
k)
b
0.
53
(0
.7
7)
0.
57
(0
.8
3)
–
0.
04
(0
.8
0)
–
0.
19
to
0.
11
FO
LA
TE
0.
56
7
U
:
A
ut
on
om
ic
(4
w
ee
k)
3.
04
(2
.9
1)
2.
94
(3
.1
5)
0.
10
(3
.0
3)
–
0.
47
to
0.
66
PL
A
C
EB
O
0.
74
U
:
A
ut
on
om
ic
(1
2
w
ee
k)
2.
89
(2
.8
5)
2.
88
(2
.9
2)
0.
00
(2
.8
9)
–
0.
54
to
0.
54
PL
A
C
EB
O
0.
99
1
U
:
A
ut
on
om
ic
(2
5
w
ee
k)
2.
61
(2
.5
8)
2.
44
(2
.9
2)
0.
17
(2
.7
5)
–
0.
35
to
0.
68
PL
A
C
EB
O
0.
52
4
U
:
O
th
er
(4
w
ee
k)
3.
74
(3
.5
4)
3.
89
(3
.5
8)
–
0.
15
(3
.5
6)
–
0.
82
to
0.
52
FO
LA
TE
0.
66
U
:
O
th
er
(1
2
w
ee
k)
**
3.
42
(3
.2
1)
4.
12
(4
.0
4)
–
0.
70
(3
.6
4)
–
1.
38
to
–
0.
02
FO
LA
TE
0.
04
5
U
:
O
th
er
(2
5
w
ee
k)
3.
36
(3
.0
7)
3.
77
(3
.8
1)
–
0.
41
(3
.4
5)
–
1.
06
to
0.
24
FO
LA
TE
0.
21
3
A
ft
er
lo
ga
rit
hm
ic
tr
an
sf
or
m
at
io
n.
A
ft
er
sq
ua
re
-r
oo
t
tr
an
sf
or
m
at
io
n.
D
iff
er
en
ce
si
gn
iﬁ
ca
nt
at
5%
le
ve
lw
ith
ef
fe
ct
si
ze
=
0.
24
.
D
iff
er
en
ce
si
gn
iﬁ
ca
nt
at
5%
le
ve
lw
ith
ef
fe
ct
si
ze
=
0.
19
.
DOI: 10.3310/hta18480 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 48O
u
C
G
C
G
C
G
C
G
U
K
U
K
U
K
U
K
U
K
U
K
U
K
U
K
U
K
U
K
U
K
U
K a b * **
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Bedson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.143
TABLE 43 Logistic analysis of ‘medium-term response to treatment’ (50% reduction in BDI-II score) at 25 weeks
Predictors β SE (β) Wald’s χ2 Signiﬁcance
Odds ratio
[Exp(β)] 95% CI for Exp(β)
Unadjusted
Serum folate (baseline) 0.026 0.026 0.946 0.331 1.026 0.974 to 1.080
Homocysteine (baseline) 0.007 0.019 0.157 0.692 1.007 0.971 to 1.045
Constant 0.332 0.349 0.908 0.341 1.394
Adjusted by stratification variables
Serum folate (baseline) 0.027 0.027 0.946 0.331 1.027 0.973 to 1.084
Homocysteine (baseline) 0.008 0.020 0.172 0.679 1.008 0.969 to 1.049
Type of ADM 0.535 0.239 5.029 0.025 1.707 1.070 to 2.725
Previous counselling 0.068 0.216 0.099 0.753 1.071 0.701 to 1.635
Previous treatment 0.760 0.268 8.020 0.005 2.138 1.264 to 3.618
Centre 4.134 0.127
Centre 1 0.544 0.268 4.126 0.042 1.722 1.019 to 2.911
Centre 2 0.299 0.304 0.964 0.326 1.348 0.743 to 2.448
Gender 0.242 0.231 1.099 0.295 1.273 0.810 to 2.001
Constant –0.985 0.537 3.361 0.067 0.373
Adjusted by stratification variables and treatment group
Serum folate (baseline) 0.027 0.027 0.950 0.330 1.027 0.973 to 1.084
Homocysteine (baseline) 0.008 0.020 0.161 0.688 1.008 0.969 to 1.049
Type of ADM (1) 0.537 0.239 5.066 0.024 1.712 1.072 to 2.733
Previous counselling 0.066 0.216 0.094 0.759 1.069 0.699 to 1.633
Previous treatment 0.762 0.269 8.052 0.005 2.142 1.266 to 3.626
Centre 4.174 0.124
Centre 1 0.547 0.268 4.165 0.041 1.728 1.022 to 2.922
Centre 2 0.300 0.304 0.973 0.324 1.35 0.744 to 2.451
Gender 0.240 0.231 1.081 0.299 1.271 0.809 to 1.998
Treatment group 0.056 0.211 0.070 0.791 1.057 0.700 to 1.598
Constant –1.012 0.548 3.418 0.064 0.363
Predictors signiﬁcant at 5% level are in bold type.
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TABLE 44 Logistic analysis of ‘short-term response to treatment (50% reduction in BDI-II score) at 12 weeks
Predictors β SE (β) Wald’s χ2 Signiﬁcance
Odds ratio
[Exp(β)] 95% CI for Exp(β)
Unadjusted
Serum folate (baseline) –0.028 0.027 1.10 0.294 0.972 0.923 to 1.025
Homocysteine (baseline) –0.011 0.018 0.417 0.518 0.989 0.955 to 1.024
Constant 1.295 0.349 13.7 0 3.649
Adjusted by stratification variables
Serum folate (baseline) –0.023 0.028 0.696 0.404 0.977 0.925 to 1.032
Homocysteine (baseline) –0.014 0.019 0.547 0.459 0.986 0.951 to 1.023
Type of ADM 0.379 0.254 2.228 0.136 1.461 0.888 to 2.403
Previous counselling 0.245 0.228 1.155 0.283 1.277 0.817 to 1.996
Previous treatment 0.252 0.29 0.75 0.386 1.286 0.728 to 2.272
Centre 4.09 0.129
Centre 1 0.535 0.279 3.664 0.056 1.707 0.987 to 2.952
Centre 2 0.132 0.311 0.181 0.671 1.141 0.621 to 2.098
Gender 1 –0.158 0.246 0.410 0.522 0.854 0.527 to 1.384
Constant 0.644 0.545 1.397 0.237 1.904
Adjusted by stratification variables and treatment group
Serum folate (baseline) –0.023 0.028 0.685 0.408 0.977 0.926 to 1.032
Homocysteine (baseline) –0.015 0.019 0.603 0.437 0.986 0.950 to 1.022
Type of ADM 0.386 0.254 2.303 0.129 1.471 0.894 to 2.422
Previous counselling 0.240 0.228 1.105 0.293 1.271 0.813 to 1.987
Previous treatment 0.258 0.291 0.788 0.375 1.295 0.732 to 2.29
Centre 4.187 0.123
Centre 1 0.543 0.280 3.762 0.052 1.722 0.994 to 2.981
Centre 2 0.136 0.311 0.191 0.662 1.146 0.623 to 2.107
Gender –0.162 0.246 0.432 0.511 0.850 0.525 to 1.379
Treatment group –0.138 0.223 0.384 0.536 0.871 0.563 to 1.348
Constant 0.715 0.558 1.645 0.200 2.045
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TABLE 45 Logistic analysis of ‘medium-term remission from depression’ (BDI-II < 8) at 25 weeks
Predictors β SE (β) Wald’s χ Signiﬁcance
Odds Ratio
[Exp(β)] 95% CI
Unadjusted
Serum folate (baseline) 0.073 0.039 3.526 0.06 1.076 0.997 to 1.161
Homocysteine (baseline) 0.011 0.026 0.191 0.662 1.011 0.961 to 1.064
Constant 1.036 0.479 4.668 0.031 2.817
Adjusted by stratification variables
Serum folate (baseline) 0.080 0.041 3.748 0.053 1.083 0.999 to 1.174
Homocysteine (baseline) 0.021 0.031 0.473 0.492 1.022 0.961 to 1.086
Type of ADM (1) 0.540 0.327 2.731 0.098 1.716 0.904 to 3.257
Previous counselling 0.299 0.279 1.144 0.285 1.348 0.780 to 2.331
Previous treatment 0.444 0.339 1.710 0.191 1.559 0.801 to 3.031
Centre 2.407 0.300
Centre 1 0.477 0.358 1.777 0.182 1.611 0.799 to 3.247
Centre 2 0.017 0.39 0.002 0.964 1.018 0.474 to 2.184
Gender 0.462 0.296 2.431 0.119 1.587 0.888 to 2.834
Constant –0.313 0.729 0.184 0.668 0.732
Adjusted by stratification variables and treatment group
Serum folate (baseline) 0.080 0.041 3.770 0.052 1.084 0.999 to 1.175
Homocysteine (baseline) 0.021 0.032 0.428 0.513 1.021 0.960 to 1.086
Type of ADM (1) 0.548 0.328 2.802 0.094 1.730 0.911 to 3.288
Previous counselling 0.292 0.280 1.093 0.296 1.340 0.774 to 2.318
Previous treatment 0.450 0.341 1.737 0.187 1.568 0.803 to 3.062
Centre 2.558 0.278
Centre 1 0.496 0.360 1.901 0.168 1.642 0.811 to 3.322
Centre 2 0.020 0.390 0.003 0.960 1.020 0.475 to 2.189
Gender 0.457 0.297 2.370 0.124 1.580 0.883 to 2.827
Treatment group –0.245 0.275 0.789 0.374 0.783 0.456 to 1.343
Constant –0.191 0.747 0.065 0.798 0.826
APPENDIX 10
146
NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 46 Logistic analysis of ‘short-term remission from depression’ (BDI-II < 8) at 12 weeks
Predictors β SE (β) Wald’s χ2 Signiﬁcance
Odds Ratio
[Exp(β)] 95% CI for Exp(β)
Homocysteine (baseline) –0.008 0.023 0.121 0.728 0.992 0.949 to 1.038
Constant 2.051 0.478 18.389 0 7.774
Adjusted by stratification variables
Serum folate (baseline) 0.018 0.042 0.193 0.661 1.019 0.938 to 1.106
Homocysteine (baseline) –0.008 0.025 0.096 0.757 0.992 0.946 to 1.042
Type of ADM 0.440 0.375 1.376 0.241 1.553 0.744 to 3.242
Previous counselling 0.298 0.322 0.856 0.355 1.347 0.716 to 2.534
Previous treatment 0.200 0.399 0.251 0.616 1.221 0.559 to 2.667
Centre 0.352 0.838
Centre 1 0.119 0.413 0.083 0.773 1.127 0.501 to 2.533
Centre 2 –0.121 0.453 0.072 0.789 0.886 0.365 to 2.151
Gender 0.111 0.340 0.107 0.744 1.117 0.574 to 2.177
Constant 1.512 0.758 3.983 0.046 4.538
Adjusted by stratification variables and treatment group
Serum folate (baseline) 0.019 0.042 0.199 0.656 1.019 0.938 to 1.107
Homocysteine (baseline) –0.009 0.025 0.144 0.704 0.991 0.943 to 1.040
Type of ADM (1) 0.453 0.377 1.448 0.229 1.574 0.752 to 3.293
Previous counselling 0.288 0.323 0.796 0.372 1.334 0.709 to 2.510
Previous treatment 0.208 0.401 0.27 0.604 1.232 0.561 to 2.705
Centre 0.394 0.821
Centre 1 0.139 0.416 0.111 0.739 1.149 0.509 to 2.594
Centre 2 –0.115 0.453 0.065 0.799 0.891 0.367 to 2.165
Gender 0.102 0.341 0.089 0.765 1.107 0.567 to 2.162
Treatment group –0.319 0.318 1.004 0.316 0.727 0.389 to 1.357
Constant 1.691 0.784 4.651 0.031 5.424
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ABLE 47 Sensitivity analysis – comparison of those without follow-up with their nearest neighbours
Participant characteristic
Nearest neighbours
(n = 35)
No follow-up
(n = 35) Signiﬁcance test
Age in years
Range 20–68 20–66
Mean (SD) 42 (13) 39 (14) F(1,68) = 0.98, p = 0.33
Marital status, no. (%)
Single 12 (48) 13 (52)
Had a partner 13 (54) 11 (46)
Have a partner 10 (48) 11 (52) χ2 with 2 df = 0.25, p = 0.88
Number of dependent children, no. (%)
0 21 (49) 22 (51)
1 6 (55) 5 (45)
2 1 (17) 5 (83)
3 or more 7 (70) 3 (30) Fisher’s p = 0.24
Employment, no. (%)
Full time employed 10 (48) 11 (52)
Part time or in education 12 (63) 7 (37)
Inactive 13 (43) 17 (57) χ2 with 2 df = 1.90, p = 0.39
Alcohol units per week, no. (%)
None 13 (57) 10 (43)
Within safe limit* 17 (52) 16 (48)
Above safe limit* 5 (36) 9 (64) χ2 with 2 df = 1.56, p = 0.46
BDI-II screening
Range 24–56 24–57
Mean (SD) 39 (09) 42 (09) F(1,68) = 1.68, p = 0.20
BDI-II baseline
Range 20–61 18–57
Mean (SD) 37 (11) 40 (11) F(1,68) = 1.00, p = 0.321
*Difference signiﬁcant at 5% level with effect size = 0.24.
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DOI: 10.3310/hta18480 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 48Appendix 11 Recruitment into clinical trialsIntroductionRandomised controlled trials have been seen in recent decades as the ‘gold standard’ for clinical
research.173 They are accepted as generally the best way to estimate the effectiveness and
cost-effectiveness of interventions, as they make strong causal connections between interventions and
their effects.174 However more than two thirds of published trials do not achieve their recruitment
targets.175 McDonald et al. looked at 114 trials funded by the MRC or the NIHR HTA programme and
found that 54% required an extension, while 41% experienced delays in starting recruitment.176 This has
large cost implications for funders, resulting in trial extensions, and even complete failure. Why some trials
recruit well and other suffer problems remains unclear.177
Several systematic reviews have sought to improve recruitment in trials. Prescott et al.177 attempted to
identify factors that affected the effective running of trials, suggesting that recruitment problems may be
reduced by piloting, using multiple recruitment strategies, making contingency plans for slow recruitment
and using recruitment coordinators. However none of these approaches had been rigorously evaluated.
Watson and Torgerson concluded that recruitment interventions were both sparse and often of poor
methodological quality.178
Campbell et al. set out to identify factors associated with good and poor recruitment in multi-centred trials
from a cohort of studies, a selection of case studies and a single in-depth case study.179 The main themes
associated with success were ﬂexibility, adaptability to unexpected issues and better training. The study
suggested that the complex nature of multi-centred trials generated unexpected difﬁculties.
Recent methods to improve recruitment have achieved some success. One such method is the business
model using marketing strategies; however these require further research to establish effectiveness
and develop useable tools for medical research where these approaches, concepts and terminology
are unfamiliar.180
Barnard et al. looked at the recruitment of participants into trials from a different perspective and aimed to
identify different models that may be useful to RCTs when estimating the recruitment of participants.181
They noted that most trials use an unconditional model of recruitment and suggested that a new model
was needed to predict recruitment to clinical trials which takes account of both centre and patient
recruitment, recognising that one drives the other.
Health services research often recruits from primary care. However Bower et al.,175 exploring recruitment
difﬁculties, responses to recruitment problems and the relationship between trial characteristics and
recruitment, found that recruitment methods requiring GPs to consent patients into trials were particularly
problematic. In a review of current literature, Bower also concludes that recruitment of patients into health
research from primary care continues to be a major hurdle.182
Goodyear-Smith et al. sought to identify barriers to recruitment in primary care,183 including lack of time
(exacerbated by the annual inﬂuenza vaccinations campaign in general practice), the need to identify staff
responsible for decision making, the need to clarify the nature of the study, and the need to be ﬂexible in
accommodating practices. Strategies to improve recruitment included providing incentives to practices
(both material and educational), using a personal approach, ensuring practices feel engaged, minimising
disruption, streamlining processes, and using doctors to recruit doctors. They also suggested that smaller
practices were easier to recruit than larger practices.153
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154In the UK in recent years, national research networks have tried to improve some of the difﬁculties in
recruiting to clinical trials and running them. These include specialised networks in key areas of NHS
research such as cancer, mental health and stroke. Overarching networks also support research in areas
like primary care and children’s research. The aim of these research networks is to improve the process of
regulatory approvals, provide infrastructure and research support to trials and facilitate the recruitment of
patients into trials.184 In Wales the NISCHR Clinical Research Centre (NISCHR CRC) was established in 2010
to provide research workforce to support and develop research activity within health and social care.185
However few reported trials have assessed the effectiveness of research networks. Those that have report
that they have been successful in improving recruitment rates into trials.185–187
So we aimed to identify barriers to recruitment and factors that facilitated recruitment in the FolATED trial.Recruitment methods
We recruited participants over three years in three centres across Wales. Recruitment methods included direct
referrals from GPs, psychiatrists and other healthcare professionals, clinical database searches and self-referral.
We reported the number of participants recruited by each method in each centre to identify differences.
Recruitment into the trial from primary care was facilitated by research staff employed directly by the trial
or by NISCHR CRC. Their Clinical Studies Ofﬁcers played a pivotal role in recruitment, including practice
recruitment through visits and presentations, development and editing of regular newsletters to recruiting
practices, and contributing to local and national meetings and conferences. NISCHR CRC staff also helped
with computer searches in practices and invitation mailings from practices.
We collected data from each centre on recruitment, including whether from secondary care, general
practices or community mental health services, and method of recruitment, for example whether
participants were directly referred by healthcare professionals or as a result of invitations from computer
searches in practices.
We sought qualitative feedback from centres through a reﬂective recruitment tool providing written
accounts of recruitment strategies, barriers and facilitators in each site (Table 50). We analysed these data
using a thematic approach. We also held monthly recruitment meetings and annual training events to
identify recruitment difﬁculties and develop new strategies.NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 50 Recruitment strategies: questions for qualitative analysis
Recruitment and retention issues and supporting data
1. General recruitment Issues. Describe any recruitment issues in your area. Below are some suggested categories but you
can alter to your own experiences. What difﬁculties arose? What worked well?
1.1 Geographical
1.2 Population demographics
1.3 Participant attributes
1.4 The GP–patient relationship
1.5 Appointment booking strategies
1.6 Other issues – e.g. stafﬁng issues, recruiting surgeries and psychiatrists, maintaining psychiatric cover, centre
approaches and structure, physical environment and travel.
2. Patient recruitment strategies. What strategies were adopted in your centre? How well did they work? Below are
suggested categories; please add or omit as appropriate to your centre.
2.1 Posters, leaﬂets, newsletters
2.2 Traditional GP referral
2.3 Psychiatrist referral
2.4 Computer searches
2.5 Other strategies
3. Increasing recruitment and retention rates. Other methods used to improve patient recruitment and retention rates.
How did these work in practice?
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We used a wide variety of strategies to help with the recruitment and retention of both recruiters to the
trial such as general practices and secondary care services, and trial participants (Table 51). We adopted a
ﬂexible approach to recruitment allowing the three centres to identify and deploy the strategies found to
be successful in their area. However some strategies were universal such as the use of trial posters,
payment of general practices, feedback to GPs of BDI-II scores, regular training events and research team
meetings. Local variations included use of research networks such as NISCHR CRC, access to direct
referrals to secondary care through ﬂagging in referral notes, different methods of referral and participant
reminders for appointments and venues.
Methods used in recruitment
We recruited participants in three centres – North East Wales, North West Wales and Swansea (Table 52).
Although several methods of recruitment were adopted by all centres, different methods were used in
different centres. North West Wales, the most successful recruiting centre, acquired their referrals mainly
from direct referrals to the psychiatric services, supplemented by computer searches at general practices
and other referrals through secondary care. North East Wales acquired the majority of their referrals
through computer searches at general practices and direct GP referrals supplemented by other mental
health referrals. Swansea acquired the majority of their referrals through direct GP referrals, supplementing
this with computer searches and other referrals from secondary care (Figure 19).155
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ABLE 51 Strategies for maintaining recruitment and retention
Recruiting practices
Raise awareness of practices
Advertising in local health board bulletin
Presentations at local GP meetings
Stands at mental health practitioner network meetings
Posters at NISCHR CRC primary care research events
Letters of invitation to general practices
Direct phone calls to general practices
Raise awareness of patients
Posters in general practices
Participant information leaﬂets in waiting rooms
Incentives for primary care
Pay £50 per patient consented to cover administration costs
Provide GP with BDI-II scores and blood results for Quality & Outcomes Framework (QOF) assessments
Provide ‘fast track’ access to psychiatric assessment
Use NISCHR CRC
Provide primary care recruitment assistance and research support in North East Wales
Provide research staff for recruitment in Swansea
Flag triage to secondary care in North West Wales
Training event e.g. recruitment ‘brainstorming’
Monthly research team meetings to discuss recruitment issues across centres
Maintaining recruitment
Monthly newsletter to recruiting practices and mental health professionals
GP feedback events
Regular personal contact with practices and feedback from researchers
Maintenance of participation in trial
Appointment reminder letters and telephone calls
Continuity of researcher for participant
Reduction in assessment at screening visit
Introduction of home visits when beneﬁcial to participants
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TABLE 52 Referral method by recruitment centre
Referral method
North
East Wales
North
West Wales Swansea
Direct GP referrals 97 (24.3%) 429 (61.5%) 314 (80.5%)
Computer search in general practice 261 (65.4%) 129 (18.5%) 32 (8.2%)
Direct psychiatrist referral 21 (5.3%) 106 (15.1%) 12 (3%)
Other secondary care professional (e.g. CMHT) 16 (4%) 32 (4.6%) 1 (0.3%)
Other primary care professional (e.g. Mental Health Practitioner) 4 (1%) 2 (0.3%) 28 (7.2%)
Unknown 0 (0%) 0 (0%) 3 (0.8%)
Total referrals 399 (100%) 698 (100%) 390 (100%)
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IGURE 19 Number and type of referrals.
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Although we adopted different methods of recruitment across sites, we identiﬁed several factors as aiding
recruitment. A major facilitator was a good relationship with recruiting practices and services. This was
seen as a key factor in North West Wales: they had a history of working with general practices and had
established good working relationships with them. Elements important in building and maintaining a good
relationship included regular contact with practices, fast responses to their queries, regular updates by
newsletters and personal contact, and small tokens of appreciation like cards at Christmas.
A perception that participation conferred beneﬁts on patients was also seen as a facilitator. Many GPs
were pleased to offer something extra to long-term patients and saw quick access to a psychiatrist as
beneﬁcial, and time with the researcher as an alternative or supplement to counselling, which was often
difﬁcult to access. Some GPs felt this would be an alternative to patients visiting the surgery.157
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158Relationships were a recurrent theme. A good patient–doctor relationship was viewed as a facilitator to
direct referrals, as small surgeries had higher referral rates. Good relationships between participants and
researchers were also seen as important in retaining participants. Follow-ups were face to face, helping
relationships to develop. Continuity also contributed to the success of relationships with researchers
encouraged to follow participants from beginning to end. Also important was personal contact through
reminder letters and phone calls.
Awareness raising and networking with gatekeepers like practice managers were important in gaining
access to recruiters. Initial contact with Local Health Boards was also seen as a facilitator by providing
advice about key contacts, monthly meetings and identifying research-active practices. Furthermore aides-
memoire facilitated recruitment by providing reminders to health professionals; these included pens, note
paper and trolley tokens with the FolATED logo.Barriers to recruitment
One common theme was the competing demands on general practice time and resources. Examples of
commitments that preoccupied practices included preparing for QOF and the contemporaneous
vaccination campaign. Also changes in staff and surgery relocation affected recruitment in some centres.
Barriers included perceptions that research might compromise practice, including concerns about increased
visits to GPs, access to the practice database, conﬁdentiality, disruption, expense, inappropriate referrals,
consequences of participation for patients, in particular those found not suitable at screening, increased
workload, availability of space in surgeries and even the validity of the study.
North East Wales reported that some practices were already taking part in other studies and did not feel
they could recruit to another study. Also previous demands by researchers for information had made
several practices reluctant to participate, fearing our study was connected in some way.
Stafﬁng problems also reduced recruitment. The Swansea centre lost several research staff within a short
time, thus halting participant recruitment during staff recruitment and training. North East Wales had only
one researcher for several months before NISCHR CRC could help. North West Wales also had to restrict
computer searches and mailings to focus on direct referrals.
Inclement weather also affected recruitment and retention during the winter of 2010. Participants and
researchers were often unable to attend appointments, particularly in rural areas.DiscussionThis study has identiﬁed facilitators of, and barriers to, recruitment and retention in the FolATED trial.
Facilitators included the importance of building good relationships with psychiatric services, practices and
participants through the interpersonal skills of researchers and continuing feedback to recruiters. Also
important was the potential beneﬁt of the intervention, and participation in the trial, to patients, as
perceived both by those recruiting and the participants themselves. Thus raising awareness and
networking with gatekeepers like practice managers reportedly improved recruitment.
Barriers included the high demand on practitioners’ time, disruption to the surgery, consequences for
ineligible patients, and worries about conﬁdentiality. It is therefore vital that researchers design trials that
minimise impact on surgeries and provide reassurance about effects on patients and their conﬁdentiality.
It is important that, when dealing with recruiters, researchers tread carefully. If future research is to be
successful they need to nurture relationships and not make undue demands. As stafﬁng levels often posed
a threat to recruitment, researchers and funders need to be realistic when designing trials. Finally the
FolATED trial experienced unforeseen disruption, notably from the volcano eruption in Iceland and the
inclement weather of the winter of 2010.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18480 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 48This study also examined the strategies and methods used in the FolATED trial for the recruitment and
retention of both those recruiting into the trial and participants in the trial. Recommendations include the
need for a ﬂexible approach to such recruitment and retention. An explicit recruitment strategy is essential
in any trial; however multi-centred complex interventions present extra challenges which require a ﬂexible
and often creative approach. However we suffered from the slow regulatory systems and long waits to
implement much needed changes. For example we waited several months to get approval for an improved
poster and information leaﬂet for GP surgeries.
Monthly research team meetings provided the platform for sharing problems and exploring ideas with
colleagues. This also encouraged the trial centres to work as a team. Annual training sessions also assisted
in exploring and sharing ideas and experiences across centres.
The resources required to recruit and run a complex intervention should not be underestimated. There is a
need to acknowledge that recruiting into trials and the day-to-day running of trials is laborous, and that
the recruitment phase of a trial is particularly so. Alongside this, trials that employ labour-intensive
methods like interviews must be costed accordingly. The competitive nature of bidding for trial funding
often results in underfunded studies risking failure of trials owing to a lack of researchers on the
ground to coordinate and perform the research. In the FolATED trial assistance from NHS staff and the
emerging NISCHR CRC was crucial in centres with limited resources, where even the most successful
recruiting centre could have handled more participants but for the limitation of research staff to provide
follow-up interviews.159
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